Reduced corticosteroid sensitivity in smokers with asthma : potential mechanisms and treatment by Spears, Mark
 
 
 
 
 
 
Reduced corticosteroid sensitivity 
in smokers with asthma: potential 
mechanisms and treatment 
 
 
Dr Mark Spears 
MBChB, BSc Hons, MRCP 
 
 
Department of Respiratory Medicine, 
Division of Immunology, Infection & Inflammation, 
Faculty of Medicine 
 
 
Submitted for the degree of PhD, 
University of Glasgow 
 
April 2009 
 
 
 
 
© Mark Spears 2009
2 
ABSTRACT 
 
Smokers with asthma display reduced responses to both inhaled and oral 
corticosteroids with associated increased symptoms, accelerated decline in lung 
function and increased use of health care services. Little work has been 
undertaken to address the possible causes of this reduced response and to find 
effective replacement therapies. Therefore this thesis was carried out with the 
aim of identifying potential mechanisms and new therapies for this group. 
The oral bronchodilator theophylline has been suggested as a treatment for 
corticosteroid insensitivity due to its ability to increase HDAC activity in-vitro. I 
undertook an exploratory proof of concept clinical trial based on the hypothesis 
that low dose theophylline would restore corticosteroid sensitivity in smokers 
with asthma through theophylline induced recovery of HDAC activity. Low dose 
oral theophylline added to inhaled corticosteroid increased pre-bronchodilator 
lung function and reduced symptoms of asthma whilst low dose theophylline 
given alone reduced symptoms but had no effect on pre-bronchodilator lung 
function. This research provides a foundation for future studies designed to 
examine the efficacy of theophylline in smokers with asthma. 
Agonists of the nuclear hormone receptor peroxisome proliferator activated 
receptor-γ (PPARγ) have been demonstrated to be effective at reducing 
inflammation in both in-vitro and animal models of asthma. Therefore to 
examine the hypothesis that PPARγ stimulation would reduce the inflammation 
present in smokers with asthma I undertook an exploratory, proof of concept 
clinical trial using the PPARγ agonist rosiglitazone. Treatment with rosiglitazone 
was associated with a trend to improvement in FEV1 and improvement in a 
marker of small airway lung function and as such may provide an alternative 
treatment for small airways obstruction in conditions such as asthma and chronic 
obstructive airways disease. This trial will enable powering of future 
confirmatory studies. 
Altered cytokine profiles, specifically the combination of increased interleukin 
(IL)-2 and 4, are observed in asthmatic subjects with corticosteroid insensitivity. 
Based on this work I examined the hypothesis that the altered response to 
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corticosteroids in smokers with asthma was associated with an altered cytokine 
milieu including raised levels of IL-2 and 4. Smokers with asthma, characterised 
as corticosteroid resistant by oral corticosteroid trial, demonstrated significantly 
raised sputum supernatant IL-6 levels and raised levels of a number of other 
sputum cytokines compared to non smokers with asthma. This altered phenotype 
suggests cigarette smoking in asthma may be associated with a deviation to Th1 
mediated inflammation and could provide an explanation for the reduced 
corticosteroid response of smokers with asthma. The cell type/s responsible for 
both this shift in immunological phenotype and production of increased levels of 
sputum cytokines is unclear and will require further study. 
Previous in-vitro and in-vivo research has identified altered histone acetylation 
patterns in subjects with relative corticosteroid resistance. Therefore I 
examined the hypothesis that smokers with asthma displayed reduced responses 
to corticosteroids as a result of a cigarette smoke induced reduction in histone 
de-acetylase (HDAC) activity. Smokers with asthma provided sputum 
macrophages and blood for peripheral blood borne monocytes to examine total 
HDAC activity. Sputum and blood macrophage total HDAC activity was equivalent 
in smokers and non-smokers with asthma. Therefore reduced blood total HDAC 
activity does not appear to explain the altered corticosteroid response in this 
group. However the number of sputum macrophages obtained may have been 
too low to allow conclusive examination of this endpoint. Another consideration 
is that contamination of the sample due to the technique used may be altering 
the signal obtained. Further work either through modification of sputum 
induction techniques to increase macrophage number or bronchoscopic sampling 
is required to conclusively address the role of alveolar macrophage HDAC activity 
in the reduced corticosteroid response displayed by smokers with asthma. 
Exhaled nitric oxide has been exploited as a useful exploratory and confirmatory 
endpoint in asthma. However exhaled nitric oxide, measured using standard flow 
rates and methodology, is unhelpful in smokers with asthma as cigarette smoking 
is associated with a marked reduction in exhaled nitric oxide levels in the 
majority of subjects. Recent research has demonstrated that measurement of 
exhaled nitric oxide at multiple flow rates followed by mathematical modelling 
reveals increased levels of alveolar nitric oxide that were unaltered by current 
smoking. Therefore to examine the hypothesis that smokers with asthma display 
4 
altered levels of alveolar nitric oxide and flow independent parameters 
compared to non-smokers with asthma I carried out a cross-sectional study. 
Alveolar nitric oxide, determined by linear modelling, was significantly reduced 
in smokers with asthma compared to non smokers with asthma. The 
concentrations observed were within the range for normal subjects and 
therefore this method does not overcome the problems inherent in measuring 
exhaled nitric oxide at standard flows. The use of non-linear modelling did 
demonstrate parity between smokers and non-smokers with asthma for alveolar 
nitric oxide. Nitric oxide flux was lower in smokers with asthma when derived by 
both linear and non-linear modelling and displayed sensitivity to oral 
corticosteroids. Therefore nitric oxide flux is worthy of further investigation as 
an exploratory endpoint in smokers with asthma. 
In conclusion treatment of smokers with asthma with low dose theophylline 
alone, the combination of low dose theophylline and inhaled corticosteroid and 
the PPARγ agonist rosiglitazone was associated with clinical improvements and 
further clinical trials to assess the role for these treatments in the management 
of smokers with asthma are justified. Smokers with asthma display an altered 
sputum cytokine profile with raised levels of the proinflammatory cytokine IL-6, 
equivalent blood total HDAC activity and reduced alveolar nitric oxide compared 
to non-smokers with asthma. Sputum HDAC activity requires further 
development before it can be confidently employed as a method of assessing 
total pulmonary HDAC activity. 
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ABBREVIATIONS 
 
ACQ  asthma control questionnaire 
ADP  adenosine diphosphate 
AFU  arbitrary fluorescence units 
AQLQ  asthma quality of life questionnaire 
AP1  activator protein 1 
ATP  adenosine trisphosphate 
BAL  bronchoalveolar lavage 
BMI  body mass index 
Calv   alveolar nitric oxide concentration 
Caw   airway wall concentration of nitric oxide 
CCL  chemokine with C-C N terminal motif 
CD  cluster of differentiation 
cGMP  cyclic guanosine monophosphate 
COPD  chronic obstructive pulmonary disease 
CXC  chemokine with C-X-C N terminal motif 
Daw   airway wall nitric oxide diffusion 
DNA  deoxyribonucleic acid 
DTT  dithiothreitol 
EBC  exhaled breath condensate 
ELISA  enzyme linked immunosorbent assay 
eNOS  endothelial nitric oxide synthase 
FEV1  forced expiratory volume in the first second 
FENO  exhaled nitric oxide concentration 
FENO50  exhaled nitric oxide concentration at flow rate of 50ml/sec 
FEF25-75 forced mid-expiratory flow rate 
FEF75  forced expiratory flow at 75% of FVC 
FVC  forced vital capacity 
GM-CSF granulocyte/monocyte-colony stimulating factor 
GR  glucocorticoid receptor 
GRα  glucocorticoid receptor alpha 
GRβ  glucocorticoid receptor beta 
HAT  histone acetyltransferase 
HDAC  histone de-acetylase 
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H2O2  hydrogen peroxide 
ICC  intraclass correlation 
ICS  inhaled corticosteroid 
IFN-α  interferon-α 
IFN-γ   interferon-γ 
IgE  immunoglobulin E 
IκB  inhibitor of κB 
IL  interleukin 
IL-1RA  IL1-receptor antagonist 
IL-2R  IL-2 receptor 
IP-10  Interferon-inducible Protein of 10 kDa (aka CXCL10) 
iNOS  inducible nitric oxide synthase 
IQR  interquartile range 
IU  international units 
Jaw  airway wall nitric oxide flux 
J’aw  maximal airway wall nitric oxide flux 
JNK  c-Jun N-terminal kinase 
kDa  kilodalton 
kg/m2  kilograms/metres squared 
LABA  long acting β2 receptor agonist 
L/min  litres per minute 
Log  logarithm 
LPS  lipopolysaccharide 
MAPK  mitogen associated protein kinase 
MCP-1  Monocyte Chemotactic Protein 1 
MEK  MAPK kinase 
MIG  Monokine Induced by IFN-γ (aka CXC9) 
MIP-1α Monocyte Inflammatory Protein 1α (aka CCL3) 
MIP-1β Monocyte Inflammatory Protein 1β (aka CCL4) 
mRNA  messenger ribonucleic acid 
NCoR  nuclear receptor co-repressor 
NFAT  nuclear factor of activated T-cells 
NFκB   nuclear factor kappa-light-chain-enhancer of activated B cells 
nNOS  neuronal nitric oxide synthase 
NO  nitric oxide concentration 
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NSAID  non-steroidal anti-inflammatory drug 
PC20 provocative concentration of methacholine causing a 20% fall in 
FEV1 
PDE  phosphodiesterase 
PEF  peak expiratory flow 
PBMC  peripheral blood borne monocyte 
PI3K  phosphatidylinositol 3 kinase 
pl/s  picolitres per second 
pl/s/ppb picolitres per parts per billion per second 
ppb  parts per billion 
PPAR  peroxisome proliferator activated receptor 
PPRE  peroxisome proliferator response element 
PTEN  phosphatase and tensin homolog deleted on chromosome ten 
p38  p38 MAPK 
RANTES regulated upon activation, normal T cell expressed and secreted 
(aka CCL5) 
RNA  ribonucleic acid 
RU486  mifepristone 
RXR  retinoid X receptor 
SAE  serious adverse event 
SD  standard deviation 
SEM  standard error of the mean 
siRNA  small interfering RNA 
SNP  single nucleotide polymorphism 
STAT  signal transducers and activator of transcription 
SUMO  small ubiquitin-like modifier 
TGFβ  Transforming Growth Factor β 
Th1  Type 1 helper T cell 
Th2  Type 2 helper T cell 
Th17  IL-17 positive T helper cells 
TNFα  Tumour Necrosis Factor-α 
Treg  Regulatory T lymphocyte 
TSA  trichostatin A 
VE   exhalation flow rate 
VNO  elimination rate of exhaled nitric oxide 
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4HNE  4-hydroxynonenal 
15d-PGJ2 15-deoxy-∆12,14-prostaglandin J2 
95% CI  95% confidence interval 
24 
PUBLICATIONS ARISING FROM THESIS 
 
1. Effect of theophylline plus beclometasone on lung function in smokers with 
asthma-a pilot study 
Spears M, Donnelly I, Jolly I, Brannigan M, Ito K, McSharry C, Lafferty J, 
Chaudhuri R,  Braganza G, Adcock IM, Barnes PJ, Wood S & Thomson NC. 
European Respiratory Journal. 2009; 33 (5): 1010-7 
 
2. Bronchodilator effect of the PPARγ agonist rosiglitazone in smokers with 
asthma 
Spears M, Donnelly I, Jolly I, Brannigan M, Ito K, McSharry C, Lafferty J, 
Chaudhuri R,  Braganza G, Bareille P, Sweeney L, Adcock IM, Barnes PJ, Wood 
S & Thomson NC. 
Clinical Pharmacology & Therapeutics. 2009; 86 (1): 49-53 
 
3. Role of symptoms and lung function in determining asthma control in smokers 
with asthma 
Chaudhuri R, McSharry C, McCoard A, Livingston E, Hothersall E, Spears M, 
Lafferty J & Thomson NC. 
Allergy. 2008; 63 (1):132-5 
4. Peroxisome proliferator-activated receptor-γ agonists as potential anti-
inflammatory agents in asthma and chronic obstructive pulmonary disease 
Spears M, McSharry CP & Thomson NC. 
Clinical & Experimental Allergy. 2006; 36 (12): 1494-504 
 
5. Corticosteroid Insensitivity in Smokers with Asthma: Clinical Evidence, 
Mechanisms and Management.  
Thomson NC, Shepherd M, Spears M & Chaudhuri R.  
Treatments in Respiratory Medicine. 2006; 5: 467-481. 
 
6. The influence of smoking on the treatment response in patients with asthma. 
Thomson NC & Spears M. 
Current Opinion in Allergy & Clinical Immunology. 2005; 5(1): 57-63. 
25 
ABSTRACTS ARISING FROM THESIS 
 
1. Exhaled Breath Condensate pH response to oral corticosteroid in smokers, ex-
smokers and non-smokers with asthma 
Spears M, Weir C, Thompson J, Brannigan M, Lafferty J, Chaudhuri R, 
Braganza G, Cameron E & Thomson NC. 
Poster. European Respiratory Society Meeting, Vienna, Oct 2009 
 
2. Comparison of extended flow nitric oxide parameters in smokers and non-
smokers with asthma before and after an oral corticosteroid trial 
Spears M, Weir C, Thompson J, Brannigan M, Lafferty J, Chaudhuri R, 
Braganza G, Cameron E & Thomson NC. 
Poster. European Respiratory Society Meeting, Vienna, Oct 2009 
 
3. Smokers with asthma display an altered sputum cytokine profile that is 
insensitive to short course oral corticosteroid therapy  
Spears M, Donnelly I, Jolly L, Winn PL, Weir C, McSharry C, Chaudhuri R, 
Thompson J, Brannigan M, Lafferty J & Thomson NC.  
Poster discussion. American Thoracic Society Meeting, San Diego, May 2009 
 
4. Efficacy of two new approaches to treatment of smokers with asthma. Spears 
M, Donnelly I, Jolly L, Brannigan M, Ito K, McSharry C, Lafferty J, Chaudhuri 
R, Braganza G, Bareille P, Sweeney L, Adcock IA, Barnes PJ, Wood S & 
Thomson NC  
Poster. RCSPG Triennial conference, Glasgow, November 2008 
 
5. Efficacy of low dose theophylline and inhaled corticosteroids in smokers with 
asthma  
Spears M, Donnelly I, Jolly L, Brannigan M, Ito K, McSharry C, Lafferty J, 
Chaudhuri R, Braganza G, Bareille P, Sweeney L, Adcock IA, Barnes PJ, Wood 
S & Thomson NC.  
Poster. European Respiratory Society Meeting, Berlin, October 2008 
 
 
 
26 
6. Efficacy of the PPARγ agonist rosiglitazone in smokers with asthma.  
Spears M, Donnelly I, Jolly L, Brannigan M, McSharry C, Chaudhuri R, Bareille 
P, Sweeney L, Lafferty J, Wood S & Thomson NC.  
Poster. American Thoracic Society Meeting, Toronto, May 2008 
27 
ORAL PRESENTATIONS OF WORK FROM THESIS 
 
1. Overcoming relative corticosteroid insensitivity and enhancing the treatment 
response of smokers with asthma.  
November 2008. Celsus meeting, University of Glasgow.  
 
2. PPARγ agonists in asthma-a proof of concept clinical trial.  
August 2008. Divisional Away Day, Division of Immunology Infection & 
Inflammation, University of Glasgow.  
 
3. Reversing corticosteroid sensitivity in Smokers with Asthma.  
August 2008. Divisional Away Day, Division of Immunology Infection & 
Inflammation, University of Glasgow. 
 
4. Efficacy of low dose theophylline and inhaled beclometasone and 
rosiglitazone alone compared to inhaled beclometasone in Smokers with 
Asthma.  
May 2008. Scottish Society of Experimental Medicine Meeting, Dundee 
Awarded Sir James Black Prize for best oral presentation 
 
5. Therapeutic impact of Rosiglitazone and low dose Theophylline in Smokers 
with Asthma. April 2008. Scottish Thoracic Society Meeting, Perth 
 
6. Rosiglitazone in Smokers with Asthma; a possible new class of anti-
inflammatory treatment? January 2008, SSPC meeting, Carnoustie 
 
7. PPARγ agonists as potential anti-inflammatory agents for Smokers with 
asthma. August 2006. Divisional Away Day, Division of Immunology Infection 
& Inflammation, University of Glasgow. 
 
8. Corticosteroid insensitivity in Smokers with Asthma. August 2005. Divisional 
Away Day, Division of Immunology Infection & Inflammation, University of 
Glasgow.  
28 
1 Introduction 
1.1 Asthma 
Asthma is a common condition, characterised by variable symptoms of 
breathlessness, cough and/or wheeze combined with variable airflow obstruction 
and inflammation (1, 2). A recent report estimated that 300 million people 
worldwide are currently affected by asthma (3). The prevalence of asthma 
varies between countries and the UK has one of the highest rates with 5 million 
people currently receiving treatment (4). Scotland is disproportionately affected 
as it has the world’s highest prevalence in children (35%) and a high proportion 
of affected adults (18%) (3). 
Whilst the majority of patients with asthma can achieve a degree of control with 
either inhaled corticosteroids, a combination of inhaled steroids and other 
inhaled or oral therapies there is still a large sub-group who fail to achieve this. 
Smokers with asthma are normally excluded from clinical trials due to a desire 
to exclude subjects with chronic obstructive pulmonary disease but recent 
research demonstrates that smokers with asthma have a poor response to 
inhaled corticosteroids (5-10) and worse symptoms from asthma as demonstrated 
by asthma questionnaire (11, 12). Therefore it can be reasonably argued, given 
the prevalence of smoking in asthma, that smokers with asthma are a large 
neglected and important group that require further study and new therapies 
(13). It is against this background that this thesis was undertaken with the aim of 
understanding and exploring possible mechanisms for improving asthma control 
in smokers with asthma. 
1.2  Smokers with asthma 
1.2.1 Prevalence of active smoking in asthma 
Despite many years of public health programmes highlighting the negative health 
effects of smoking this habit is still surprisingly common in asthmatics. Current 
estimates suggest twenty to thirty five percent of adult asthmatics in Northern 
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Europe are current smokers and at least half the adult population with asthma 
are current or ex-cigarette smokers (11, 14, 15). The prevalence of smoking is 
higher in asthmatics that visit emergency departments with asthma 
exacerbations (16, 17) or who have died from asthma (18, 19) than general 
population estimates of current smoking in asthma and the death rate six years 
after admission to hospital with a near fatal asthma attack is higher amongst 
smokers compared to non-smokers (20). Even when mild forms of asthma are 
included in analyses smokers with asthma have worse symptoms compared to 
matched non smoking asthmatics (11, 12) and smokers with asthma display an 
accelerated decline in lung function (15, 21). This phenomenon is associated 
with evidence of an altered response to both inhaled (5-10) and oral 
corticosteroids (22-24) in smokers with asthma. 
1.2.2 Clinical evidence for reduced corticosteroid sensitivity in 
smokers with asthma 
The first prospective randomised controlled trial to demonstrate corticosteroid 
insensitivity in smokers with asthma compared the effect of three weeks 
treatment with inhaled fluticasone propionate (1000 mcg daily) to placebo in a 
cross-over study of 17 smokers and 21 non-smokers with corticosteroid-naïve 
asthma (7). Non-smokers demonstrated a significant increase in FEV1, PEF, PC20 
and a decrease in proportion of sputum eosinophils. This contrasted with the 
smokers with asthma who did not demonstrate improvements for any of these 
endpoints. 
However a potential criticism of this study was its short duration and therefore 
another clinical trial addressed this issue (8). Inhaled beclometasone at doses of 
either 400 mcg or 2000 mcg daily were allocated for 12 weeks to smokers and 
non-smokers in a double blind randomised controlled fashion. At the conclusion 
of the trial the non-smoking subjects treated with 400 mcg significantly 
improved their morning PEF compared to smokers (figure 1.1). This was 
associated with a reduction in asthma exacerbations and was in contrast to the 
smokers with asthma who did not demonstrate any significant improvements. 
However when treated with 2000 mcg inhaled beclometasone there was no 
significant difference between smokers and non-smokers with asthma. This 
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result would appear to indicate that higher doses of corticosteroids can produce 
an equivalent level of lung function response to that produced in non smokers 
with asthma using standard low doses. However an interaction analysis suggested 
that the higher dose was not performing significantly better than the lower 
dose. Therefore further trials using high dose inhaled corticosteroids in smokers 
with asthma are required to clarify this point. 
 
Figure 1.1 Mean (95% CI) change in morning PEF (L/min) in smokers compared to non-
smokers with asthma.  
Mean change above the line demonstrates greater improvement in non-smokers with 
asthma.  *; p<0.05. Adapted from (20). 
 
A further study carried out by a separate group examined the corticosteroid 
response of smokers with asthma with lower pack year histories (9). The multi-
centre randomised cross-over trial undertaken by the Asthma Clinical Research 
Network in the USA examined the treatment response of a group of smokers with 
asthma (compared to non-smokers with asthma) to eight weeks of 400mcg 
inhaled CFC free beclometasone (‘QVARTM’) or montelukast. The mean pack year 
history in the smokers was 7 years. Treatment with inhaled beclometasone 
improved FEV1, PEF and PC20 in the non-smokers but not in the smokers.  
weeks 
Chapter 1  31 
A post hoc analysis of a large management trial designed to achieve total control 
of asthma through the use of inhaled fluticasone and the combination of 
fluticasone and salmeterol for one year confirmed and strengthened this finding 
of reduced response to inhaled corticosteroids in subjects with low pack year 
histories (10, 25). Logistic regression analysis demonstrated that smokers with 
asthma with less than ten pack years had an odds ratio for poorly controlled 
asthma of 2.8 (95% CI 2.0-3.7) despite treatment with inhaled fluticasone (23). 
At the conclusion of the trial only 40% of smokers had achieved well controlled 
asthma on inhaled fluticasone alone compared to 63% of non-smokers (10). 
The lung function response in smokers with asthma to a short-term course of oral 
corticosteroids has also been examined. An early study found that current 
smoking predicted an impaired FEV1 response to oral corticosteroids in patients 
with unstable asthma (22). In a subsequent randomised, placebo-controlled 
crossover trial, 14 smokers, 10 ex-smokers and 26 never-smokers with asthma 
took oral prednisolone 40 mg daily or placebo for two weeks (23). This study 
demonstrated that pre-bronchodilator FEV1, morning PEF and asthma control 
score improved in the never-smokers. However no change was observed in the 
smokers with asthma. A larger study examining corticosteroid response in 
smokers and non smokers with asthma found no difference in FEV1 response 
when smokers and non smokers with asthma responses were compared. However 
non smokers with asthma demonstrated a larger PEF response than smokers with 
asthma (24). 
An important diagnostic issue for the studies discussed above is whether the 
smokers recruited have asthma rather than chronic obstructive pulmonary 
disease (COPD) given the widespread recognition that subjects with COPD have a 
reduced response to corticosteroids (26). There can of course be overlap 
between the two conditions with some subjects displaying clinical features of 
both asthma and COPD. However the smokers recruited to the discussed studies 
had features that were more in keeping with asthma rather than a COPD 
phenotype. For example, the average onset of asthmatic symptoms were either 
early twenties (7, 9, 23) or mid thirties (8, 25). Patients were also required to 
demonstrate either airway hyperreactivity (7, 9) or reversible airflow 
obstruction following inhaled salbutamol of >12% (9) or >15% FEV1 (23, 25) as a 
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requirement for entry to the trial helping to reduce the number of participants 
with COPD. 
1.3 Corticosteroids-Role in the treatment of asthma and 
mechanisms of action 
1.3.1 Corticosteroids-Discovery and therapeutic role 
Following the discovery of the chemical structure and effects of corticosteroids 
synthetic analogues were rapidly developed for clinical use. As a result of their 
ability to control previously refractory inflammation, corticosteroid preparations 
became crucial to the management of patients suffering from debilitating 
inflammatory diseases including asthma. However the side effects associated 
with the prolonged use of oral preparations led to a rapid reduction in their 
prescription. Inhaled versions were subsequently developed for the treatment of 
asthma to reduce systemic exposure and alternative disease modifying 
medications have superseded corticosteroids in the management of rheumatoid 
arthritis and inflammatory bowel disease.  
Since their introduction inhaled corticosteroids have become established as the 
cornerstone of asthma management due to their consistent ability to reduce 
symptoms, asthma exacerbations, improve lung function, suppress non-invasive 
markers of airway inflammation, eosinophil numbers, inflammatory cell 
activation and inflammatory gene transcription in the majority of patients (2, 
27). 
1.3.2 Corticosteroid resistance  
However there are a significant minority of patients with asthma (and other 
inflammatory conditions) who fail to demonstrate the expected improvements in 
response to corticosteroids. Corticosteroids have been estimated to fail to 
control symptoms in 5-10% of non smoking asthmatics and this group is thought 
to be responsible for 50% of the total costs of asthma due to their increased 
symptoms and frequent admissions to medical wards and intensive care units 
(28, 29). However if also we include data from a recent asthma management 
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trial, total control of asthma by inhaled corticosteroids alone can only be 
achieved in 40% of non-smoking subjects with asthma (25). 
Smokers with asthma are traditionally excluded from studies examining the 
efficacy of new treatments because of concerns about recruitment of subjects 
with chronic obstructive pulmonary disease. As a result little was known about 
their treatment response to corticosteroids until recently. However it is now 
clear that smokers with asthma display reduced therapeutic responses to 
corticosteroids. 
1.3.3 Corticosteroids-Mechanisms of action 
The activities of glucocorticoids can be divided into genomic and non-genomic 
effects based on the interactions with and through the glucocorticoid receptor 
with genomic being mediated via the glucocorticoid receptor (GR) and non 
genomic via both the GR and the cell membrane (30, 31). 
The GR consists of three domains with differing functions. These are an N 
terminal domain, which carries out transactivation functions, a DNA binding 
domain and a ligand-binding domain. This receptor structure is common to the 
nuclear hormone receptor family which also contains the receptors for vitamin 
D, thyroxine, peroxisome proliferator-activated receptor- γ (PPARγ) and retinoic 
acid. However the GR has some unique features. It has a unique dimerisation 
domain, two charge clamps instead of one (unlike the other nuclear hormone 
receptors) and a distinct agonist binding pocket (32). 
The gene for the GR is localised on chromosome 5 and consists of nine exons. 
Due to alternative splicing from these exons the GR has several isoforms (32, 
33). The ubiquitously expressed and best studied form is glucocorticoid receptor 
alpha (GR-α). The GR-α is a 95 kDa protein composed of 777 amino acids. There 
is also heterogeneity within the GR-α as a number of variants are produced 
through differences in ribosomal translation. These variants have different 
ligand affinities and post ligand binding behaviour providing a mechanism for 
differing tissue corticosteroid sensitivities and between subject variation in 
corticosteroid response (33).   
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1.3.3.1 Cellular localisation and chaperones 
Unbound, the GR resides in the cytoplasm, associated with a number of 
chaperone proteins including heat shock proteins 40, 56, 70, 90, the 
immunophilins p23 and Src and members of the mitogen associated protein 
kinase (MAPK) family (30, 32). Upon steroid binding the GR dissociates from 
these proteins, allowing formation of a homodimer and active nuclear 
translocation by importins due to exposure of its nuclear localisation sequence. 
1.3.3.2 Transactivation 
Glucocorticoid receptor homodimers interact with DNA response elements 
upstream of genes and recruit transcriptional co-activator proteins, which 
enhance transcription. This process is part of what is commonly referred to as 
transactivation. The DNA response elements contain palindromic repeats that 
facilitate glucocorticoid receptor binding and once bound the glucocorticoid 
receptor can increase and decrease gene expression (27, 30-32, 34). Through 
transactivation glucocorticoids can increase the production of a number of genes 
such as the NFκB chaperone protein IκB, dual specificity mitogen associated 
protein kinase phosphatase-1, glucocorticoid inducible leucine zipper, 
lipocortin/annexin-1, the cytokine IL-10, and surfactant protein D (32) and can 
also down regulate genes via negative gene regulation elements. Transactivation 
can also involve displacing transcription factors from response elements for 
inflammatory genes on DNA and occupying the vacated area (30, 32). 
1.3.3.3 Transrepression 
The glucocorticoid-GR complex can suppress inflammatory gene expression as a 
monomer through transrepression. This mechanism is postulated to be the main 
method by which corticosteroids suppress inflammatory gene expression (32). 
Transrepression can be performed through: 
• Direct inhibition. Direct physical interaction between the GR and 
inflammatory transcription factors such as NFκB and AP1. 
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• Chaperone proteins. GR can stimulate increased production of chaperone 
proteins for inflammatory transcription factors such as the NFκB 
chaperone IκB. 
• Co-factor competition. Competition for transcription co-factors required 
by both the GR and inflammatory transcription factors can reduce 
inflammatory gene expression. 
• Epigenetic mechanisms. The GR can alter the behaviour of inflammatory 
transcription elements through actively recruiting multiprotein complexes 
capable of adding or removing covalent compounds such as acetyl and 
phosphate groups. This activity alters their affinity for their response 
elements and hence their behaviour (27, 30-32, 34). 
1.3.3.4 Epigenetic effects 
The field of epigenetics examines the effect of post-translational modifications 
of chromatin and associated proteins on the control of gene expression. This 
group of processes appear to be an important transrepressive mechanism 
exploited by corticosteroids. 
The transcription machinery protein, RNA polymerase II, is unable to access 
promoter regions of DNA within chromatin’s tertiary structures in chromatin’s 
resting state due to DNA being tightly complexed with histone proteins. Histones 
consist of globular bodies with peripheral mobile tails and an overall positive 
charge which facilitates chromatin compaction. The addition of small molecules 
to histone tails such as acetyl or methyl groups and other modifications such as 
phosphorylation, ADP–ribosylation and SUMOylation have been demonstrated to 
affect transcription. Acetylation of histones has been recognised to be 
associated with increased gene expression for many years (35) and research 
using an in-vitro model has led to the estimate that approximately half of the 
immunosuppressant activity of corticosteroids is mediated through the removal 
of acetyl groups from histone tails (36). 
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1.3.3.5 Post translational modifications of glucocorticoid receptor 
The GR is also subject to epigenetic modifications with resultant alteration in its 
behaviour. For example GR phosphorylation status affects its corticosteroid 
affinity, nuclear sub localisation and transactivation potential. Acetylation of 
the GR is also an important control mechanism as it affects its ability to interact 
with NFκB (32, 37). This raises the importance of post translational 
modifications of the GR by the mitogen associated protein kinase family and 
nuclear co-activator complexes to the response to corticosteroids. 
1.3.3.6 Non-genomic effects of glucocorticoids 
The non-genomic mechanisms by which glucocorticoids act are much more rapid 
than the genomic mechanisms but can still be inhibited by glucocorticoid 
receptor antagonists. These include effects produced by high concentrations of 
glucocorticoids where glucocorticoids are incorporated into both cell and 
mitochondrial membranes altering their properties. This results in a reduction in 
calcium and sodium ion transmembrane flux and mitochondria membrane ATP 
leakage (30). 
Other non-genomic effects may be mediated through GRs imbedded in the cell 
membrane and through rapid changes in cytoplasmic concentrations of unbound 
GR chaperone proteins (30, 32). High concentrations of glucocorticoids also 
appear to be able to alter mRNA stability resulting in increased degradation of 
inflammatory gene mRNA and reduced inflammatory protein complex production 
(32). 
1.3.3.7 Heterodimer formation 
So far I have only considered homodimerisation and undimerised glucocorticoid 
receptors. However nuclear hormone receptors are capable of forming 
heterodimers with other transcription factors and the glucocorticoid receptor is 
no exception. 
Recent work has identified functional interactions between the GR and the 
signal transducers and activator of transcription (STAT) and Ets families (32) and 
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with another nuclear hormone receptor, peroxisome proliferator activated 
receptor-γ (PPARγ)(38). For example GRα association with STAT5, a member of 
the STAT family, results in increased expression of β casein (32) and co-
stimulation of cells with dexamethasone and a PPARγ agonist results in enhanced 
suppression of inflammation (38). The GRα can also form heterodimers with 
other members of the GR family such as GRβ leading to altered behaviour (32). 
1.4 Potential mechanisms of reduced corticosteroid 
sensitivity in smokers with asthma  
Many defects in the complex action of corticosteroids have been described in a 
variety of clinical settings, but few have been directly attributed to cigarette 
smoking (32, 39, 40). However previous research examining corticosteroid 
resistance in non smokers with severe asthma & subjects with COPD coupled to 
in-vitro research examining the corticosteroid pathway and research utilising 
induced sputum in smokers with asthma can provide insights and evidence of 
possible causes. 
1.4.1 Clinical studies-Sputum differential and supernatant 
Smokers with asthma have been demonstrated to have altered sputum 
differentials and supernatant cytokine profiles compared to non smokers with 
asthma. One study comparing smokers and non smokers with asthma found that 
smokers with asthma displayed increased sputum cellularity, sputum neutrophils 
and reduced eosinophils (41). Smokers with asthma were also found to have 
increased sputum interleukin 8 (IL-8) levels. Sputum IL-8 was also found to 
positively correlate with sputum neutrophilia and pack years and to negatively 
correlate with lung function (FEV1 pre bronchodilator). Another study 
demonstrated that sputum IL-18 expression and transcription is reduced in 
smokers with asthma and normal smokers compared to non-smokers with asthma 
and normal non-smokers (42). The smokers with asthma recruited to this study 
also had increased sputum neutrophils and reduced sputum eosinophils 
compared to non smoking asthmatics. The reduction in IL-18 was thought to 
reflect an alteration of the inflammatory profile in smokers with asthma as IL-18 
has the ability to promote both Th1 and Th2 inflammation.  Smokers with 
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asthma may therefore have a different Th1/Th2 profile to non smokers with 
asthma. 
However smokers with asthma do not consistently display higher sputum 
neutrophils compared to non-smokers with asthma. A recent study found 
equivalent levels of sputum neutrophils in smokers and non smokers with asthma 
and in the same study sputum eosinophils were similarly suppressed in both 
groups (24). However this lack of a difference in sputum neutrophils may have 
been due to the two groups having more severe asthma and therefore more 
neutrophilia in the non smoking asthma group compared to the previous studies. 
The finding of equivalent levels of sputum eosinophils in this study can be 
explained by the increased use of inhaled corticosteroids in asthma compared to 
the preceding studies and hence suppression of sputum eosinophilia in the non-
smokers with asthma. 
The presence of sputum neutrophilia in some smokers with asthma is of interest 
given the association of airway neutrophilia with non smoking severe asthma. 
This group demonstrate relative corticosteroid resistance and worse asthma 
control (43-45). However not all smokers with asthma display sputum 
neutrophilia and therefore the presence of neutrophilia in a subgroup of smokers 
with asthma cannot explain all of the corticosteroid insensitivity displayed by 
this group.  
Should smokers with asthma therefore be regarded to be part of what has been 
termed non-eosinophilic asthma? Non-eosinophilic asthma has been suggested to 
be comprised of two subgroups; a neutrophilic subgroup based on a cut off of 
sputum neutrophils >61% combined with poor asthma control and a paucicellular 
group with a normal sputum profile and good control (46). Smokers with asthma 
do not easily fit either of these subgroups given that neutrophilia is not present 
in all in this group and their level of asthma control cannot be described as 
good. This suggests that the alteration in airway cell proportions observed in 
smokers with asthma should be viewed as indicative of an alternative 
inflammatory response. 
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1.4.2 Clinical studies-Exhaled markers of inflammation 
Exhaled nitric oxide (NO) has generated considerable interest due to its 
potential as a non-invasive marker of airway inflammation. Previous research 
suggests that exhaled NO may have a role in the monitoring of asthma due to 
correlation between exhaled NO levels and airway eosinophilia (47, 48). Exhaled 
NO levels have been assessed in smokers with asthma with comparison to non 
smokers with asthma (24, 49). A consistent finding is that smokers with asthma 
have an exhaled NO concentration level that is lower than non-smokers with 
asthma and equivalent to (or lower than) that observed in normal subjects. 
Exhaled NO concentrations also demonstrate a strong reciprocal correlation with 
pack year histories (50). The mechanism that produces this reduction in exhaled 
NO is not fully understood but may be due to increased consumption of NO (51, 
52), competition for substrate from other inflammatory pathways (53) or 
reduction in production by inducible NO synthase (52, 54, 55). The consistent 
reduction of exhaled NO in smokers with asthma again suggests that a different 
form of inflammation is present in this group. 
Exhaled breath condensate (EBC) is currently being examined as a potential non-
invasive measurement of airway lining fluid (56). Studies utilising this method 
have principally focused on non smokers with asthma. A potentially important 
observation is that subjects with unstable asthma have reduced EBC pH which 
normalises with clinical improvement (57). One study has examined EBC pH in 
smokers and non-smokers with asthma and demonstrated a reduced EBC pH in 
smokers with asthma (58). 
1.4.3 Clinical studies-Bronchoscopic samples 
The airway wall has recently returned as a focus of attention in asthma due to 
the hypothesis that epithelial damage may be driving the inflammatory response 
(59) and the recognition that differing patterns of inflammation and structural 
responses are present in bronchial biopsies from different asthma sub types (60). 
A recent study compared bronchial biopsies from smokers with mild asthma with 
low pack year histories (mean (SEM) 16.7 (+/- 2.2)) against never smokers with 
mild asthma and found increased squamous metaplasia of the airway epithelium, 
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subepithelial neutrophils, subepithelial neutrophil elastase, intraepithelial IL-8 
and interferon-γ mRNA expression in the smokers relative to non smokers (61). 
The authors concluded that their group of smokers with asthma displayed early 
evidence of a corticosteroid resistant phenotype similar to COPD and severe 
asthma. 
Another bronchial biopsy study from the same group examined nitric oxide 
production in a group of smokers with asthma with low pack year histories (mean 
(SEM), 16.7 (+/- 2.2))(53). The amino acid L-arginine is the substrate for both 
the nitric oxide synthases and arginase-1 and hence is a point for substrate 
competition between the nitric oxide and ornithine pathways. In this small study 
a clear difference was evident in the expression of arginase 1 and ornithine de-
carboxylase, with increased levels of both in smokers with asthma. Smokers and 
non smokers with asthma were found to have equal levels of the inducible nitric 
oxide enzyme iNOS. This finding supports the previous finding of reduced 
exhaled nitric oxide concentrations in smokers with asthma and suggests that 
smoking could be associated with a deviation from production of nitric oxide to 
proline and polyamines and hence increased airway remodelling.  
A recent study which examined bronchial biopsies in smokers and non smokers 
with asthma considered the possibility that altered dendritic cell numbers 
and/or behaviour could contribute to the altered phenotype displayed by 
smokers with asthma (62). Smokers with asthma displayed lower levels of CD83 
positive (a marker of mature dendritic cells) and CD20 positive cells (a marker 
for B lymphocytes) and preservation of Langerhans’ cell numbers. The authors 
concluded that the altered dendritic cell and B cell phenotypes were the result 
of a different maturation state or the result of migration of both cells out the 
respiratory tract and that this alteration could be partly responsible for the 
altered response to corticosteroids in smokers with asthma. 
A recently published study has examined the effect of smoking on alveolar 
macrophage inflammatory responses in asthma (63). Smokers with asthma 
displayed greater concentrations of macrophages in BAL fluid and BAL 
macrophages from smokers with asthma displayed a reduced cytokine response 
to LPS. This manifested as smaller increases in IL-6, 8 and TNFα in response to 
LPS compared to non-smoking asthmatics. However no difference was evident in 
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alveolar macrophage corticosteroid response. No baseline comparisons in 
bronchoalveolar cytokine levels were reported from this cohort. The authors 
suggested that this muted response to LPS may be indicative of an increased 
susceptibility to bacterial infection in smokers with asthma. 
1.5 Alteration of the glucocorticosteroid pathway 
Could the altered response to corticosteroids displayed by smokers with asthma 
be a result of alteration in the glucocorticoid pathway or in processes affected 
by this pathway? Previous research examining the corticosteroid pathways in-
vitro and corticosteroid responsiveness in non smokers with severe asthma and 
subjects with COPD may provide insights for the investigation and treatment of 
smokers with asthma. 
1.5.1 Glucocorticoid receptor 
1.5.1.1 Cytokine induced corticosteroid resistance 
Previous research examining corticosteroid resistance in non-smokers with 
asthma has identified associated alterations in pulmonary cytokine environments 
(64, 65). Could altered levels of pulmonary cytokines induce corticosteroid 
resistance or are they reflective of the reduced effect of corticosteroids? A 
partial answer has been provided through the use of the combination of IL-2 and 
4 to induce corticosteroid resistance in-vitro. Kam and colleagues (66) 
demonstrated a reversible reduction in glucocorticoid receptor affinity in 
peripheral blood T-lymphocytes in subjects with corticosteroid resistant asthma. 
T lymphocytes from the recruited subjects had reduced glucocorticoid receptor 
affinity which recovered after a few days in culture. However on addition of a 
combination of IL-2 & 4 this binding defect was restored. This finding has been 
replicated a number of times (67-69) and is reversible following the addition of 
IFNγ (66, 69).  
The mechanisms by which the combination of IL-2 and 4 could induce altered 
glucocorticoid receptor behaviour have been examined in a series of 
experiments (68, 69). One group used peripheral blood mononuclear cells (PBMC) 
pre-treated with IL-2 and IL-4 and subsequent exposure to lipopolysaccharide to 
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demonstrate that the defect in ligand binding to the glucocorticoid receptor was 
due to activation of the p38 MAPK pathway and phosphorylation of the 
glucocorticoid receptor (68). This work has subsequently been confirmed and 
appears to be reversed by concomitant administration of IFNγ (69). Another 
study examined LPS stimulated cytokine responses in alveolar macrophages 
obtained by bronchoalveolar lavage from non-smoking subjects with severe and 
mild asthma and normal volunteers (70). Alveolar macrophages from subjects 
with severe asthma demonstrated a reduced anti-inflammatory response to 
dexamethasone with associated increased p38 MAPK activation. GRα is a target 
for phosphorylation by both JNK and p38 MAP kinase, and activation of these 
pathways leads to a reduced corticosteroid response (68-71). Therefore cigarette 
smoke induced alteration in the pulmonary cytokine environment may be 
capable of altering corticosteroid responses through activation of MAPK 
pathways. 
1.5.1.2 Alternative glucocorticoid receptor isoforms 
The corticosteroid receptor exists in several forms, with the best studied being 
the alpha (GRα) and beta (GRβ). The GRα is responsible for the therapeutic 
effects of corticosteroids. In contrast GRβ can interfere with GRα function in a 
dominant negative fashion. This has led to their being termed decoy receptors 
and research has demonstrated a potential role in steroid resistant asthma for 
GRβ with a reduced ratio of α: β and increased β-receptor levels being linked to 
corticosteroid resistance (72-76). 
A small sub-study has provided evidence for cigarette smoke exposure producing 
a reduction in both GRα and β expression in normal smokers and subjects with 
COPD (77). Research examining the α:β receptor ratio in peripheral blood 
mononuclear cells from smokers with asthma has also demonstrated a reduced 
α:β ratio suggesting that an increase in the β form and/or a decrease in the α 
form may have a role in corticosteroid resistance in smokers with asthma (78). 
1.5.1.3 Altered glucocorticoid receptor kinetics 
Glucocorticoid receptor density and ligand binding characteristics have been 
examined in peripheral blood mononuclear cells (PBMCs) from non smoking 
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subjects with severe asthma (79, 80). In a small study of subjects with 
corticosteroid sensitive and resistant asthma PBMC GR binding affinity and GR 
number was found to be equivalent (79). This finding has been corroborated in a 
slightly larger study comparing subjects with mild and severe asthma (80).  
However evidence does exist for differences in GR binding in severe asthma. 
PBMC nuclear extracts from subjects with severe asthma demonstrated reduced 
GR binding affinity in one trial (68) and in another study reduced binding affinity 
in peripheral blood T lymphocytes was present in some subjects with severe 
asthma with evidence for reduced GR concentrations in a small subgroup (67).  
Therefore it is feasible that smokers with asthma may display altered GR binding 
behaviour, receptor number, an increase in the β or reduction in the α subtype 
or post translational modifications compared to non-smokers with asthma. 
Future work should examine the GR in smokers with asthma in light of this work. 
1.6 Acquired defects in HDAC activity and potential 
implications for corticosteroid responses 
Corticosteroids exert their effects on gene expression via many mechanisms and 
pathways. One important mechanism is the control of epigenetic changes. 
Epigenetics involves the addition of small molecules such as acetyl or methyl 
groups and other modifications such as phosphorylation, ADP–ribosylation and 
SUMOylation (SUMOylation = reversible conjugation of a small ubiquitin-related 
modifier protein to another protein) to histone tails and other proteins and the 
effect that this has on transcription. I shall now briefly examine how control of 
protein acetylation by corticosteroids through manipulation of HDACs and 
histone acetyltransferases (HAT) could affect chromatin structure and gene 
expression and how alteration of these mechanisms could be responsible for the 
altered response to corticosteroids in smokers with asthma. 
Several enzymes have been identified to have HDAC activity. 18 HDAC isoforms 
are currently recognised and are divided into three groupings, class I & II and the 
sirtuins. HDACs form part of several important intracellular multiprotein 
complexes that are involved in transcription control and are expressed 
throughout the lung, with the highest levels found in airway epithelial cells and 
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alveolar macrophages (81). A proposed mechanism for the reduced response to 
corticosteroids in COPD and steroid resistant asthma is that oxidative stress, 
either from active smoking or other sources, reduces HDAC activity impairing the 
ability of corticosteroids to reduce inflammation (27, 82). No published work is 
available from studies in smoking asthmatic patients examining HDAC activity, 
but inferences can be drawn from in-vitro studies and from several studies in 
non smokers with asthma, subjects with COPD and normal smokers.  
1.6.1 HDAC activity and expression in asthma  
Bronchial biopsies from atopic non smokers with mild asthma (treated with β-
agonists alone) and mild to moderate non-smoking asthmatics (treated with 
inhaled corticosteroids) were compared to a group of normal non-smoking 
volunteers in one study (83). The intensity of staining for the isoforms HDAC1 & 
2 was reduced in asthmatics compared to normal subjects. However subjects 
with asthma treated with inhaled corticosteroids demonstrated a restoration of 
total HDAC activity and HDAC2 expression and reduction in HAT activity towards 
normal levels. In a subsequent study, which examined acetylation status in 
airway macrophages, HDAC1 expression was found to be reduced in mild 
asthmatics with no alteration in HDAC2 or 3 expression (84). Another study from 
the same group examined PBMC cytokine responses in subjects with severe 
asthma, mild asthma and normal subjects and identified a reduction in HDAC 
activity in subjects with severe asthma which was associated with a reduced 
anti-inflammatory effect of dexamethasone in-vitro (85). 
1.6.2 HDAC in COPD  
Two trials have examined acetylation balance in COPD (86, 87). The first study 
(86) examined both HDAC and HAT activity and HDAC isoform expression levels in 
peripheral lung tissue from subjects with COPD of various degrees of severity. 
When compared with normal subjects total HDAC activity was reduced in 
subjects with severe COPD. This reduction was found to positively correlate with 
FEV1 and was associated with a reduction in expression of HDACs 2, 5 and 8. No 
difference was found in the level of expression of HDACs 1, 3, 4, 6 and 7. Similar 
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results were obtained using bronchial biopsies and macrophages obtained by 
bronchoalveolar lavage. 
Another study examined subjects with milder COPD using tissue obtained from 
lung resections (87). Smoking played a critical role in acetylation status. 
Smokers with and without COPD were found to have a doubling in acetylated 
histone-4 levels compared to normal non-smokers suggesting a reduction in HDAC 
activity. In contrast ex-smokers with COPD demonstrated a return to normal 
non-smokers’ histone acetylation levels. This reduction was not global however 
as the ex-smokers with COPD were found to have a quadrupling of acetylated 
histone-3 levels compared to normal non-smokers. In contrast to the first study 
(86), HDAC2 nuclear expression was equivalent. However this may reflect the 
milder phenotypes recruited. 
1.6.3 Oxidative stress, smoking and HDAC 
How cigarette smoke alters HDAC activity and gene expression is not fully 
understood but recent research has identified a role for increased oxidative 
stress due to cigarette smoking.  Cigarette smoke contains at least 1015 free 
radicals per inhalation in a mixture of short lived species such as superoxide and 
longer living compounds such as tar-semiquinone (88). Each substance is capable 
of altering airway cell composition and intracellular signalling (89) and oxidative 
stress appears to play a crucial role in the development of COPD (90, 91).  
Experimentally induced oxidative stress is able to reduce HDAC activity to the 
levels seen in COPD and asthma. For example, hydrogen peroxide (H2O2) added 
to cell lines reduces HDAC expression and dexamethasone mediated suppression 
of cytokines to a level seen in smokers (92). Cigarette smoke condensate and 
H2O2 can both increase histone 4 acetylation and HAT activity and reduce HDAC2 
expression and HDAC activity (93). Exposure of rats to cigarette smoke also 
reduces HDAC2 activity with associated increased histone acetylation and 
corticosteroid resistant inflammatory gene expression (94). 
The reduction in HDAC activity following oxidative stress may be due to post-
translational covalent modification of HDAC enzymes. HDAC2 exposed to 
cigarette smoke contains increased 4-hydroxynonanol (4HNE) and nitrated 
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tyrosine motifs compared to controls (93, 94). Similar findings have been found 
when H2O2 was used as the oxidative stimulus (95). The relevance of cigarette 
smoke induced IL-8 production and its relationship to HDAC activity in COPD has 
been also examined in-vitro (96). IL-8 production was found to be increased on 
exposure to cigarette smoke with associated reductions in HDAC1, 2 and 3 
expression and HDAC activity. Cigarette smoke also altered HDAC1, 2 and 3 as 
they demonstrated increased immunoreactivity for 4HNE and nitrotyrosine 
antibodies. The mechanism by which this modification reduces HDAC activity is 
thought to be via the addition of 4HNE to histidines within the HDAC active site 
and/or destruction of HDACs via the ubiquitin-proteasome pathway. 
A recent publication examined the effect of cigarette smoke extract on HDAC2 
in cell lines and a mouse model, and provided evidence for a role for HDAC 
phosphorylation and subsequent destruction via the ubiquitin-proteasome 
pathway in oxidative stress induced reduction in HDAC activity (97). Exposure of 
cells to cigarette smoke extract resulted in a decrease in expression of HDAC1 
and 2 by four hours. Cigarette smoke extract was also demonstrated to cause 
rapid and transient phosphorylation of HDAC2 which peaked within half an hour 
of exposure and was reversed by two hours. The reduction in phosphorylation 
was followed by ubiquitination and evidence of destruction of HDAC2 via the 
ubiquitination-proteasome pathway. 
1.6.4 Corticosteroids and HDAC 
What are the cellular pathways that link glucocorticoids, the glucocorticoid 
receptor, HATs and HDACs? One group has examined the effect of 
dexamethasone on a model of inflammation and the relevance of these 
mechanisms (98). IL-1β induced GM-CSF expression and response to the 
application of dexamethasone was assessed in an epithelial cell line. 
Dexamethasone reduced IL-1β mediated acetylation of the tail of histone 4 
lysine residues 8 and 12 and GM-CSF expression. This effect on GM-CSF 
production required dexamethasone binding to the glucocorticoid receptor and 
increased HDAC activity. Half of the reduction in GM-CSF was due to a 
dexamethasone induced increase in HDAC activity as demonstrated through the 
application of an HDAC inhibitor. Further examination identified increased 
Chapter 1  47 
binding of the HDAC2 isoform to the NF-κB subunit p65 following dexamethasone 
suggesting increased recruitment of HDAC2 to NF-κB was responsible for the 
inhibitory effect of dexamethasone at low doses. Therefore at low doses of 
corticosteroids the glucocorticoid receptor is able to carry out transrepression of 
gene expression through stimulating the interaction of HDAC2 with the p65 
subunit of NF-κB.  
Subsequent work, utilising the same model, which compared the effect of the 
dissociated steroid RU486 (mifepristone) and dexamethasone confirmed this 
observation (36). HDAC2 activity is crucial for this corticosteroid mediated 
inhibition of inflammation as demonstrated by graded reduction of HDAC2 with 
siRNA (36, 37). HDAC2 knockdown did not affect either GR nuclear translocation, 
GR-GRE binding, glucocorticoid induced gene expression or the ability of high 
dose dexamethasone to inhibit GM-CSF production. However following HDAC2 
knockdown the GR is not recruited to the NF-κB-DNA complex and therefore is 
unable to inhibit NF-κB activity. 
The glucocorticoid receptor is also subject to acetylation with effects on its 
transrepressive activity (37). When interacting with and inhibiting the NF-κB-
DNA complex the glucocorticoid receptor is normally not acetylated. However 
following acetylation of the receptor a strongly correlated reduction in 
dexamethasone mediated inhibition of NF-κB is observed. Airway macrophages 
obtained by bronchoalveolar lavage from patients with COPD were also found to 
have increased levels of glucocorticoid receptor acetylation and reduced HDAC2 
expression. HDAC2 expression levels were then restored through vector induced 
HDAC2 over-expression resulting in reduced GR acetylation and restoration of 
suppression of GM-CSF expression. 
1.7 Theophylline, HDAC and corticosteroids 
Based on the existing clinical research it is clear that inhaled corticosteroids, 
the best therapy for asthma, are less effective than would be desired in smokers 
with asthma. This is certainly true for their short term ability to improve lung 
function, reduce symptoms and exacerbations. The most obvious clinical 
approach to the management of smokers with asthma is to encourage smoking 
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cessation. Smoking cessation is useful in this group as it has been demonstrated 
to produce large improvements in lung function (49). Unfortunately successful 
quitters take many years to achieve complete cessation (99). Clearly demanding 
smoking cessation alone for smokers with asthma is therefore an unacceptable 
approach for management of this group.  
An alternative approach would be to investigate the effect of high dose inhaled 
corticosteroids in smokers with asthma based on previous research (8, 10). 
However this is unlikely to be a successful approach given the increased side 
effects and reduced compliance that would occur as a result. Therefore the 
search should begin for alternative effective treatments for this group. Again we 
can extrapolate from previous research examining alternative treatments in non 
smoking subjects with severe asthma, subjects with COPD and from in-vitro 
research and animal models of asthma. 
The oral bronchodilator theophylline has been utilised in asthma and COPD for 
many years and is currently advocated as an add-on therapy in those subjects 
not controlled on inhaled steroids +/- LABA (1). Theophylline appears to have a 
number of mechanisms of action (100). It produces its bronchodilator effects 
through blockade of phosphodiesterase (PDE) activity, specifically PDE isoforms 
3, 4 & 5, resulting in an increase in intracellular cAMP and smooth muscle 
relaxation. However significant PDE inhibition is unlikely to be achieved 
clinically due to the large doses that would be required and it has been 
suggested that at recommended doses theophylline is producing only about 5-
10% of its maximum possible PDE inhibition (100). Theophylline has also 
demonstrated activity as an adenosine receptor antagonist and can block A1 and 
A2 receptors producing relaxation of airway smooth muscle and stabilising mast 
cells as a result. However the relative contribution of this activity to control of 
bronchospasm and inflammation is currently unclear. Another therapeutic effect 
that has been demonstrated for theophylline is an ability to increase HDAC 
activity at low serum concentrations (around 3-7mg/dl, normal range 10-
20mg/dl). 
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1.7.1 Theophylline increases HDAC activity & potentiates 
corticosteroid mediated suppression of inflammation 
In a double blind crossover trial incorporating bronchial biopsies, 14 mild stable 
asthmatics treated with β-agonist alone were treated with low dose theophylline 
for one month (101, 102). Treatment with theophylline was associated with 
increased HDAC activity in bronchial biopsies. This increase in HDAC activity was 
due to increased HDAC1 expression as HDAC2 was unaltered. Theophylline serum 
levels were low with a mean concentration of 6.1 mg/dl. 
Subsequent to this trial a model of inflammation based on stimulating BAL 
macrophages with LPS was utilised to examine interactions between low dose 
theophylline and corticosteroids (102). After exposure to LPS, BAL macrophages 
displayed reduced HDAC activity and increased IL-8 production which was 
insensitive to 10-10M dexamethasone. Dexamethasone at 10-6M did succeed in 
restoring HDAC activity to normal levels and this was associated with a 60% 
reduction in the level of IL-8 production. Theophylline alone at a dose of 10-5 M 
was able to restore HDAC activity to normal without reducing IL-8. At higher 
concentrations the ability of theophylline to boost HDAC activity was lost. 
Theophylline (10-5 M) was then combined with low dose corticosteroid (10-10M) 
resulting in increased HDAC activity and reduced IL-8. To further examine the 
ability of low dose theophylline to increase HDAC activity the HDAC inhibitor 
Trichostatin-A (TSA) was then applied. TSA reversed the suppression produced by 
the combination of 10-5 M theophylline and 10-10M corticosteroid and reduced the 
suppressive ability of 10-6M dexamethasone by 50%. Theophylline was found to 
increase the HDAC activity of HDAC1 and 3 but did not alter HDAC2. 
A similar study has also been carried out using BAL macrophages from COPD 
patients, normal smokers and normal non-smokers (103).  HDAC activity was 
significantly reduced in BAL macrophages from subjects with COPD and this 
correlated with the HDAC2 expression level. Low dose theophylline increased 
HDAC activity without altering IL-8 levels and low dose dexamethasone again 
reduced IL-8 when combined with theophylline. The IL-8 response to 
dexamethasone in normal smokers and subjects with COPD was reduced 
compared to normal non-smokers and was associated with increased NF-κB 
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nuclear translocation. The addition of theophylline to LPS-stimulated BAL 
macrophages from subjects with COPD potentiated the suppression of IL-8 
produced by dexamethasone. Immunoprecipitated HDAC1 and 2 from normal 
smokers’ BAL macrophages and a cell line were exposed to theophylline and in 
contrast to previous findings (102), both HDAC1 and 2 demonstrated increased 
HDAC activity on exposure to theophylline. 
Low dose oral theophylline has also been examined in the recovery phase of 
COPD exacerbations (104). Subjects randomised to theophylline in addition to 
normal care (which included oral corticosteroids) demonstrated increased 
sputum macrophage HDAC activity and greater suppression of IL-8 and TNFα 
compared to subjects receiving standard care alone. 
1.7.2 Mechanisms by which theophylline may increase HDAC 
activity 
Several potential mechanisms by which theophylline could increase HDAC 
activity have been addressed in one study (102). Theophylline is known to cause 
bronchodilatation through non-specific inhibition of phosphodiesterases (PDE). 
The ability of theophylline to inhibit PDEs and the effect of this on HDAC activity 
was examined using non-specific and selective PDE inhibitors. The authors 
demonstrated that PDE inhibition was not contributing to theophylline’s ability 
to increase HDAC activity. Previous research has also demonstrated that 
phosphorylation of HDAC isoforms can increase their HDAC activity (105-108). 
Therefore the effect of phosphatases on the ability of theophylline to increase 
HDAC activity were also examined using alkaline phosphatase, a p38 MAPK 
inhibitor (SB203580) and a MEK inhibitor (PD098059). Pre-treatment with 
alkaline phosphatase was found to reduce theophylline’s ability to increase 
HDAC activity by about 40%, providing evidence for a role for phosphorylation in 
increasing HDAC activity. The p38 inhibitor SB203580 also reduced HDAC activity 
suggesting that theophylline utilises p38 activation to increase HDAC activity. 
However inhibiting p38 did not completely abolish theophylline’s HDAC effect so 
another phosphorylation pathway or other mechanisms may be involved. No 
effect on HDAC activity was seen with MEK inhibition. The final potential 
mechanism examined in this study was the possibility that theophylline utilises 
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allosteric interactions with HDAC enzymes to increase their activity. 
Theophylline’s improvement in HDAC activity ranged from a 40% increase at pH 8 
to 75% at pH 7.8 suggesting that theophylline may also employ allosteric 
interactions in addition to HDAC phosphorylation to increase HDAC activity.  
Oxidative stress may also play a role in the ability of theophylline to restore 
corticosteroid sensitivity. Work using cell lines has demonstrated that oxidative 
stress reveals intracellular targets for theophylline with associated restoration of 
corticosteroid sensitivity and reduction in histone acetylation at inflammatory 
genes (109). In the context of oxidative stress theophylline was also able to 
induce genes that counteract the effects of this stress and to suppress the 
expression of genes related to oxidative stress induced pathways. 
Recent work has also identified that theophylline can act as a 
phosphatidylinositol 3 kinase (PI3K) inhibitor and it has been suggested that this 
ability may be responsible in part for theophylline’s ability to increase HDAC 
activity (110-112). Investigation of the PI3Kδ isoform has been carried out in an 
animal model of cigarette smoking pulmonary inflammation (77). Work using this 
model demonstrated that PI3Kδ is involved in the development of reduced 
corticosteroid sensitivity following exposure to cigarette smoke. This was 
associated with a reduction in total HDAC activity and increased tyrosine 
nitration of HDAC2. 
1.7.3 Possible role for theophylline in the treatment of smokers 
with asthma 
The available research suggests that HDAC activity may be low in patients with 
COPD and asthma and that this can be corrected through the use of low dose 
theophylline. However this is likely to only have clinical benefits when subjects 
are treated with inhaled corticosteroids in combination with theophylline as 
increased HDAC activity alone does not appear to be sufficient to suppress 
inflammation. Smokers with asthma display a blunted response to inhaled and 
oral corticosteroids but the mechanism by which this occurs is unknown. 
Previous research has suggested that smokers with asthma may partially respond 
to high dose inhaled corticosteroids (8, 10). This response mirrors the results 
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discussed in the preceding section. It is tempting to speculate that the reduced 
response to inhaled and oral corticosteroids displayed by smokers with asthma is 
a result of cigarette smoke mediated inhibition of HDAC activity and that this 
could be restored by low dose theophylline. The studies discussed above suggest 
that the addition of low dose theophylline in-vitro can produce the same effect 
as increasing dexamethasone dose by 100-1,000 times. This effect is unlikely to 
be as marked in-vivo due to local mechanisms which exert control over 
corticosteroid concentrations. However examination of low dose theophylline in 
combination with low dose inhaled corticosteroids appears to be merited in 
smokers with asthma based on the available evidence. 
1.8 PPARγ and inflammation 
1.8.1 Is there a role for PPARγ agonists in smokers with asthma? 
Given the failure of corticosteroids to produce their expected effects in smokers 
with asthma alternative therapies are required for this group. Could a new class 
of therapeutic agents directed at an alternative anti-inflammatory pathway 
reduce the cigarette smoking induced inflammation that is present in smokers 
with asthma? A large body of literature detailing the anti-inflammatory effects 
of peroxisome proliferator-activated receptor (PPARs) agonists in animal and in-
vitro models of asthma has developed over the past decade and has led to an 
interest in the possible role for PPARγ stimulation in the treatment of asthma 
and other inflammatory conditions (113, 114).   
1.8.2 PPARs-Discovery & structure 
PPARs, like the glucocorticoid receptor and the receptors for thyroxine and 
vitamin D, belong to the nuclear hormone receptor superfamily and are ligand-
inducible transcription factors. PPARs were first described following the 
observation that certain compounds (for example; fibrates, phthalate esters, 
non-steroidal anti-inflammatory drugs) could increase the number and activity of 
liver peroxisomes after chronic high dose administration to rodents (115, 116). 
Peroxisomes are intracellular organelles, which perform diverse metabolic 
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functions including β-oxidation of fatty acids and have a role in cholesterol 
metabolism. 
PPAR possesses four structural domains. The A/B region is a ligand-independent 
transcriptional activation domain (also known as activation-function 1/AF-1). 
The C domain encodes the DNA binding domain that contains two zinc finger 
motifs. The D domain codes for a hinge which is thought to allow movement of 
the ligand-binding domain relative to the DNA binding domain. The E domain is 
responsible for ligand binding, dimerisation, nuclear translocation and 
association with activators and repressors of transcription through its 
transactivation domain (activation function 2/AF-2).  
1.8.3 PPAR family  
PPARs exist in three isoforms; PPARα, PPARβ/δ and PPARγ. The PPARs differ in 
gene and chromosome origin, display varied effects and have different tissue 
distributions. However the known PPAR isoforms do display strong structural and 
sequence homology. PPARα is expressed in heart, liver, kidney, adipose tissue 
and skeletal muscle, PPARβ/δ is widely expressed in tissues such as bowel, 
heart, muscle, lung and adipose tissue and PPARγ is found at highest 
concentrations in adipose tissue (115, 116). PPARγ is also expressed in the lung 
epithelium, submucosa and airway smooth muscle and expression appears to be 
upregulated in response to inflammation (117).  
1.8.4 PPARγ-Endogenous ligands 
Previous research has led to proposals for the reaction products of 
polyunsaturated fatty acids and eicosanoids to be recognised as the endogenous 
PPARγ ligands. Polyunsaturated fatty acids are metabolised to produce agonists 
such as α-linoleic, γ-linolenic, arachidonic and eicosapentaenoic acids. 
Eicosanoid metabolites produce the agonists 15-deoxy-∆12,14-prostaglandin J2 
(15d-PGJ2), 9-hydroxyoctadecanoic acid (9-HODE), and 13- hydroxyoctadecanoic 
acid (13-HODE). 15d-PGJ2 is formed from PGD2 and has been demonstrated to 
bind to PPARγ and has been proposed to be the principle endogenous PPARγ 
agonist (113, 118). However there is substantial evidence that 15d-PGJ2 acts 
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through more than just PPARγ stimulation (119-124). Examples include 
experiments where saturating concentrations of synthetic PPARγ ligands fail to 
block the effects of 15d-PGJ2 in-vitro (125) and different concentrations of 15d-
PGJ2 have been observed to exert differing effects (126). Therefore 
interpretation of results from experiments using 15d-PGJ2 as a pure PPARγ 
agonist effect has been criticised (127). 
1.8.5 PPARγ-Synthetic Ligands 
Commonly prescribed drugs can stimulate PPARγ. These include non-steroidal 
anti-inflammatory drugs (NSAIDs), fibrates (128), retinoids (129) and the 
thiazolidinediones. Thiazolidinediones are potent PPARγ agonists and were 
designed to exploit the beneficial effect of PPARγ stimulation in the treatment 
of diabetes mellitus. The use of these compounds in PPARγ research has led to a 
better understanding of the role of PPARγ in metabolism and inflammation.  
Similar to 15d-PGJ2 there has been some debate over whether the anti-
inflammatory effects of thiazolidinediones are mediated exclusively via the 
PPARγ receptor (130-132). However an analogy can be drawn with 
glucocorticoids which can exert anti-inflammatory actions via and independent 
of the glucocorticoid receptor. Given the family homology there are some 
similarities in the mode of action of PPARγ and the glucocorticoid receptor and 
PPARγ can also reduce inflammation via transactivation and transrepression and 
via a number of non-genomic pathways  
1.8.6 Anti inflammatory effects of PPARγ and thiazolidinediones 
Following the discovery of PPARγ and the evidence for its involvement in 
resolution of inflammation many groups have investigated its role in disease 
models and patients. As a result PPARγ’s role in a variety of inflammatory 
conditions such as atherosclerosis (133-135), inflammatory bowel disease (136, 
137), acute lung injury (138) and pulmonary fibrosis (139) has come under 
investigation. A large body of evidence also exists for PPARγ agonists having 
anti-inflammatory effects in in-vitro and animal models of asthma and 
inflammatory airways disease.  
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Specific examples include: 
• Eosinophils. Reduced eosinophilic inflammatory response in ovalbumin 
allergen challenge models (140-142). 
• Neutrophils. Reduced neutrophilic response to LPS in an animal model 
designed to simulate neutrophilic ling disease (143) and reduced 
neutrophil chemotaxis (144). 
• T lymphocytes. Inhibition of T lymphocyte clonal proliferation (119, 145-
148) and induction of T lymphocyte apoptosis (149). 
• Dendritic cells. Altered dendritic cell maturation and behaviour in 
response to stimulation (141, 150, 151). 
• Macrophages. Altered macrophage maturation (119, 123, 128, 152-155), 
cytokine production (119, 123, 152, 156, 157) and evidence of PPARγ 
stimulation resulting in increased phagocytic potential for apoptotic 
neutrophils (154). 
• Airway Epithelial cells.  Increased expression of PPARγ in human asthma 
(117) and animal models (158) and reduction in airway 
hyperresponsiveness and  mucus production, collagen deposition, 
basement membrane thickness and transforming growth factor-β (TGFβ) 
synthesis (158) and reduced epithelial cell cytokine expression (159, 160). 
• Airway Smooth muscle. Reduced smooth muscle cell proliferation (124) 
and cytokine expression (38, 161). 
• Airway Fibroblasts. Inhibition of differentiation to myofibroblasts and 
cytokine production (162). 
1.8.7 PPARγ modes of action 
There are similarities between corticosteroids and PPARγ agonists in their ability 
to inhibit multiple inflammatory cells and their efficacy in animal models of 
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asthma. Similarities also exist in their multiple modes of action. PPARγ has been 
demonstrated to exert its anti-inflammatory effects using the following 
mechanisms. 
1.8.7.1 Transactivation  
The binding of an agonist to PPARγ induces a conformational change. This allows 
dissociation of co-repressor molecules and association with co-activators. PPARγ 
then forms heterodimers with retinoic X receptor (RXR) and binds to peroxisome 
proliferator response elements (PPREs) in DNA altering gene expression. As a 
result PPARγ exerts control over a wide number of overlapping but distinct genes 
from the glucocorticoid receptor (163). 
1.8.7.2 Transrepression 
PPARγ stimulation may produce its effects via inhibition of inflammatory gene 
transcription (transrepression) and there are a number of ways that this may 
occur (115, 164, 165):  
• Sequestration of shared co-activators. PPARγ activation may reduce the 
supply of common co-activators reducing their availability to 
inflammatory transcription factors. 
• Control of IκB kinase (IΚΚΒ kinase). IKKB releases NF-κB from inhibition 
by phosphorylating its inhibitory protein IκB (which subsequently leads to 
its degradation and increased NF-κB activity)(120). 
• SUMOylation of the PPARγ ligand-binding domain. SUMOylation of PPARγ 
facilitates PPARγ mediated transcriptional suppression of inflammatory 
genes (165, 166) 
• Inhibition of inflammatory transcription factors. Examples exist for NF-κB 
(167), NFAT (128, 164, 168) & AP1 (146). 
• Upregulation of anti-inflammatory genes. The tumour suppressor 
molecule PTEN (phosphate and tensin homologue deleted on chromosome 
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ten) is a phosphatase known to be downregulated in asthma. PPARγ 
stimulation increases its concentration in animal models of asthma with 
associated reduced inflammation (142). 
1.8.7.3 Non genomic effects 
• MAPK stimulation. PPARγ agonists exert some of their effects far too 
rapidly to be working via gene transcription or suppression, and recent 
evidence has suggested that they can produce some of these rapid effects 
via mitogen associated protein kinases (MAPK) (128, 157, 169-172). 
• Intracellular organelles. PPARγ agonists exert some effects via 
intracellular organelles independent of PPARγ: 
o Endoplasmic reticulum. Ciglitazone and troglitazone have been 
demonstrated to increase intracellular calcium by directly 
stimulating its release from the endoplasmic reticulum (173). 
o Mitochondria. Other groups have demonstrated interaction 
between mitochondria and PPARγ agonists (132, 174, 175). 
Thiazolidinediones alter mitochondrial respiration but appear to 
have effects beyond this as illustrated by their ability to increase 
the heat shock response (132). 
1.8.7.4 Modulation and utilisation of the glucocorticoid receptor by PPARγ  
Two independent groups have demonstrated a functional interaction between 
PPARγ and the glucocorticoid receptor (GR). Nie et al (38) demonstrated direct 
physical interaction between PPARγ and the dominant glucocorticoid receptor, 
GRα, following 15d-PGJ2 application in human airway smooth muscle cells. This 
interaction was functional as it resulted in the inhibition of eotaxin production 
by the cells following stimulation with TNF-α. Ialenti et al (176) have also 
examined PPARγ and GR interaction in a model of inflammation.  Glucocorticoid 
receptor blockade with RU486 (a glucocorticoid receptor antagonist) removed a 
substantial portion of the anti-inflammatory effect of the PPARγ agonists 
rosiglitazone and ciglitazone. A PPARγ antagonist used in conjunction with RU486 
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was necessary to remove all the anti-inflammatory effects.  In the same paper 
rosiglitazone and ciglitazone were observed to stimulate GR nuclear 
translocation in a PPARγ deficient cell line leading to the conclusion that PPARγ 
agonists could produce anti-inflammatory effects via GR activation. This work 
suggests that PPARγ agonists may be able to modulate existing glucocorticoid 
receptor activity to reduce inflammation and that combined therapy with PPARγ 
agonists and corticosteroids may produce a greater degree of control over 
inflammation than corticosteroids can achieve alone. 
A recent paper has demonstrated evidence for direct stimulation of the 
glucocorticoid receptor by thiazolidinediones (177). In this study rosiglitazone 
was found to induce glucocorticoid receptor phosphorylation, nuclear 
translocation and increased expression of a glucocorticoid receptor dependent 
gene. The authors also demonstrated similar effects for other thiazolidinediones 
and suggested that thiazolidinediones may be exerting some of their anti-
inflammatory and anti-diabetic actions through stimulation of the glucocorticoid 
receptor as a partial agonist. 
1.8.7.5 PPARγ & HDAC 
PPARγ appears to mediate part of its transrepressive actions via HDAC containing 
multiprotein complexes (165). A murine model of inflammation based on 
macrophage stimulation by lipopolysaccharide and production of iNOS 
demonstrated that the multiprotein complex NCoR, which contains HDAC3, 
suppresses transcription of a number of inflammatory genes in unstimulated cells 
by binding to gene promoters. Upon stimulation of the cell with LPS, NCoR was 
removed permitting NF-κB responsive inflammatory gene production. However 
addition of the PPARγ agonist rosiglitazone was found to result in SUMOylation of 
PPARγ on its ligand binding domain followed by PPARγ binding to the NCoR 
complex localised at the iNOS promoter. This prevented NCoR removal and 
transcription of NF-κB responsive inflammatory genes. This prolongation of 
transrepression was dependent on the HDAC activity of the NCoR complex, as 
rosiglitazone mediated transrepression was abolished through the use of the 
HDAC inhibitor Trichostatin A and siRNAs for HDAC3. 
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1.8.8 PPARγ & asthma 
Few researchers have addressed the relevance of PPARγ to humans with asthma. 
One study has examined PPARγ expression in bronchial biopsies from 
corticosteroid naive asthmatic patients (117). The authors demonstrated that 
PPARγ expression was increased in corticosteroid naive asthmatic subjects 
compared to controls. This increased expression was evident in all epithelial 
compartments (epithelial cells, smooth muscle cells and bronchial mucosal cells) 
and PPARγ expression was reduced towards normal levels following treatment 
with inhaled corticosteroids. 
 
What is the role played by PPARγ in asthma and what could be the reason behind 
its suppression following corticosteroid treatment? PPARγ is upregulated by IL-4, 
due to IL4 response elements within the PPARγ gene. A reciprocal relationship 
exists as PPARγ stimulation also inhibits IL-4 and this and similar work has led to 
a discussion over PPARγ having a role as an innate mechanism for resolution of 
inflammation (128). PPARγ stimulation also suppresses a number of other 
inflammatory cytokines of relevance to asthma and its upregulation by cytokines 
would support a role in the resolution of inflammation. 
 
Variations in PPARγ also appear to be relevant to asthma control. A recent study 
examined single nucleotide polymorphisms (SNPs) in PPARγ in a large cohort of 
young subjects with asthma (178). Three previously characterised haplotypes 
were examined, Pro12Ala, C1431T & C-681G, using buccal cells. The subjects 
homozygous for the Pro12 and C1431 SNPs had increased asthma exacerbations 
and the combination of Pro12 and C1431 was associated with increased school 
absences and hospital admissions. Subjects homozygous for the Ala12 and T1431 
SNPs in contrast had better asthma control. In summary the human research so 
far supports the animal and in-vitro data suggesting that PPARγ may have a role 
in the control of inflammation in asthma. 
 
1.8.9 PPARγ and smokers with asthma 
A central theme to this thesis is that smokers with asthma fail to gain the 
expected benefits from inhaled corticosteroids and require new therapies. The 
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presented evidence for PPARγ suggests that it has a role to play in the control of 
inflammation and as such may offer an alternative approach for the treatment of 
smokers with asthma. PPARγ expression is upregulated in asthma and reduces in 
response to corticosteroids. It is tempting to speculate that PPARγ expression is 
upregulated in smokers with asthma in correlation with their reduced 
corticosteroid response and as a result PPARγ stimulation could provide an 
alternative method for the reduction of inflammation in this group. Whilst 
evidence in support of this particular hypothesis is not available for smokers with 
asthma there is sufficient evidence to justify examination of a PPARγ agonist in 
smokers with asthma in an exploratory clinical trial. 
 
1.9  Non-invasive assessment of inflammation  
1.9.1 Rationale for use of non-invasive methods 
Previous research investigating asthma has utilised autopsy tissue from cases of 
fatal asthma and samples obtained by bronchoscopic biopsies. Whilst autopsy 
samples are obviously not reflective of normal asthma, bronchoscopy does allow 
sampling of airway cells and bronchial tissue from a variety of subjects over a 
number of timepoints. Unfortunately bronchoscopy is associated with a degree 
of risk, albeit small in most, but significant in those with poor lung function. 
Bronchoscopy is also expensive both for the research unit due to the number of 
staff required to perform the test and for the patient given the amount of time 
required to recover. Therefore whilst bronchoscopy provides useful insights into 
asthma, concern over the high cost and validity of extrapolation to other 
subjects has resulted in the development of a number of non-invasive measures 
for the assessment and phenotyping of asthma and to follow treatment 
responses. 
1.9.2 Induced sputum 
The examination of patient's sputum for infective organisms is a well established 
diagnostic tool. The examination of sputum from asthmatics with respect to the 
cellular profile led to several important early observations including the 
association between sputum eosinophilia and good corticosteroid response (179). 
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However the use of spontaneous sputum is not ideal. Not all patients can 
produce sputum spontaneously and even when possible spontaneous sputum 
specimens can be difficult to use due to the high squamous cell contamination 
and a high proportion of necrotic cells (180). Induced sputum has risen in 
popularity as it is felt to reflect inflammation of the main airways and therefore 
provides similar but not identical information to bronchial washes and 
bronchoalveolar lavage (181-183). However induced sputum does not correlate 
well with bronchial biopsy findings (181, 182). With increasing recognition of the 
potential of induced sputum as a non-invasive measure, methods for the 
technique have been refined with the aim of employment in clinical trials (180, 
181, 184, 185). There is currently a debate as to the role for induced sputum 
monitoring in the management of asthma but it is unlikely to be employed 
outside specialist secondary care asthma clinics (48). 
1.9.3 Induced sputum methodology 
1.9.3.1 Induction method 
The common thread in all sputum induction protocols is the inhalation of 
nebulised sterile saline from a high output ultrasonic nebuliser, the need for the 
administration of pre induction bronchodilator and for regular monitoring of the 
participant’s symptoms and FEV1 during the induction period (181, 184). Beyond 
this there is a difference in opinion as to the optimal method. A range of time 
periods and concentrations of sterile saline have been employed by different 
centres and by multicentre studies. Some centres expose subjects to nebulised 
saline for periods of five minutes and others use periods of seven or more 
minutes. There is also some variation with regards the concentration of saline 
used with some groups increasing the saline concentration with each new 
inhalation period and others keeping a constant concentration. Our group 
currently employs seven minute inhalation periods and 3, 4 & 5% saline. The 
subject moves onto the next highest concentration if their lung function allows 
(180, 181). 
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1.9.3.2 Sputum processing 
The processing of induced sputum samples has also been the cause of some 
debate with some groups advocating the use of the whole sample and others 
selection of sputum plugs (186). A recent working group concluded that both 
methods of selection are useful for differentiating health and disease but were 
felt to not be interchangeable and it was advised to keep to one method for the 
duration of a trial (186). Our group currently employs the whole sample method. 
Once processed a sample of the sputum is added to a slide and processed for 
counting. The current consensus is that a minimum number of 400 non-squamous 
cells are required for a representative count (186). The count should consist of a 
total cell count, squamous cell count and a differential of non-squamous cells 
with samples being discarded when the percentage of squamous cells is greater 
than 80% (187). Induced sputum results expressed as a percentage of non 
squamous cells bypasses concerns about dilution in the whole sample method 
and allows for good reproducibility (187, 188).  
1.9.4 Induced sputum-Clinical trials 
Induced sputum has been demonstrated to be highly reproducible in asthma 
(180), to respond appropriately to allergen challenge and corticosteroid 
treatment (181) and to correlate with bronchial provocation testing and exhaled 
nitric oxide levels in adults (189) and children (190) (although these findings are 
not consistent (191, 192)).  
1.9.4.1 Induced sputum-Eosinophilia 
Induced sputum facilitates sub-categorisation of asthma into groups that respond 
to conventional treatments based on the predominance of certain cell types 
(essentially as an extension of previous work in spontaneous sputum (179)). 
Therefore induced sputum has become employed as a study endpoint in cross 
sectional and intervention trials. Treating subjects with sputum eosinophilia with 
corticosteroids to reduce the percentage of eosinophils below a pre-set target 
has been demonstrated to result in a greater improvement in asthma control 
relative to standard clinical measures (193) whilst the absence of sputum 
eosinophilia indicates that corticosteroid dose reduction can be performed safely 
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(193). The degree of sputum eosinophilia also negatively correlates with FEV1 
(194).  
1.9.4.2 Induced sputum-Neutrophilia and paucicellular sputum 
Sputum neutrophilia is associated with a reduced response to corticosteroid 
treatment in asthma as a raised sputum neutrophil count has been described in 
smokers with asthma (41, 42) and subjects with severe asthma (195-199). In 
prospective clinical trials sputum neutrophilia has also been demonstrated to 
correlate with steroid resistant inflammation (44, 46). 
In subjects with raised sputum neutrophils there is evidence of an inverse 
correlation with FEV1 (194, 200) and irreversible airflow obstruction (200). In 
some subjects with asthma an induced sputum profile is observed which has 
neither a raised eosinophil nor neutrophil count. This group has been described 
as ‘paucicellular’ or ‘paucigranulocytic’ and appears to indicate a milder form of 
asthma as it is associated with better asthma control (46).  
1.9.4.3 Induced sputum-Definition of eosinophilia and neutrophilia  
The definition of sputum eosinophilia has been developed through research 
examining sputum profiles from normal subjects. This work has resulted in the 
current consensus for the cut off being an eosinophil percentage of >2% (44, 46, 
201, 202). The definition of neutrophilia is slightly more problematic as the 
sputum neutrophil percentage increase with age (200, 202). A correction based 
on subject age may enable further examination of the importance of sputum 
neutrophilia (194). A pragmatic approach that has been advocated is to define 
neutrophilia as a sample with greater than 50% neutrophils. However the need 
for research addressing normal ranges for induced sputum is clear and a call for 
further work has recently been made (203). 
1.9.4.4 Induced sputum-Reproducibility 
Induced sputum demonstrates good reproducibility with intraclass correlation 
co-efficients (ICC) for eosinophils of 0.85 and neutrophils of 0.57 (187) for whole 
sputum sampling. Selected sputum processing has been associated with ICCs of 
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0.63 for eosinophils and 0.57 for neutrophils (204) in one study and 0.94 for 
eosinophils and 0.81 for neutrophils in another (180). 
1.9.5 Sputum supernatant cytokines 
Investigation of the possible mechanisms responsible for the development of 
asthma and allergy in animal models, in-vitro systems and clinical studies has 
led to the identification of pathways in the innate and adaptive immune system 
that may be activated in asthma. The cytokines and chemokines associated with 
these pathways can be detected in the supernatant phase of sputum samples 
obtained from patients using immunological techniques.  
In recent years the number of antibodies available for the cytokine/chemokine 
of interest has increased and it is now possible to detect multiple signals within 
the same sample using commercially available systems. Therefore researchers 
are able to examine the symphonic orchestration of the immune response in 
contrast to the limited and potentially biased examinations in the past. Using 
these new approaches it should be possible to determine the relative 
contribution from the innate and adaptive immune arms of the immune system.  
1.9.5.1 Effect of sputum processing on supernatant cytokines 
However the examination of cytokines and chemokines in induced sputum 
presents some unique difficulties due to the use of the reducing agent 
dithiothreitol (DTT) (181, 205-207). DTT is routinely employed in the preparation 
of induced sputum as it reduces the viscosity of the sample enabling easy 
removal of sputum plugs. An unfortunate side effect is loss of antigenicity of 
some cytokines due to the disruption of thiol bonds within their structure (205, 
206). Recent work employing removal of DTT post sputum processing using 
dialysis cassettes (206), removal of sputum supernatant prior to addition of DTT 
or use of lower concentrations have been attempted with improvements in 
detection levels. Despite the availability of techniques to examine cytokines in 
induced sputum the identification of a consistent sputum cytokine profile 
predictive of a treatment response remains elusive perhaps as a result of this 
issue. 
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1.9.6 Exhaled markers of inflammation-Nitric oxide 
Nitric oxide (NO) is abundant in the human body, where it has many roles 
including vasomotor control and neurotransmission. NO is produced from L-
arginine by nitric oxide synthases (NOS) through oxidative conversion (208). 
There are three forms of NOS and two of the three are constitutively expressed-
neuronal nitric oxide synthase (nNOS) and endothelial nitric oxide synthase 
(eNOS). Both nNOS and eNOS are activated by increased intracellular calcium as 
a result of their calmodulin binding region. nNOS has a role in non-cholinergic 
non-adrenergic bronchial smooth muscle relaxation and eNOS in bronchial 
epithelial ciliary beat frequency (208). The third NOS, inducible nitric oxide 
synthase (iNOS), is upregulated by immunological and inflammatory stimulation, 
is relatively insensitive to intracellular calcium levels and produces much larger 
amounts of NO compared to nNOS and eNOS (208).  
NO is present in exhaled breath and was first detected in humans in 1991 (209) 
and in subjects with asthma soon after (210). Expelled air from the lungs does 
contain NO but it is present at much higher levels in the nose and paranasal 
sinuses (210). However with adherence to good measurement techniques nasal 
NO can be excluded through closure of the soft palate in the majority of 
subjects (47). Bronchial epithelial cells, airway smooth muscle, macrophages, 
neutrophils and alveolar cells all express iNOS and contribute to the production 
of exhaled NO but the bronchial epithelium is responsible for the lion’s share 
(208, 211, 212). The role of nitric oxide in the lung is complex as it is highly 
reactive and it can form reactive nitrogen species such as peroxynitrite, react 
with cysteine residues on proteins to form S-nitrosothiols and hence interfere 
with zinc finger motifs of transcription factors, interact with guanylate cyclase 
synthase to increase intracellular cGMP levels and alter mitochondrial 
metabolism (208, 211, 212). 
1.9.7 Nitric oxide in asthma 
The ability of iNOS to be induced by inflammation coupled to the effect of 
increased nitric oxide on cellular processes and the observations that exhaled 
nitric oxide is increased in asthma exacerbations and reduces with steroid 
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treatment has led to an interest in the monitoring of exhaled NO in asthma. 
Exhaled NO has subsequently become established as an endpoint for the 
assessment of new therapies targeted against inflammation. In recognition of 
this recent consensus guidelines have provided expert guidance aiding both 
comparison of studies and avoidance of errors in assessment (47). Unfortunately 
the specificity of raised single flow measurement of NO for asthma is less than 
desired as production is increased in other inflammatory conditions, for example 
cirrhosis (213), systemic lupus erythematosis (214), COPD (215) and lung 
transplant rejection (216). 
1.9.7.1 Employment in asthma control algorithms 
However there are also problems with exhaled NO and its utilisation in the 
management of asthma which has led to questions over its usefulness in clinical 
research. Several groups have explored the utility of exhaled NO in the 
management of asthma (217-219) but no reduction in asthma exacerbations 
occurred when exhaled NO was used to guide management. In the largest 
management trial to date (219) the use of NO in conjunction with clinical 
assessment resulted in increased inhaled corticosteroid usage without 
improvement in asthma control, lung function, unscheduled visits or need for 
hospitalisation. 
1.9.7.2 Reference ranges 
Measurement of NO using one standard exhaled flow rate also suffers from less 
than ideal sensitivity and specificity. There is difficulty with cut offs given the 
degree of overlap that exists between subjects with asthma and normal 
subjects. However a NO level of <16ppm (measured at 50ml/sec) appears to 
indicate of an absence of eosinophilia and >26ppm correlates with sputum 
eosinophilia (albeit weakly) (213, 215). However other cut offs have been 
employed (219) and one manufacturer suggests that a value of greater than 50 
ppb in adults is suggestive of eosinophilic inflammation (Aerocrine AB, Sweden). 
I would agree that similar to induced sputum there is an urgent need for 
research addressing normal values for this non-invasive marker (203). 
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1.9.7.3 Effects of cigarette smoking 
Another major problem for the employment of exhaled NO in research and 
clinical practice is the effect of current smoking on exhaled NO levels. Smoking 
acutely increases exhaled nitric oxide levels, reflecting the concentration of 
nitric oxide within the cigarette (51, 54) and chronic smoking results in a 
reduction of exhaled NO with measurements in smokers with asthma usually 
being in the normal range (50, 220). However a recent study does suggest that a 
percentage change in the exhaled NO concentration may reflect changes in 
asthma control and therefore may overcome some of the problems with the use 
of this endpoint in smokers with asthma (221).  
The mechanism responsible for the reduced exhaled NO concentration displayed 
by this group has been debated. Some authors propose that the high 
concentration of NO in cigarette smoke could be inhibiting iNOS (52, 54) and 
others that the increased oxidative stress results in consumption of airway NO 
(51, 52). A recent study comparing smokers with asthma to non smokers with 
asthma demonstrated equal levels of iNOS in the smokers and non smokers with 
asthma but raised arginase 1 and ornithine de-carboxylase expression in smokers 
suggesting that substrate competition may be contributing to the reduced NO 
levels in smokers with asthma (53).  
1.9.7.4 Extended flow nitric oxide analysis 
Early work examining exhaled nitric oxide noted that the nitric oxide 
concentration level in exhaled breath varied with the flow rate of exhalation 
with an inverse exponential relationship between flow rate and exhaled nitric 
oxide concentration being evident (222). The production rate of NO (VNO) also 
increases linearly with the rate of exhalation similar to heat exchange in a pipe. 
These characteristics of exhaled NO led researchers to develop models based on 
the principle that the lungs could be divided into two compartments or phases; a 
fixed volume conducting airways region and an expandable alveolar region. 
This two compartment model allows for the derivation of estimates for alveolar 
NO levels (Calv, ppb), airway wall NO diffusion (Daw, pl/s/ppb), airway wall nitric 
oxide flux (Jaw, pl/s) and airway wall NO concentration (Caw, ppb) depending on 
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the flow rates used and the regression model employed. Plotting nitric oxide 
production against flow rate for a variety of flow rates allows derivation of these 
parameters using linear and non linear regression. This alternative approach to 
the assessment of exhaled NO has led to hopes that extended flow analysis will 
increase the sensitivity and specificity of exhaled NO. Alveolar NO levels may 
reflect inflammation in the smaller airways (223) and recent work has employed 
this endpoint in the examination of new formulations of inhaled corticosteroids 
in the hope of detecting a reduction in small airway inflammation (224). Alveolar 
NO also appears to be unaffected by smoking so could be useful as a measure of 
inflammation in COPD and smokers with asthma (225, 226). The technique may 
also be able to improve the specificity of exhaled NO through the definition of 
extended flow profile ‘signatures’ for different conditions. For example, 
different conditions may have different rates of airway wall NO production, 
airway wall diffusion and alveolar and airway NO levels. Steroid naïve non-
smoking asthmatics have raised alveolar NO, diffusion and flux compared to 
steroid treated asthmatics who display raised diffusion only (227). Extended flow 
rate nitric oxide measurement has not been studied in smokers with asthma and 
given the absence of an impact of smoking on alveolar NO in normal smokers and 
smokers with COPD extended profile analysis may provide a useful non-invasive 
marker of inflammation in smokers with asthma. 
1.9.8 Exhaled breath condensate  
Exhaled breath contains vapours and aerosols that can be analysed by collecting 
via cooling and precipitation (228, 229). This phase of exhaled breath, known as 
exhaled breath condensate (EBC), has been utilised since the early nineteen 
eighties as a non-invasive method of examining airway lining fluid and its 
chemical environment composition. EBC has been demonstrated to contain non-
volatile compounds such as cytokines, lipids, surfactant, ions, oxidation 
products, adenosine, histamine, acetylcholine and serotonin and over 200 
volatile compounds such as ammonia, H2O2 and ethanol can be detected (229, 
230). EBC has subsequently been used to examine a number of disease states 
(for example asthma, cystic fibrosis and bronchiectasis) and their response to 
treatment (228, 231-233). 
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1.9.8.1 Exhaled breath condensate-methodological considerations 
EBC gained interest as it was initially thought to have the potential to obtain 
equivalent samples to invasive procedures such as bronchoscopy and broncho-
alveolar lavage and non-invasive procedures that require specialist processing 
such as induced sputum. However there are methodological issues that need to 
be addressed and hence concerns over the applicability of EBC data. For 
example, EBC has recently been demonstrated to have poor correlation with 
bronchoalveolar lavage for a number of measurements (234). There is also a 
need for a reliable marker to calculate the degree of dilution of exhaled 
biomarkers by water in the EBC (235-237). Work is currently ongoing to develop 
a suitable reference marker. 
1.9.8.2 Exhaled breath condensate pH 
Another avenue of examination in exhaled breath condensate is EBC pH. Hunt et 
al have demonstrated that asthmatics admitted with acute exacerbations have a 
reduced EBC pH that normalises within forty eight hours of treatment (228). EBC 
pH has subsequently been examined in a number of conditions including COPD 
(232), bronchiectasis (238) and cystic fibrosis (239, 240). Measurement of pH 
after de-aeration with argon has been demonstrated to be consistent day to day, 
week to week and person to person and to be stable over a range of 
temperatures of collection and for 2yrs in storage (232, 241). Similarly EBC pH is 
unaffected by hyper and hypoventilation (242) and methacholine induced 
bronchoconstriction (241).  
1.9.8.3 Mechanisms responsible for EBC acidification 
What causes the airway acidification demonstrated by EBC pH? One potential 
mechanism is alteration of airway cell numbers and proportions. Both 
neutrophils and eosinophils can cause airway acidification. Neutrophils can form 
hypochlorous acid via the myeloperoxidase catalysed reaction between H2O2 and 
chloride. Eosinophils can produce acid via eosinophil peroxidase which catalyses 
a reaction between H2O2 and halides to form hypohalous acids. Hunt et al did not 
examine induced sputum in their study so we do not know the relative 
contribution of either cell to the drop in pH observed in that trial. However 
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induced sputum neutrophilia has demonstrated a strong negative correlation 
with EBC pH in subjects with COPD and bronchiectasis and a strong negative 
correlation between sputum eosinophilia and pH in subjects with asthma (238). 
Further research comparing smokers and non-smokers with asthma has 
demonstrated that smoking is associated with a lower EBC pH (58). No difference 
was present in percentage neutrophil counts between the two groups in this 
study. 
An alternative mechanism for airway acidification in asthma could be alterations 
in the airway epithelium. Activation of cell surface exchange pumps such as Na+-
H+ exchange protein 1 and anion exchange proteins 1 and 3 in the context of 
reduced airway lining fluid buffering have been suggested as potential causes of 
acidification of inflamed airways (243). Other potential mechanisms for EBC 
acidification include inappropriate collection of gastric air & micro aspiration of 
gastric contents. 
1.10 Hypotheses and aims 
The overall aim of this thesis was to examine two potential new therapies for 
smokers with asthma and to gain understanding of the altered inflammatory 
processes present in this group.  
The following hypotheses were examined in the two studies conducted for this 
thesis: 
1.10.1 Theophylline & Rosiglitazone 
• Low dose theophylline will restore corticosteroid sensitivity in smokers 
with asthma due to a restoration of HDAC activity 
• The oral PPARγ agonist rosiglitazone will demonstrate superiority to low 
dose inhaled beclometasone 
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1.10.2 Corticosteroid sensitivity study 
• Smokers with asthma display a muted lung function response to an oral 
corticosteroid trial compared to non-smokers with asthma 
• Smokers with asthma have an altered pulmonary and systemic cytokine 
environment compared to non-smokers with asthma 
• Smokers with asthma display a reduced sputum and blood total HDAC 
activity compared to non-smokers with asthma 
• Smokers with asthma display alterations in flow independent nitric oxide 
parameters compared to non-smokers with asthma 
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2 Methods 
2.1 Regulatory approval 
The studies presented in this thesis were reviewed and approved by the West 
Glasgow Ethics Committee. The study examining the efficacy of rosiglitazone in 
smokers with asthma was also submitted for review and approval by the 
Medicines and Health Regulatory Authority. All subjects received an information 
sheet and attended for a discussion of the associated study protocol prior to 
consent and enrolment. 
2.2 Recruitment methods 
The majority of patients that took part in the studies presented in this thesis 
were recruited from general practices in the Greater Glasgow and Clyde and 
North and South Lanarkshire Health Board areas. The practices were approached 
by letter and those willing to participate were visited by a member of the study 
team who undertook a search of the practice records to identify potential 
recruits, taking care to exclude subjects who failed to meet entry criteria. A list 
of potential recruits was then left with the practice for review and vetting to 
prevent inappropriate approaches. Once this process was completed a further 
visit to the practice was arranged where the study team member produced an 
approach pack containing an invitation letter, a response form and a stamped 
address envelope. The practice then posted the approach pack to the potential 
recruits in their normal mail. Interested subjects who contacted the asthma 
research unit were vetted by phone call and those who were deemed suitable 
were invited to discuss the study. 
Commercial adverts approved by the local ethics committee were also used to 
help recruitment to the theophylline and rosiglitazone study. Two radio 
advertisement campaigns were utilised along with a month of posters placed at 
major transport hubs in the Glasgow area. A small number of subjects who had 
previously participated in trials run by the Asthma Research Unit were also 
suitable and agreed to participate after approach by letter. 
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2.3 Study design 
2.3.1 Efficacy of theophylline and rosiglitazone in smokers with 
asthma 
This study was a randomised, prospective, double-blind, double-dummy, active 
comparator, parallel group design. Mild to moderate (2) stable asthmatics aged 
18 to 60 on ≤1000 mcg beclometasone (or equivalent) per day who were regular 
smokers of ≥5 cigarettes per day and with a pack year history of ≥5 pack years 
were eligible for enrolment. Subjects who were willing to participate were 
offered smoking cessation advice and those unwilling to quit smoking at that 
time and did not have conditions excluding participation were enrolled.  
All subjects had to demonstrate reversible airflow obstruction with a FEV1 
bronchodilator response of ≥12% (and >200ml). Subjects were also monitored for 
asthma stability for up to six weeks and underwent a corticosteroid weaning and 
monitoring phase that lasted one month within this period. Subjects were 
excluded from randomisation if they experienced an exacerbation of asthma at 
any point during this run-in phase. An asthma exacerbation was defined as a 
reduction in morning peak flow (PEF) of 30% or more from baseline or asthma 
exacerbation requiring oral corticosteroids or hospitalisation or emergency 
department/general practice visit or the presence of asthma symptoms deemed 
unacceptable to either the study co-ordinator or study subject.  
Other exclusion criteria included: 
• Asthma exacerbation or respiratory tract infection within six weeks of 
screening  
• Additional respiratory condition e.g. bronchiectasis 
• Plan to reduce or stop cigarette smoking 
• Pregnancy or plan to conceive 
• Diabetes mellitus 
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• Recent myocardial infarction/unstable angina or any history of cardiac 
failure (past 6 months) 
• Anaemia or abnormal renal or hepatic laboratory values 
• Contraindication to treatment with either theophylline, rosiglitazone or 
inhaled corticosteroid 
• Recent drug or alcohol abuse 
• Morbid obesity (defined as BMI>40) 
• Inability to perform spirometry 
• Requirement for treatment with any other asthma medications (except 
inhaled salbutamol and allocated trial medication) from screening until 
study completion. 
At the end of a two-week inhaled corticosteroid free period each subject 
attended for a randomisation visit, which comprised spirometry and PEF 
recordings, completion of an asthma control questionnaire (ACQ)(244), induced 
sputum for differential count, supernatant and sputum macrophage HDAC 
activity assay and routine bloods for safety (full blood count, renal and liver 
function testing) and characterisation (total and specific IgE, total cholesterol, 
LDL, HDL and triglycerides levels). 
Subjects were then randomised to either 100mcg twice a day inhaled 
hydrofluoroalkane beclometasone dipropionate (Qvar©, IVAX, Runcorn, Cheshire, 
UK) [Equivalent to approximately 400mcg per day chlorofluorocarbon 
beclometasone] (245), 4mg twice daily oral rosiglitazone (Avandia®, GSK, 
Greenford, Middlesex, UK), 200mg twice daily oral theophylline (Uniphyllin® 
Continus®, NAPP, Cambridge, UK) or 200mg twice daily oral theophylline in 
combination with 100mcg twice a day inhaled hydrofluoroalkane beclometasone 
dipropionate. Subjects returned for pre-bronchodilator lung function at two 
weeks and repeated the assessments carried out at the baseline visit (spirometry 
pre and post bronchodilator, peak flow, induced sputum and supernatant, blood 
and serum & ACQ) after four weeks. This visit was performed at the same time 
of day (+/- 2 hours) as the baseline visit. Continued regular smoking was 
confirmed through the measurement of exhaled carbon monoxide and urinary 
cotinine metabolites. Subjects were instructed to omit smoking for three hours 
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prior to each study visit and were informed that if they did not adhere to this 
request their visit would be re-scheduled and where this was not possible they 
would be excluded from the study for non-compliance. If an excessively raised 
carbon monoxide level was detected subjects were challenged over their 
compliance with abstinence from smoking. 
The primary endpoint was change in pre-bronchodilator FEV1 from baseline to 
day 28. Secondary endpoints were change from baseline to day 28 in pre-
bronchodilator PEF, FVC, FEF25-75, FEF75 & asthma control questionnaire score. 
Exploratory endpoints included sputum differential count, sputum cytokine 
profile & sputum macrophage histone deacetylase activity (HDAC). 
2.3.2 Determinants of corticosteroid insensitivity in smokers with 
asthma 
The study was a cross-sectional design with open label, unblinded use of oral 
dexamethasone. Smokers, ex-smokers and non-smokers with mild to moderate 
asthma were recruited to the study. Subjects were allowed treatment with up to 
a maximum of 2000 mcg beclometasone (or equivalent), long acting β2 agonists 
and leukotriene receptor antagonists. Theophylline was withdrawn (if 
prescribed) for 6 weeks prior to the start of the steroid trial and restored at the 
end of the study. Smokers with asthma were eligible if they were currently 
smoking ≥5 cigarettes per day and had a ≥5 pack year history. Ex-smokers with 
asthma were eligible if they had ceased smoking 2 or more years from the date 
of recruitment and had a ≥5 pack year history. Non smoking subjects were 
required to have no history of regular smoking and to be current non-smokers. 
All subjects performed urine cotinine and exhaled carbon monoxide testing at 
each visit to confirm smoking status. Smokers with asthma were instructed to 
omit smoking for 3 hours prior to each visit and were informed that if they did 
not adhere to this request their visit would be re-scheduled and when not 
possible they would be excluded from the study for non-compliance. If an 
excessively raised carbon monoxide level was detected subjects were challenged 
over their compliance with abstinence from smoking. 
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All recruited subjects had to demonstrate either reversible airflow obstruction 
with a FEV1 bronchodilator response of ≥12% (and >200ml), PEF lability or a 
positive methacholine test to be eligible to perform the oral corticosteroid trial. 
If subjects did not demonstrate a positive FEV1 bronchodilator response then 
they returned after completing a PEF diary. If this did not demonstrate PEF 
lability then a methacholine test was performed. Baseline measurements 
included spirometry and PEF, exhaled nitric oxide measurement, exhaled breath 
condensate and induced sputum collection, asthma control questionnaire score 
and blood for HDAC activity and cytokine assessment. Corticosteroid sensitivity 
was assessed using a two week trial of oral dexamethasone, adjusted for body 
surface area. Each subject was allocated a daily dose of 6mg/1.74 m2 oral 
dexamethasone and steroid response was assessed as the change in pre-
bronchodilator FEV1 at two weeks. The assessments carried out at baseline were 
also repeated with the inclusion of blood cortisol to check compliance with 
corticosteroids. If blood cortisol was suppressed below 50nmol/l then subjects 
were deemed to be compliant with therapy and their post steroid trial data was 
assessed. This visit was performed at the same time of day (+/- 2 hours) as the 
baseline visit. A subset of subjects returned at one month to repeat some of the 
assessments to determine the duration of oral corticosteroid effect. 
Exclusion criteria were: 
• Patients with unstable asthma; defined as the presence of 1 or more of 
the following events in the month prior to study [Emergency/’out of 
hours’ visit to GP for asthma exacerbation; GP visit to patient at home for 
asthma exacerbation or A & E attendance/hospital admission for asthma 
exacerbation] 
• Treatment with oral corticosteroids in the past month 
• Need for maintenance oral corticosteroid therapy 
• Need for treatment with theophylline for course of study 
• Pregnancy or planning to become pregnant over course of study 
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• Presence of medical condition likely to be exacerbated by treatment with 
oral corticosteroids 
• Plan for smoking cessation or reduction during course of study 
2.4 Demonstration of eligibility for recruitment to trials 
2.4.1 Reversibility testing 
Improvement in airflow obstruction in response to inhaled bronchodilator in a 
subject with a history consistent with asthma is accepted as diagnostic for the 
condition (1, 2) and is a frequently used entry criteria for clinical trials. 
In both trials reversibility testing was performed in all subjects by administering 
2.5mg of nebulised salbutamol for five minutes following suitable baseline 
spirometric recordings. Subjects then performed spirometry from 30 minutes 
post nebuliser. A minimum of three acceptable efforts were obtained and a 
maximum of eight efforts was allowed to meet this criterion. The highest FEV1 
and FVC obtained were used for analysis. Subjects were asked to withhold 
inhaled and oral treatments according to consensus recommendations (table 2.1) 
(246). Reversible airflow obstruction was defined as an improvement in FEV1 of 
12% or greater (and 200ml or more in volume) and was calculated using the 
formula: 
% reversibility = ((post bd FEV1 – pre bd FEV1)/ pre bd FEV1) * 100 
where bd = bronchodilator 
 
Treatment Withdrawal period 
Short acting inhaled bronchodilator 4 hours 
Long acting inhaled bronchodilator 24 hours 
Oral bronchodilator 24 hours 
Table 2.1 Withdrawal periods for bronchodilators prior to reversibility testing.  
Based on (246). 
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2.4.2 Peak flow lability 
Spontaneous variation in peak flow is recognised as a defining characteristic of 
asthma and is a reflection of the variable nature of the dyspnoea experienced by 
some subjects with asthma (1). Entry to the trial examining the corticosteroid 
responses of smokers, ex-smokers and non-smokers with asthma was therefore 
permitted if variable airflow obstruction was demonstrated through peak flow 
recordings if spirometric reversibility testing was negative at the first visit.  
Subjects were issued with a diary card and peak flow meter (EN 13826, Clement 
Clarke, Harlow, UK) and were instructed to perform three adequate efforts in 
the morning and evening and to record the highest recording in their diary for 
one to two weeks prior to review. The threshold of peak flow lability required 
for entry to the trial followed published methodology i.e. 20% variation in 
amplitude over 3 days in the period of diary recording (with a minimum change 
of 60 litres)(1). 
2.4.3 Bronchial provocation testing 
The demonstration of bronchial hyperreactivity in a subject with a high pre-test 
probability of asthma is accepted as diagnostic for the condition (247) and this 
approach is frequently applied as an eligibility criteria in clinical research where 
subjects cannot demonstrate peak flow lability or significant FEV1 improvement 
post nebulisation due to good asthma control. Testing for the presence of 
bronchial hyperreactivity centres on the administration of a challenging agent, 
most commonly histamine or methacholine, in serial doubling doses via a 
modified Wright’s nebuliser (Airlife Sidestream® high efficiency nebuliser, 
Cardinal Health, UK) calibrated to supply 0.13ml/min of solution. 
In the study examining the corticosteroid responses of smokers, ex-smokers and 
non-smokers with asthma participation was allowed if subjects had a positive 
methacholine test and a history compatible with asthma. Non-smokers and ex-
smokers with asthma were allowed to perform methacholine testing if their FEV1 
was greater than or equal to 60% predicted.  However smokers with asthma were 
required to have a pre bronchodilator FEV1 of greater than or equal to 80% 
Chapter 2  79 
predicted to minimise recruitment of subjects with chronic obstructive 
pulmonary disease. 
In preparation for the test subjects were asked to omit asthma medications, 
anti-histamine medications and foods and drinks containing caffeine as per 
recommendations (247)(table 2.2). Female subjects underwent pregnancy 
testing and were only allowed to perform methacholine testing if not pregnant. 
Treatment Duration of withdrawal (hours) 
Short acting β2 agonist 8 
Long acting β2 agonist 48 
Short acting anti-muscarinic 24 
Long acting anti-muscarinic 48 
Leukotriene receptor antagonists 24 
Theophylline 48 
Anti-histamines 48 
Caffeine containing food or drinks 
(chocolate, tea, coffee, soft drinks) Day of study 
Table 2.2 Advised durations of withdrawal from medications and foods.  
Table adapted from (247). 
 
Subjects initially performed pre-challenge spirometry to determine their best 
pre-challenge FEV1. Nebulised saline was then administered as an initial 
challenge for two minutes. The target drop of 20% was calculated from the 
highest post saline FEV1 following repeat spirometry. The subject then inhaled 
increasing doses of methacholine in two minute dosing periods by tidal breathing 
whilst wearing a nose clip. On completion of each nebulisation phase spirometry 
was performed at 30, 90 and 180 seconds. If the subject’s FEV1 did not drop by 
20% or more in response to the methacholine dose then this was followed by a 
subsequent dose of methacholine until the subjects FEV1 declined by 20% from 
their highest post saline measurement or the final dose (16mg/ml) was 
completed. The dose of methacholine used started at 0.03mg/ml and this was 
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followed by 0.0625mg/ml, 0.125mg/ml and then on in doubling doses up to 
16mg/ml. Three millilitres of each methacholine solution was placed in the 
nebuliser just prior to administration. Methacholine was obtained from the 
hospital pharmacy (Western Infirmary & Gartnavel General Hospital, Sterile 
Production Unit) and was kept refrigerated to maintain stability. New stock was 
supplied every six months.  
The provoking concentration of methacholine required to produce a fall in FEV1 
by 20% (PC20) for each subject was calculated by linear interpolation using the 
formula: 
 
C1 = second to last methacholine concentration, C2 = last methacholine concentration, R1 = 
% fall in FEV1 after C1, R2 = % fall in FEV1 after C2 
Figure 2.1 Methacholine calculation method. Table adapted from (247) 
 
A PC20 of <8mg/ml in the context of a clinical history consistent with asthma, 
appropriate symptoms during the test (chest tightness, dyspnoea) and good 
quality spirometric efforts was considered to confirm the diagnosis of asthma 
and eligibility for entry to the trial. 
2.4.4 Urine cotinine 
Smoking history was confirmed by measurement of nicotine metabolites in a 
specimen of the subjects urine using the SmokeScreenTM sampling system (GFC 
Diagnostics, Stourbridge, UK). The SmokeScreenTM system detects the 
metabolised derivatives of nicotine through their reaction with 
diethylthiobarbituric acid in the sampling system as this turns the urine pink. 
This method removes the problems associated with the measurement of urine 
cotinine alone such as conversion to other metabolites. 
The level of nicotine metabolites present was objectively assessed using the 
SmokeScreenTM colorimeter (GFC Diagnostics, Stourbridge, UK). The colorimeter 
takes a baseline reading after mixing the sample and then repeats the 
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measurement 5 minutes later. Previous research has demonstrated that the 
reaction of nicotine metabolites occurs in a predictable linear fashion and hence 
the change in colour over time can be converted to concentration of nicotine 
metabolites (248). The colorimeter performs this calculation and displays a 
‘cotinine-equivalent’ concentration (0-20 µg/ml) and a category of ‘smoking’ 
(non-smokers, passive smoker, mild, moderate and severe smoker). The cotinine 
equivalent concentration ranges for each category are non-smokers (0.0-0.3 
µg/ml), passive smoker (0.4-1.0), light smoker (1.1-5.0), medium smoker (5.1-
10.0), heavy smoker (10.1-15.0) and v heavy smoker (15.1-21.0). 
2.4.5 Exhaled Carbon Monoxide measurement 
All subjects performed exhaled carbon monoxide at each timepoint in both 
studies to provide substantiation to their assertion that their smoking history was 
unchanged. Exhaled carbon monoxide was detected using a Pico Smokerlyser® 
(Bedfont Scientific Ltd, Rochester, UK). The Smokerlyser® detects exhaled 
carbon monoxide using an incorporated electrochemical sensor and presents the 
result as percentage carboxyhaemoglobin, parts per million and as a ‘traffic-
light’ read out. The concentration range was 0-80 parts per million with an 
accuracy of +/- 2%. The non-smoking range was defined as 0-7 parts per million 
and current smoking 8 parts per million and above (249).  
Previous research has demonstrated that it takes 2-8 hours for the carbon 
monoxide level to reduce by half (250-252) and at least 24 hours of smoking 
cessation is required for a smoker’s carbon monoxide level to return to that of a 
non-smoker (252). A grossly elevated level of carbon monoxide resulted in 
questioning of the volunteer with regards their compliance with omission of 
smoking for the visit. Non-smokers and ex-smokers had to demonstrate levels 
consistent with no current smoking. Smokers had to demonstrate elevation of 
their carbon monoxide level consistent with current smoking. 
Subjects performed three readings and the mean was used for analysis. Subjects 
inhaled and held their breath for 15 seconds and, when prompted by the 
Smokerlyser®, exhaled completely into the D-piece valve via a cardboard 
mouthpiece. Both the valve and mouthpiece are single use only. The valve 
contains a filter that prevents false readings due to alcohol and other organic 
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compounds. Calibration was carried out every six months using a cylinder of 
carbon monoxide certified at 20 parts per million (Bedfont Scientific Ltd, 
Rochester, UK). 
2.5 Clinical endpoints 
2.5.1 Spirometry 
Spirometric recording was performed in all subjects using electronic 
pneumotachograph spirometers (Vitalograph Ltd, Maids Moreton, Buckingham, 
UK) to the standards set by the joint ATS/ERS guidelines on spirometry (253). 
Calibration of each spirometer was carried out every day prior to first use with a 
3 litre reference syringe with adjustment for ambient temperature (253). 
Servicing was also carried out on an annual basis by Vitalograph technicians. 
Spirometric manoeuvres were consistent with published recommendations (253). 
To ensure consistent and valid performance of spirometry subjects observed a 
demonstration by the study doctor or research nurse prior to their first attempt. 
The subject was then instructed to take a maximum breath in and to then 
immediately place the mouthpiece in their mouth and blow out with maximum 
effort into the mouthpiece until no further air could be expelled. Active 
encouragement to continue exhalation until a suitable effort had been 
performed was provided by the supervising staff member. The procedure was 
repeated until three acceptable manoeuvres were available ensuring proper 
understanding of the technique and consistency in performance. A maximum of 
eight efforts was allowed to facilitate this process. An acceptable exhalation 
manoeuvre was defined as one which demonstrated a good rapid start, was free 
from artefact (cough, sub-maximal effort, glottis closure etc) and that had a 
satisfactory duration of exhalation. The duration was satisfactory if a plateau 
was reached and a minimum of six seconds of exhalation had been performed. 
Inter-manoeuvre variability was reduced by accepting efforts where the last two 
FEV1 results did not vary by more than 5% or 150ml.The highest FEV1, FVC, FEF25-
75 and FEF75 efforts were recorded for analysis. 
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2.5.2 Peak expiratory flow 
All patients were required to perform peak flow measurement at visits where 
spirometry was performed. Clement Clarke meters with EU scale EN 13826 were 
used for all measurements (Clement Clarke, Harlow, UK). PEF procedure was 
first demonstrated by the study nurse or doctor and subjects were then asked to 
stand upright and blow with maximum effort into the peak flow meter. The 
highest of three acceptable readings was recorded. 
2.5.3 Asthma Control Questionnaire  
The Juniper Asthma Control Questionnaire (ACQ) is a simple, reliable and 
sensitive questionnaire that was developed to allow quick assessment of asthma 
control in all severities of asthma and has been demonstrated to effectively 
demonstrate the impact of asthma treatment interventions (244).  
The score produced by the questionnaire is based on a series of seven questions. 
The first six questions cover the symptoms that the respondent has experienced 
in the past week with regards night time wakening, limitation of normal daily 
activities, early morning wakening, dyspnoea and wheeze and frequency of use 
of inhaled β2 agonist. Each question is answered by the respondent selecting one 
choice from six and the severity of choices ranging from responses which signal 
no symptoms or none to maximum severity for that particular symptom. The 
final question is answered by the clinic staff using the respondent’s FEV1 result 
from spirometry performed on the day of the assessment.  
The respondent’s score is the mean for all seven fields, resulting in maximum 
control being represented by a score of zero and the worst level of control a 
score of six. Recent research has determined that a score less than 0.75 is 
indicative of good asthma control, a score of greater than 1.5 indicative of 
inadequate control and a change in subjects ACQ score of 0.5 or more is 
considered clinically significant (254). 
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2.5.4 Exhaled Nitric Oxide 
Exhaled nitric oxide (FENO) was measured at multiple flow rates (30, 50, 100, 150, 
200, 250 & 300ml sec-1) using a Niox-Flex analyser (Aerocrine AB, 
Sundbybergsvägen 9, SE-171 73 Solna, Sweden) which meets joint ATS/ERS 
criteria for the measurement of on-line FENO (47). 
The Niox-Flex measures FENO by chemiluminescence. Briefly the principle of 
detection involves the subject’s FENO reacting with ozone produced within the 
machine. This generates nitrogen dioxide with electrons in an excited state i.e. 
that are occupying a higher energy level than normal. Subsequent return of the 
electrons to their normal excitation level is associated with the discharge of 
electromagnetic radiation at a wavelength of 600-3000nm. This is detected by a 
photomultiplier tube incorporated within the machine and as a linear 
relationship exists between the level of radiation emitted and the FENO exhaled 
enables derivation of FENO. The Niox-Flex has a published measuring range of 0-
200 ppb, a detection limit of 1 ppb, a sampling frequency of 20Hz, a response 
time of <1.5 seconds and an accuracy of +/- 2.5 ppb for levels < 50 ppb and +/- 5 
% of values >50 ppb. Calibration was carried out every two weeks or as required. 
Prior to performing the test subjects received an explanation on how to 
correctly perform the test from the supervising doctor or nurse. Following this 
the subject performed the test according to consensus guidelines (47). The Niox-
Flex requires subjects to take a deep inspiration both in and then exhale out 
through the machine’s mouthpiece. This ensured scrubbing of inhaled air which 
passed through the mouthpiece to the subject. The Niox-Flex automatically 
calculates nitric oxide output (VNO) and exhaled nitric oxide concentration, 
discarding measurements inconsistent with previous results at that flow rate and 
which did not demonstrate a plateau. Visual feedback was provided by the 
machine to maintain exhalation pressure above that required for closure of the 
velum, reducing nasal nitric oxide contamination.  
The results obtained from the multiple flow rates performed by the subjects in 
the Niox-Flex were used to calculate estimates for extended flow parameters for 
each subject based on modelling equations from previously published research 
(52, 222, 227). Extended flow analysis allows the derivation of several estimates 
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of nitric oxide metabolism including alveolar nitric oxide as a result of modelling 
of the lung as a compartment divided into two parts. The first consists of a non-
expandable conducting airway which corresponds to the trachea to division 16 of 
Weibel’s model of the airways and an expandable alveolar region that comprises 
division 17 of the same system onwards (figure 2.2). 
The tissue surrounding the airway and the alveolus is assumed to produce nitric 
oxide at a constant rate and that this can either: 
• Diffuse into the blood, which acts as an infinite sink 
• Diffuse into the airway 
• Be consumed by reactions with substances within the cell (superoxide, 
metalloproteins, thiols, oxygen)  
Therefore nitric oxide is diffusing into and out of the airway and alveolus at a 
rate dependent on the level of nitric oxide in the airway, the rate of NO 
production and NO diffusion into the bloodstream. Using these assumptions it is 
possible to use the exhaled nitric oxide concentration, rate of NO production 
and flow rate of exhalation to estimate the alveolar nitric oxide level and a 
number of other parameters. 
Tsoukias and George’s method (222) involves plotting the rate of NO production 
(VNO) against the rate of exhalation and performing linear regression to fit a line 
to the points obtained. This results in the intercept of the Y-axis providing an 
estimation of airway nitric oxide flux and the gradient of the derived line 
providing an estimate of alveolar NO from the equation: 
VNO = Calv.VE + J’awNO 
Where VNO= elimination rate of exhaled nitric oxide (ml/s), VE = exhalation flow rate (ml/s), 
Calv= alveolar NO concentration (ppb), J’awNO=maximum NO flux (pl/sec). 
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Figure 2.2 Schematic of 2-compartment model for nitric oxide pulmonary exchange.  
First compartment represents relatively nonexpansile conducting airways; second 
compartment represents expansile alveoli. Each compartment is adjacent to a layer of 
tissue that is capable of producing and consuming nitric oxide (NO). Exterior to tissue is a 
layer of blood that represents bronchial or pulmonary circulation and serves as an infinite 
sink for NO. VE and VI, expiratory and inspiratory flow, respectively; CE and CI, expiratory 
and inspiratory concentration, respectively; Cair and Calv, airway and alveolar 
concentration, respectively; VAIR and VALV, airway and alveolar volume, respectively; 
Jt:g,air and Jt:g,alv, total flux of NO from tissue to air and from alveolar tissue, respectively; 
t, time; V, volume. Adapted from (227). 
 
Silkoff and colleagues developed a non-linear regression method (255) that 
correlated well with measurements of exhaled NO at 9 flow rates (4.2, 8.5, 10.3, 
17.2, 20.7, 38.2, 75.6, 850 & 1550 ml/sec) and enabled calculation of the 
parameters above. Solving for the following equation provides estimates for 
alveolar nitric oxide, nitric oxide flux and airway wall nitric oxide concentration 
and diffusion: 
FENO = CawNO + (Calv - CawNO)e
(-DawNO/VE) 
Where FENO=exhaled NO concentration (ppb), CawNO=airway wall concentration (ppb), 
DawNO=diffusion from airway wall to airway (pl/s/ppb), Calv =alveolar NO level (ppb), 
VE=flow rate of exhalation (ml/sec) 
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Nitric oxide flux and airway wall nitric oxide diffusion and concentration can 
also be obtained by linear regression using the VNO and FENO results from the 30 
and 50ml/sec flow rates (255). VNO is plotted against FENO and linear regression 
carried out through the points. Nitric oxide flux can then be obtained from the 
y-intercept and nitric oxide diffusion from the reciprocal of the slope gradient. 
Airway wall concentration is obtained from the relationship (255): 
 
J’awNO = CawNODawNO 
Where J’awNO=maximum NO flux (pl/sec), CawNO=airway wall concentration (ppb), 
DawNO=diffusion from airway wall to airway (pl/s/ppb) 
 
Extended flow analysis has demonstrated elevated levels of alveolar nitric oxide 
in subjects with severe asthma (compared to subjects with mild asthma) (256, 
257) and subjects with COPD (225, 258) although this finding is not consistent 
(52). Smoking does not appear to reduce alveolar nitric oxide levels in normal 
subjects (226, 259) and alveolar nitric oxide levels are equivalent in smokers and 
ex-smokers with COPD (52, 225). This suggests that extended flow analysis may 
provide useful insights into nitric oxide metabolism in smokers with asthma. 
Given the uncertainties as to the best method for calculating extended flow 
nitric oxide parameters and the potential that smokers with asthma may have 
alterations in some or all extended flow nitric oxide parameters both linear and 
non-linear models were employed. The inherent variability of the presented 
parameters was not determined in this thesis. 
2.5.5 Exhaled breath condensate pH 
Exhaled breath condensate (EBC) collection was performed using a Jaeger 
EcoScreen® (VIASYS GmbH, Leibnizstrasse 7, D-97204 Hoechberg, Germany) 
which complied with expert opinion (56). Subjects performed tidal breathing 
into the apparatus mouthpiece for a minimum of ten minutes whilst wearing a 
nose-clip. Subjects were allowed brief rests if required and were instructed to 
cease breathing into the mouthpiece prior to removal of nose-clip and to avoid 
expelling flatus into the mouthpiece. If an insufficient amount of EBC was 
collected after ten minutes the subjects were asked to continue for a further 5 
minutes. A final further five minutes were allowed if there was still insufficient 
fluid after fifteen minutes. 
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The EBC sample obtained was processed as per expert opinion (56, 232). One ml 
of the sample was aliquoted into a 1.5ml eppendorf and de-aerated for ten 
minutes with argon resulting in the removal of carbon dioxide from the solution 
and stabilisation of pH. Recordings of pH were taken using a MINITRODE P 
electrode (VWR International, Lutterworth, UK) and HANNAH pH 210 digital 
meter (VWR International, Lutterworth, UK) which had been calibrated prior to 
use using pH 4 and 7 buffers. Reproducibility of EBC pH measurement was not 
addressed in this thesis. 
2.5.6 Sputum induction 
Sputum was obtained using a procedure modified from that of Pin et al (184) and 
Pavord et al (181). Subjects performed spirometry and then were pre-treated 
with nebulised salbutamol followed by spirometry after thirty minutes. The 
highest post salbutamol FEV1 obtained was recorded for post saline evaluation. 
Subjects inhaled nebulised saline using an ultrasonic nebuliser (Sonix 2000, 
Medix Ltd, Harlow, Essex, UK) for three seven minute periods resulting in a 
maximum of 21 minutes of nebulisation. Hypertonic saline at concentrations of 
3, 4 and 5% (Western Infirmary & Gartnavel General Hospital, Sterile Production 
Unit) were employed. 
To ensure no bronchospasm had occurred during the procedure all subjects 
performed spirometry after each nebulisation period. If no change in FEV1 was 
detected (defined as a drop in FEV1 of less than 10% from post nebuliser values, 
an increase in FEV1 or no change) then the subject continued onto the next 
concentration of saline. However if a drop of more than 20% from the post 
nebuliser level was observed the procedure was terminated and the subject was 
treated with nebulised salbutamol. A drop in FEV1 of less than 20% and greater 
than 10% resulted in the subject repeating nebulisation at the same 
concentration of saline. Subjects were encouraged to expectorate into a sterile 
container at any time during the procedure. The sterile containers were kept in 
ice during the procedure and all samples were processed in less than two hours.  
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2.6 Processing of biological samples 
2.6.1 Sputum processing 
The sputum obtained was processed using the method of Popov et al (260) with 
some modifications. Upon arrival in the laboratory the whole sample was 
decanted, weighed and examined by the technicians. Macroscopic appearances 
were recorded (quality, obvious salivary contamination etc). The volume of the 
sample dictated the volume of dithiothreitol (DTT) (‘Sputolysin’, Calbiochem-
Novabiochem (UK) Ltd, Nottingham, UK) diluted in Hanks Balanced Salt Solution 
(HBSS) (Invitrogen, Paisley, UK) to be added to the sample. For samples less than 
5ml, 250µl of 0.1% DTT diluted in 750µl HBSS was added to the sample. 
Thereafter for every 1ml increase in sample volume a further 50µl was added 
and the HBSS reduced by 50µl i.e. for samples of 6ml 300µl of 0.1% DTT and 
700µl HBSS was added. This increase in DTT concentration continued until the 
samples were greater than 10ml in volume and then 500µl of DTT and 500µl of 
HBSS was added to the sample regardless of increase in volume. 
Mechanical separation of the sample was then performed for at least ten 
minutes using a sterile Pasteur pipette to ensure proper separation of the 
specimen. Once this was achieved the sample was then diluted to 30ml using 
HBSS and forced through a 70µm cell strainer (VWR International, Lutterworth, 
UK) into a pre-weighed 50ml sterile tube. The tube was then re-weighed and the 
volume of filtrate obtained was recorded. A total cell count was then performed 
using a Neubauer haemocytometer with 20µl of the sample diluted 1:1 in Trypan 
blue (Sigma-Aldrich, Gillingham, UK). The total number of cells, number of dead 
and alive and squamous cells were recorded and the total number of viable cells 
(excluding squamous cells) obtained was then calculated. 500µl of a 1x106 
concentration of sputum cells was aliquoted off for cytospin slides and the rest 
of the sample was then centrifuged at 1500 rpm for 10 minutes at 4˚C. Four 1ml 
samples of supernatant were aspirated off and stored for future cytokine 
analysis and the sample pellet was washed and re-suspended in Roswell Park 
Memorial Institute medium (RPMI 1640) with 10% Foetal Calf Serum added (RPMI-
FCS, SIGMA-ALDRICH Ltd, Gillingham, UK) for measurement of sputum 
macrophage HDAC activity. 
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2.6.2 Sputum differential counting 
Three cytospin slides were produced, air fixed and stained (Romanowsky 
staining; Lamb Quick-stain kit, Thermo Fisher Scientific Ltd, UK). The 
differential cell count was performed by counting 400 non-squamous cells from a 
representative area of the slide and the total and relative percentage of each 
cell type recorded. Two technicians examined two of the slides independently 
and the mean of the counts was used for analysis.  The third slide was kept in 
reserve in case of damage to one of the main slides. 
2.6.3 Measurement of HDAC activity in sputum macrophages  
HDAC activity was assessed using the Fluor-de-LysTM HDAC activity kit from 
BIOMOL (BIOMOL Int, Exeter, UK). The cell suspension obtained at the end of 
sputum processing was plated out in a six well plate (VWR International, 
Lutterworth, UK) with three wells being used per patient and 1ml of suspension 
per well. The plate was incubated at 37˚C with 5% CO2 supplementation for 1 
hour to stimulate adherence of macrophages. 
HDAC substrate was then added to two wells at a concentration of 200µM per 
well. The HDAC inhibitor Trichostatin A (TSA) was also added to one of the wells 
containing HDAC substrate at a concentration of 1µM. The wells were then 
labelled TSA + and TSA- depending on which had TSA in addition to substrate. 
The plate was again incubated for one hour at 37˚C with 5% CO2 
supplementation. After one hour the non-adherent cells were removed and the 
adherent cells washed with RPMI-FSC and lysed with HDAC lysis buffer. The 
adherent cells were not inspected or subject to a differential count. The cell 
lysate was then aspirated into labelled eppendorfs which were stored at -80˚C 
until development. The remaining well was used for cell counting. HDAC activity 
of the samples was determined through the addition of Fluor-de-LysTM developer 
(BIOMOL Int, Exeter, UK) to 10µL of each of the samples in a white 96 well plate. 
The plate was covered in tin-foil and placed in the dark at room temperature for 
30 minutes. The samples were then excited in a fluorimeter and the emitted 
light was then recorded. The HDAC activity of the sample was calculated using 
this result, the result from the blank and control wells and the standard curve. 
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Correction was performed for the cell count obtained from the third well of the 
six well plate for each sample. Assay variability testing was not performed. 
2.6.4 Measurement of sputum supernatant and plasma cytokines 
The sputum supernatant and plasma obtained in the study examining the 
corticosteroid responses of smokers, ex-smokers and non-smokers with asthma 
was examined for a number of cytokines and chemokines using a commercially 
available multiplex immunodetection system (25-plex cytokine assay, Invitrogen 
Ltd, 3 Fountain Drive, Inchinnan Business Park, Paisley, UK) and a Luminex 100TM 
analyser (Luminex Corporation, 12212 Technology Blvd, Austin, Texas, USA). This 
system enables the detection of multiple cytokines and chemokines of interest in 
small volumes through the use of antibody labelled microspheres in a solid phase 
sandwich immunoassay. The microspheres bind to the analyte of interest due to 
their conjugated antibody and the microspheres enable detection of the 
concentration of analytes due to their internal dyes which when excited by the 
lasers incorporated within the Luminex 100TM emit specific wavelengths of 
radiation. The emitted radiation is detected by the analyser and due to each 
bead having a different ‘signature’, the detected radiation is converted to a 
concentration of cytokine/chemokines for each analyte using results obtained 
from standard curves. The cytokines detected using this approach were eotaxin, 
granulocyte/monocyte-colony stimulating factor (GM-CSF), interferon-α (IFN-α), 
interferon-γ (IFN-γ), interleukin (IL) 1-receptor-antagonist (IL-1RA), IL-1β, IL-2, 
IL-2 receptor (IL-2R), IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-10, IL-12 (p40/p70 
form), IL-13, IL-15, IL-17, Interferon-inducible Protein of 10 kDa (IP-10 aka 
CXCL10), Monocyte Chemotactic Protein 1 (MCP-1), Monokine Induced by IFN-γ 
(MIG aka CXC9), Monocyte Inflammatory Protein 1α (MIP-1α aka CCL3), Monocyte 
Inflammatory Protein 1β (MIP-1β aka CCL4), Regulated upon Activation, Normal 
T cell Expressed and Secreted (RANTES aka CCL5), and Tumour Necrosis Factor-α 
(TNF-α). 
Validation of the Luminex technique was carried out using a 30-plex cytokine 
and supplied cytokine standards. Serial dilutions confirmed the linearity of the 
assay for all cytokines in the working range (figure 2.3-IL-6 result). Addition of 
the reducing agent DTT at concentrations of 0.05 and 0.00125% had no effect on 
Chapter 2  92 
antigenicity (figure 2.3-IL-6 result). Spiking of samples also demonstrated good 
correlation between the spiked concentration and sample concentration as 
detected by Luminex (r=0.64, p<0.001) (figure 2.4). 
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Figure 2.3 Linearity of IL-6 detection and effect of two concentrations of DTT on antigenicity 
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Figure 2.4 Result of spiking experiment for 30 cytokines 
 
In the studies examining theophylline and rosiglitazone in smokers with asthma 
and the study examining the corticosteroid responses of smokers, ex-smokers 
and non-smokers with asthma sputum supernatant selected cytokines were also 
Chapter 2  93 
assessed using pre-coated enzyme linked immunosorbent assays (ELISAs). Sputum 
supernatant from the study examining theophylline and rosiglitazone was 
examined for interleukin (IL)-8, myeloperoxidase (MPO) and Regulated on 
Activation, Normal T Expressed and Secreted (RANTES)/CCL5 levels (IL-8, R&D 
Systems, Abingdon, UK, MPO, Immundiagnostik, Oxford Biosystems, Oxford, UK, 
RANTES/CCL5, Invitrogen Ltd, Paisley, UK). Sputum supernatant from the study 
examining the corticosteroid responses of smokers, ex-smokers and non-smokers 
with asthma was examined for IL-6 using a high sensitivity ELISA (Abcam plc, 
Cambridge, UK). Each ELISA plate was processed according to manufacturer’s 
instructions. Briefly the pre-coated plates were loaded with samples followed by 
incubation with shaking, washing with supplied wash buffer and then 
streptavidin-horse radish peroxidase was then added to the plates. This was then 
followed by a further shaking step and a further wash cycle. Developer was then 
added and the reaction stopped once sufficient colour had developed. The plate 
was then read on a plate reader with the primary and secondary wavelengths 
required for the assay and the output determined using the standards within 
each plate. 
2.6.5 Blood tests 
2.6.5.1 Peripheral blood monocyte selection 
Blood was obtained using lithium heparin vacutainers and the monocyte fraction 
selected by density centrifugation. Whole blood was diluted 1:1 in RPMI-1640, 
carefully layered on top of Histopaque® (SIGMA-ALDRICH Ltd, Gillingham, UK) 
and then centrifuged at 1800rpm for 30 minutes at room temperature. The white 
cell fraction then became obvious as a creamy white layer at the interface 
between the Histopaque® and serum. This was carefully aspirated off and 
washed in RPMI by centrifuging twice for 5 minutes at 1400 rpm at 4˚C. The 
concentration of cells within the pellet was then determined by cell counting 
and diluted as appropriate. The pellet obtained was used for the assessment of 
PBMC HDAC activity. 
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2.6.5.2 PBMC HDAC activity 
HDAC activity in peripheral blood borne monocytes was assessed using the Fluor-
de-LysTM system (BIOMOL Int, Exeter, UK). Briefly the PBMC cell pellet 
suspension was plated out into three wells of a six well plate and left to adhere 
for one hour. The non-adherent cells were removed and the HDAC substrate was 
added to two wells and TSA to one of the two wells. The third well was used for 
cell counting. After one hour incubation the reaction was stopped using lysis 
buffer and the resultant lysate scraped off using a cell scraper and aspirated off 
into three eppendorfs for storage at -80˚C. The HDAC activity of the subjects 
PBMCs was then assessed by the addition of Fluor-de-Lys developer to the 
sample. The result was obtained using a fluorimeter as before with correction 
for cell count. Assay variability testing was not performed. 
 
2.6.5.3 Biochemical assays 
Routine biochemistry testing was performed by the North Glasgow Hospital 
Trust’s Biochemistry laboratory, Gartnavel General Hospital, Glasgow. Samples 
were processed in the study examining theophylline and rosiglitazone for renal 
function and electrolytes, liver function tests, adjusted calcium, total 
Cholesterol, glucose and theophylline levels. Serum cortisol concentrations were 
assessed in the study examining corticosteroid response. All samples were 
processed and results generated using an automated processing system 
(ARCHITECT c8000, Abbot Diagnostics, Maidenhead, UK). 
2.6.5.4 Differential blood counts 
Differential blood counts were performed in the study examining theophylline 
and rosiglitazone by the North Glasgow and Clyde NHS trust Haematology 
laboratory at Gartnavel General Hospital, Glasgow using an automated X-Class 
SYSMEX machine (SYSMEX, Hamburg, Germany). This provided haemoglobin 
concentration, total and differential white cell count and platelet concentration 
and a number of other parameters. 
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2.6.5.5 Serum IgE and IgE antibodies against common allergens 
The serum concentrations of IgE and specific immunoglobulin E (IgE) antibody 
activity against allergens from cat dander, grass pollen and house dust mite 
were measured by fluorescent enzyme immunoassay (FEIA, UniCAP-100 System, 
Pharmacia, Milton Keynes, UK) by the North Glasgow and Clyde NHS trust 
Immunology laboratory, Western Infirmary, Glasgow, in the study examining 
theophylline and rosiglitazone in smokers with asthma.  
The method of FEIA is based on the binding of the patient’s serum 
immunoglobulins to the antigen/s of interest, which is bound to a flexible 
cellulose matrix, housed within a small permeable container. This is followed by 
a wash to remove unbound immunoglobulins. IgE bound to the allergen is then 
detected by binding of beta-galactosidase-labelled anti-IgE, and any unbound 
secondary antibody is removed by washing. The bound enzyme activity is then 
measured by catalysing the production of a fluorescent product, umbelliferone, 
from a colourless substrate. The fluorescence produced is proportional to the IgE 
antibody concentration, and is quantified by comparison to a standard curve. 
The assay system has a working range of 0.35-100 arbitrary units per litre 
(AU/L). A level of greater than 0.35 AU/L for specific IgE is considered raised. 
Total serum IgE was measured as above, with the exception that all the serum 
IgE was captured by anti-IgE bound to the cap matrix. Serum IgE has a log 
normal distribution, and concentrations greater than 120 IU/L are considered 
significantly raised, as values above this level are associated with atopy and 
clinical allergy. 
2.7 Data handling and statistical analysis 
2.7.1 Data handling 
All data for the trial examining theophylline and rosiglitazone was entered into a 
specially designed case report form (CRF) provided by GlaxoSmithKline (GSK) and 
sent to their data entry team for generation of the research database. The 
quality of CRF completion was assessed by an independent monitor employed by 
GSK who examined ten per cent of the completed CRFs prior to sending for entry 
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and generated queries for areas which required clarification. Where areas of 
uncertainty within the data were identified I clarified and corrected where 
required. 
I designed the CRFs and performed all data entry and checking for the study 
examining corticosteroid responses. 
2.7.2 Statistical analysis 
2.7.2.1 Approach and performance of analysis 
The lung function data in the trial examining theophylline and rosiglitazone was 
performed by a professional statistician (Dr Lisa Sweeney) employed by GSK 
using SAS v 8.2 (SAS Institute Inc., NC, USA) on a UNIX system. I performed all 
other analyses and comparisons in this trial using MINITAB 15 (Minitab Inc. State 
College, PA, USA). The study analysis was performed with an intention to treat 
approach. 
The majority of the analysis for the trial examining the oral corticosteroid 
responses of smokers, ex-smokers and non-smokers with asthma was performed 
by a professional statistician (Dr Chris Weir, Robertson Centre for Biostatistics, 
University of Glasgow) using SAS v 9.1 (TS1M3) for Windows (SAS Institute Inc., 
NC, USA). I performed all additional analyses and comparisons using MINITAB 15 
(Minitab Inc. State College, PA, USA). This study was analysed as a per-protocol 
study. Subjects non-compliant with oral corticosteroids formed part of the 
baseline comparisons but their post oral corticosteroid data was not utilised. 
In both studies parametric data was analysed by t–testing and ANOVA as 
appropriate. Non-parametric data was assessed by Mann Whitney or log 
transformed prior to normality testing (using Anderson-Darling) and if parametric 
as a result was analysed by t-testing. Difference of adjusted means analysis 
(ANCOVA) was performed for the lung function data in the theophylline and 
rosiglitazone trial due to differences in the baseline characteristics of the groups 
which were deemed by the statistician to influence the result. All analyses 
performed for the thesis were two sided with alpha set at 5%. 
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2.7.2.2 Power calculations 
The theophylline and rosiglitazone study did not have a formal power analysis 
performed due to a lack of information on responses to both drugs in the study 
population. However the study was informed by the confidence intervals 
observed in the response of smokers with asthma to an oral corticosteroid trial 
(23). This resulted in the estimation that 22 subjects were required per group to 
detect a 230ml difference in FEV1 between the treatment arms and to allow for 
a 10% drop-out rate. 
The study examining oral corticosteroid responses was informed by a previous 
trial (23). This resulted in the estimate that 22 subjects were required to 
provide 80% power to demonstrate a difference of 336ml in FEV1 response to oral 
corticosteroids between smokers and non-smokers with asthma and to allow for 
a 10% drop-out rate. 
2.7.2.3 Multiple comparison issues 
Both of the studies presented in this thesis are susceptible to false positive 
results due to multiple comparison issues. These have arisen for several reasons.  
In the study examining theophylline and rosiglitazone there is the possibility of a 
type 1 error despite the use of a pre-defined primary endpoint and alpha level. 
This is due to the use of four treatment groups and a failure to adjust the alpha 
level to conserve the family-wise error rate for the trial design. However 
correction for this issue would have resulted in the study becoming unfeasible 
for a thesis and for one site to conduct in a reasonable time. The pre-defined 
secondary endpoints are used to support and confirm the primary endpoint 
findings in an attempt to reduce erroneous conclusions. Finally a number of 
exploratory endpoints are permitted for examination of the database to 
generate future research leads. 
The study examining the oral corticosteroid response of smokers, ex-smokers and 
non-smokers with asthma is again an exploratory study. Given the nature of the 
study and volume of data generated a number of false positive results are 
possible given that alpha is set at the traditional value of 5%. However 
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established methods for correction for multiple analyses were felt to be 
unhelpful as they are unnecessarily punitive for a study of this size and would 
obscure potential important observations. 
Therefore the conclusions drawn in this thesis are constrained by the likelihood 
of the presence of false positive results. To compensate, the data is presented 
as exploratory rather than conclusive. This approach is designed to temper the 
conclusions and whilst this cannot correct for possible type 1 errors it reminds 
the reader of the need for confirmation of all findings in adequately powered 
and informed trials. The final consideration is that adequately powered and 
conclusive clinical trials in smokers with asthma will now be feasible as a result 
of the data presented in the following chapters. 
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3 Reversal of corticosteroid insensitivity in 
smokers with asthma 
3.1 Introduction 
Inhaled corticosteroids are recommended as the first-line treatment for chronic 
persistent asthma (1, 2). However a significant proportion of individuals with 
asthma fail to establish complete control despite this approach (25).  
Smokers with asthma comprise part of this poorly controlled group and exhibit 
an impaired response to both inhaled and oral corticosteroids compared to non 
smokers with asthma (5-10, 22-24). Previous research has also demonstrated 
that smokers with asthma have worse symptoms (11), an accelerated decline in 
lung function (15, 21) and increased frequency of emergency department visits 
for asthma (16, 17) compared to matched non-smoking asthmatics. 
The prevalence of smoking in asthma reflects that of the general population and 
therefore smokers with asthma represent a large group of patients with poorly 
controlled disease (261). Smoking cessation is the obvious route for practitioners 
and smokers with asthma to pursue and has been demonstrated to be an 
effective therapy in this group (49), but as sustained quitting rates are low, 
improvements on current treatments, additional or alternative therapies are 
required  for individuals with asthma who continue to smoke. 
What mechanisms are responsible for the reduced response to corticosteroids 
displayed by smokers with asthma? Corticosteroids reduce inflammation via a 
number of different mechanisms including inhibition of pro-inflammatory 
transcription factors through both competition for co-factors and direct 
inhibition, increased expression of anti-inflammatory genes and repression of 
inflammatory gene expression (27, 32). One mechanism that corticosteroids use 
to suppress inflammatory gene expression and that may be of relevance in 
smokers with asthma has come to light through the research discipline of 
epigenetics. Epigenetics examines the effect of post-translational covalent 
modifications of chromatin on the control of gene expression. It has been 
demonstrated in-vitro that approximately half of the immunosuppressant 
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activity of corticosteroids is produced through stimulating the removal of acetyl 
groups at areas of active transcription (36). Cigarette smoke reduces HDAC 
activity in-vitro (92), which could explain corticosteroid insensitivity in smokers 
with asthma. At standard doses, theophylline produces bronchodilation, whereas 
low doses increase HDAC activity with associated reductions in inflammatory 
gene expression when given in combination with corticosteroids (102, 103). One 
of the main aims of this study was to test the hypothesis that low dose 
theophylline restores HDAC activity in smokers with asthma leading to a 
restoration of corticosteroid sensitivity which when theophylline was given in 
combination with inhaled corticosteroid would improve lung function to a 
greater degree than inhaled corticosteroids alone. 
Therefore, I undertook an exploratory clinical trial to examine the effect of low 
dose theophylline in combination with low dose inhaled corticosteroid on lung 
function and other outcomes in a group of smokers with asthma. 
3.2 Methods 
3.2.1 Subjects 
Subject characteristics, inclusion/exclusion criteria and recruitment methods 
were as described in the general methods chapter. 
3.2.2 Study design 
A full description of the study is provided in the general methods chapter. In 
brief the study was a randomised, prospective, double-blind, double-dummy, 
active comparator, parallel group design. Subjects were randomly allocated to 
one of four treatment groups, three of which are discussed in this chapter. The 
treatments discussed in this chapter are; twice a day 100mcg inhaled 
hydrofluoroalkane beclometasone dipropionate alone, the combination of low 
dose oral theophylline (200mg bd) and inhaled beclometasone dipropionate and 
theophylline alone (figure 3.1). 
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Figure 3.1 Randomisation schedule 
 
Subjects performed a number of assessments at baseline and repeated the 
assessments after twenty eight days of treatment. A short visit at fourteen days 
was performed to assess lung function. The West Glasgow Research Ethics 
Committee approved the study and all patients gave written informed consent. 
3.2.3 Measurements 
A full description of the measurements is provided in the general methods 
chapter. Lung function assessments conformed to consensus guidelines (246). 
Sputum induction, differential count, HDAC measurement and supernatant 
analysis were performed as discussed in the general methods chapter.  HDAC 
assay variability testing was not performed. Continuation of smoking during the 
study was confirmed by history and the detection of urinary nicotine 
metabolites. Subjects were regarded as current smokers if their category was 
mild smoker or greater and their urine cotinine level was greater than 
1.1mg/ml. Treatment compliance was assessed by tablet count, inhaler weight 
and serum theophylline level.  
3.2.4 Statistical analysis 
The reduced response to inhaled corticosteroids in smokers with asthma 
prevented standard power calculations. The study was informed by FEV1 changes 
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from a previous clinical trial employing oral corticosteroids in smokers with 
asthma (23). This resulted in the estimation that 22 subjects were required per 
group to detect a 230ml difference in FEV1 between the treatment arms and to 
allow for a 10% dropout. A slightly higher dropout rate occurred (13%) during the 
trial resulting in a larger numbers of subjects being randomised to treatment. 
The primary endpoint was difference in pre-bronchodilator FEV1 between the 
treatments and beclometasone alone at 28 days. The secondary endpoints were 
change in pre and post bronchodilator PEF, FVC, FEF25-75, FEF75 & ACQ. 
Exploratory endpoints were change in sputum differential, sputum HDAC activity 
and sputum supernatant. Lung function changes were examined using ANCOVA 
(incorporating Kenward & Roger’s method (262)) using SAS v8.2 (SAS Institute 
Inc, NC, USA). All data obtained after day 1 of treatment was used for analysis. 
The remaining statistical analysis was performed using Minitab 15 (Minitab Inc. 
State College, PA, USA). α was set at 0.05. Due to the exploratory nature of the 
trial the analyses were not corrected for type 1 errors due to multiple 
comparisons. 
3.3 Results 
A total of 3895 subjects with asthma were invited to participate between August 
2005 and May 2007, of whom 294 gave positive responses. Following telephone 
screening, visits were arranged for 187 subjects and 91 subjects met criteria for 
randomisation (figure 3.2). Sixty-eight subjects were randomised to the portion 
of the study that is discussed in this chapter. The remaining subjects were 
randomised to treatment with rosiglitazone and the results for this treatment 
are discussed in the following chapter. Twenty-three subjects were allocated to 
the inhaled beclometasone alone and theophylline alone groups and twenty-two 
to theophylline and inhaled beclometasone. The baseline demographic, clinical 
(including previous inhaled corticosteroid and long-acting β2-agonist use) and 
inflammatory characteristics of recruited subjects in each group were well 
matched (tables 3.1 & 3.2). All the endpoints presented from this point are the 
changes seen relative to the inhaled beclometasone group 
response.
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Figure 3.2 CONSORT diagram showing flow of participants through the trial.  
SAE; serious adverse event 
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Table 3.1 Baseline demographics.  
Data presented as median (IQR) unless stated otherwise. Abbreviations; SD; standard 
deviation, BMI; Body Mass Index, FEV1; Forced expiratory volume in 1 second, pre BD; pre- 
bronchodilator, ACQ; Asthma Control Questionnaire score (range, 0 to 6, with higher scores 
indicating worse asthma control), IgE; immunoglobulin E, LABA; long-acting β2-agonist. 
 
 
 
Inhaled 
beclometasone 
Theophylline & 
Inhaled 
beclometasone 
Theophylline 
Number of patients 23 22 23 
Age (years) 
 
42 
(36, 53) 
 
44 
(31, 52) 
46 
(38, 50) 
 
Gender 
Female (% of total) 
 
61 55 65 
 
BMI (kg/m²) 
Mean (range) 
 
25.5 
(18.4, 34.2) 
26.0 
(17.3, 36.1) 
26.6 
(18.6, 37.1) 
 
Pack years 
 
24 
(15, 30) 
25 
(11, 40) 
30 
(15, 35) 
 
Duration of asthma (years) 
 
16 
(8, 31) 
15 
(9, 21) 
16 
(9, 30) 
Inhaled corticosteroid use at 
screening 
 
(% of total) 
 
Dose, beclometasone equivalent 
(mcg) 
 
 
65 
 
800 
(400, 800) 
 
 
68 
 
800 
(400, 950) 
 
 
74 
 
400 
(400, 900) 
LABA use at screening (%) 26 36 35 
Specific IgE antibody positive (%) 61 50 52 
 
Total IgE level (IU/ml) 
 
87 
(34, 396) 
91 
(31, 383) 
40 
(9, 346) 
 
Spirometry (pre-BD) 
FEV1 (% predicted) 
 
75 
(72, 89) 
78 
(65, 84) 
73 
(64, 84) 
 
Reversibility 
FEV1 % improvement 
 
16 
(13, 20) 
15 
(14, 18) 
18 
(14, 24) 
 
Asthma Control 
Questionnaire score (0 to 6)  
Mean (SD) 
 
1.8 
(0.9) 
1.8 
(0.7) 
2.1 
(0.5) 
Chapter 3  105 
Table 3.2 Baseline sputum counts and HDAC activity.  
Data expressed as median (IQR) except where expressed. 95% CI; 95% confidence interval. 
 
3.3.1 Lung function 
3.3.1.1 Theophylline and inhaled beclometasone 
After two weeks of treatment with low dose theophylline and beclometasone 
there was a trend for improvement in pre-bronchodilator PEF (24.9 L/min (95% 
CI –1.5 to 51.2), p=0.064) (figure 3.3) and pre-bronchodilator FVC (132 ml (-23 to 
286), p=0.094). There were no detectable differences in other lung function 
endpoints (table 3.3). After four weeks, treatment with the combination of 
theophylline and inhaled beclometasone demonstrated a borderline significant 
improvement in mean pre-bronchodilator FEV1 (mean difference 165 ml (-13 to 
342), p=0.069) (table 3.3 & figure 3.4) and a significant improvement in pre-
bronchodilator PEF (39.9 L/min (10.9 to 68.8), p=0.008) (table 3.3 & figure 3.3) 
and pre-bronchodilator FVC (254 ml (63 to 445), p=0.010) (table 3.3).  
 
Inhaled 
beclometasone 
Theophylline & 
Inhaled 
beclometasone 
Theophylline 
Sputum total cell count  
(106) 
4.3 
(2.6, 7.3) 
5.1 
(3.1, 9.4) 
6.0 
(2.4, 16.1) 
Eosinophils % 0.9 (0.3, 1.6) 
0.8 
(0.4, 1.8) 
1.3 
(0.5, 2.3) 
Eosinophils (104) 2.1 (0.8, 5.8) 
3.7 
(1.9, 19.5) 
6.3  
(1.7, 28.4) 
Neutrophils % 25.5 (9.6, 44.6) 
23.5 
(8.6, 42.3) 
16.6 
(8.4, 40.3) 
Neutrophils (104) 122.7  (25, 188) 
83.0  
(35, 302) 
80.0  
(25, 323) 
Macrophages % 52.8 (32.0, 64.4) 
45.1 
(38.1, 60.8) 
52.1 
(39.1, 64.3) 
Macrophages (104) 184.2  (96, 437) 
271.8 
(165, 452) 
78.0  
(147, 729) 
Lymphocytes % 1.3 (0.6, 2.6) 
1.6 
(1.0, 2.7) 
1.0 
(0.5, 2.5) 
Lymphocytes (104) 4.9  (2.3, 11.2) 
12.4  
(3.2, 20.7) 
7.1  
(1.5, 22.6) 
Bronchial epithelial cells % 10.5 (8.3, 15.4) 
16.4 
(8.0, 28.9) 
12.3 
(6.1, 27.2) 
Bronchial epithelial cells (104) 40.7  (20.5, 99.4) 
119.1  
(63.8, 157.6) 
83.7  
(22.1, 168.2) 
HDAC activity 
AFU/106 cells 
mean (95% CI) 
2.25 
(0.54, 3.95) 
3.75 
(0.34, 7.16) 
3.62 
(0.61, 6.64) 
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Figure 3.3 Change in PEF (L/min) by 28 days of treatment.  
Paired t-test (error bars represent 95% confidence intervals). p-values were derived from 
comparison of groups to beclometasone dipropionate changes using ANCOVA. Figure key- 
ICS; inhaled beclometasone, Theo; theophylline, T+ICS; theophylline and inhaled 
beclometasone combination. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Change in FEV1 (ml) by 28 days of treatment.  
Paired t-test (error bars represent 95% confidence intervals). p-values were derived from 
comparison of groups to beclometasone dipropionate changes using ANCOVA. Figure key- 
ICS; inhaled beclometasone, Theo; theophylline, T+ICS; theophylline and inhaled 
beclometasone combination 
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Theophylline & 
inhaled 
beclometasone 
Theophylline 
Day 14 133 
(-27, 293) 
52 
(-109, 214) ∆ Pre BD FEV1 
ml (95% CI) 
Day 28 165 (-13, 342) 
128 
(-51, 307) 
Day 14 25 (-1, 51) 
6 
(-20, 33) ∆ Pre BD PEF 
L/min  (95% CI) 
Day 28   40 * (11, 69) 
22 
(-7, 51) 
Day 14 132 (-23, 286) 
15 
(-141, 171) ∆ Pre BD FVC 
ml (95% CI) 
Day 28    254 * (63, 445) 
176 
(-16, 368) 
∆ ACQ score 
(95% CI) 
 –0.47 * 
(-0.91, -0.04) 
  –0.55 * 
(-0.99, -0.11) 
∆ Sputum total 
cell count 
Cells x 106 
(95% CI) 
-2.0 
(-6.3, 1.7) 
-1.7 
(-6.2, 2.1) 
∆ Sputum 
eosinophil 
% 
(95% CI) 
 
Absolute (104) 
(95% CI) 
0.0 
(-1·1, 0·6) 
 
-1.62 
(-9·58, 1·82) 
-0.6 
(-1.7, 0.3) 
 
-5.53 
(-17.87, 1.68) 
∆ Sputum 
neutrophil 
% 
(95% CI) 
 
Absolute (104) 
(95% CI) 
0.3 
(-12.3, 17.7) 
 
46.8 
(-65.1, 236.2) 
-2.5 
(-22.5, 12.8) 
 
-16.0 
(-199.5, 116.1) 
∆ Sputum 
macrophage 
% 
(95% CI) 
 
Absolute (104) 
(95% CI) 
0.5 
(-11.8, 11.3) 
 
-52.7 
(-251.4, 118.7) 
-2.5 
(-21.0, 15.3) 
 
-0.9 
(-250.0, 186.3) 
∆ Sputum 
lymphocyte 
% 
(95% CI) 
 
Absolute (104) 
(95% CI) 
  -0.8 * 
(-1.4, -0.1) 
 
  -10.99 * 
(-18.15, -1.65) 
-0.6 
(-1.3, 0.2) 
 
-3.98 
(-10.30, 1.36) 
∆ Sputum 
bronchial 
epithelial cell 
% 
(95% CI) 
 
Absolute (104) 
(95% CI) 
1.2 
(-5.8, 7.4) 
 
-20.9 
(-85.1, 50.5) 
-1.0 
(-11.3, 5.7) 
 
-12.9 
(-100·8, 57·3) 
∆ Sputum IL-8 pg/ml (95% CI) 
-562.5 
(-2131.0, 131.4) 
  -1201.3 * 
(-2409.6, -76.6) 
∆ Sputum MPO ng/ml (95% CI) 
-126.6 
(-433.9, 58.1) 
  -215.0 * 
(-556.0, -36.7) 
∆ HDAC activity AFU/10
6
 cells 
(95% CI) 
-3.5 
(-23.7, 5.0) 
-2.2 
(-23.4, 3.5) 
Table 3.3 Change in lung function and biomarkers following treatment (relative to response 
to treatment with inhaled beclometasone alone).   
*; p<0.05 
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3.3.1.2 Theophylline 
The group treated with theophylline alone did not demonstrate efficacy for any 
lung function outcome except for post-bronchodilator FVC at four weeks (304 ml 
(95% CI 5 to 604), p=0.046). 
3.3.1.3 ACQ score 
After four weeks, the combination of theophylline and inhaled beclometasone 
produced a significant improvement in ACQ score (-0.47 (95% CI –0.91 to –0.04), 
p=0.033) (figure 3.5 and table 3.3). Theophylline alone also reduced the ACQ 
score (-0.55 (–0.99 to –0.11), p=0.016). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Change in ACQ score by 28 days of treatment. 
Paired t-test (error bars represent 95% confidence intervals). p-values were derived from 
comparison of groups to beclometasone dipropionate changes using ANCOVA. Figure key- 
ICS; inhaled beclometasone, Theo; theophylline, T+ICS; theophylline and inhaled 
beclometasone combination 
 
3.3.2 Sputum samples 
3.3.2.1 Induced sputum cytology 
Ninety-seven percent of the subjects who completed the trial produced a sample 
adequate for analysis both pre and post-treatment. Treatment with the 
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combination of theophylline and inhaled beclometasone was associated with a 
reduction in the mean absolute (-10.99 (95% CI -18.15, -1.65), p=0.018) and 
percentage sputum lymphocyte count (-0.8% (-1.4, -0.1), p=0.028) (table 3.3). 
No other relative treatment differences in sputum proportions were observed. 
Given the change in sputum lymphocytes, sputum supernatant RANTES levels 
were subsequently examined. However no difference was detected in RANTES 
expression following treatment with theophylline and inhaled beclometasone (-
0.131pg/ml (-0.849, 0.528), p=0.487). 
3.3.2.2 Inflammatory biomarkers in sputum 
At four weeks, treatment with theophylline alone was associated with a 
reduction in sputum supernatant IL-8 (-1201.3 pg/ml (95% CI, -2409.6, -276.6), 
p=0.009) and MPO (-215.0 ng/ml (-556.0, -36.7), p=0.026) measured by ELISA 
(table 3.3). No significant changes were detected in sputum IL-8 or MPO in the 
group treated with theophylline and inhaled beclometasone. 
3.3.2.3 HDAC activity 
HDAC activity was measurable for a subgroup within each treatment group 
[inhaled beclometasone n=4, theophylline alone n=7, theophylline and inhaled 
beclometasone n=7]. The majority of samples had a low level of HDAC activity. 
No difference was obvious between the groups at baseline or after treatment 
(Tables 3.2 & 3.3 and figure 3.6). 
3.3.3 Serum theophylline levels 
Serum concentrations were below the current recommended target range (10-
20µg/ml). The mean serum concentration for the theophylline alone group 
(4.9µg/ml, SD 2.4) was similar to that achieved in the theophylline and inhaled 
beclometasone group (4.3µg/ml, SD 2.0). 
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Figure 3.6 Change in HDAC activity from randomisation to 28 days of treatment.  
Individual plots of HDAC activity shown. Error bars represent 95% confidence intervals. 
Figure key- ICS; inhaled beclometasone, Theo; theophylline, Theo + ICS; theophylline and 
inhaled beclometasone combination 
 
3.3.4 Compliance 
Eighty seven percent of the subjects who completed the trial achieved greater 
than 80% compliance with therapy. 
3.3.5 Adverse events 
Two serious adverse events occurred during the trial. Both occurred in the 
theophylline alone arm. One subject was admitted with viral meningitis and 
another with chest pain due to gastro-oesophageal reflux (a pre-existing 
condition). Neither subject withdrew from the study. There were two 
withdrawals due to adverse events. One each occurred in the inhaled 
beclometasone alone (diarrhoea and vomiting) and theophylline and inhaled 
beclometasone (headache) arms. The frequency of headache was equal between 
the groups (six reported for theophylline and inhaled corticosteroids, seven for 
theophylline and five for low dose beclometasone). Gastrointestinal upset was 
common in the theophylline alone group with fourteen episodes being reported.  
Two subjects reported nausea whilst on theophylline and low dose 
beclometasone but no other gastrointestinal symptoms were reported. 
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Pharyngitis was reported by three subjects in the low dose beclometasone alone 
group.  
3.4 Discussion 
Previous research has demonstrated that the therapeutic response to inhaled 
corticosteroids is impaired in smokers with asthma (7,, 8-10), highlighting the 
need for alternative treatment approaches for this large subgroup of asthma. 
This exploratory clinical trial examined the efficacy of an alternative approach 
to treatment of smokers with mild to moderate asthma with the aim of restoring 
corticosteroid sensitivity. The hypothesis behind the study was based on previous 
research that suggested that the addition of low dose theophylline to an inhaled 
corticosteroid would improve lung function to a greater degree than inhaled 
corticosteroid alone due to a restoration of HDAC activity. This study shows that 
the combination of theophylline and inhaled corticosteroid produces 
improvements in several indices of lung function and improves asthma control in 
smokers with asthma. 
Treatment with the combination of oral theophylline and inhaled beclometasone 
was associated with a borderline significant increase in pre-bronchodilator FEV1 
after 28 days of treatment and with a large improvement in both pre-
bronchodilator PEF and FVC. The improvement seen in both PEF and FVC (and 
the associated drop in ACQ score) make it likely that the observed improvement 
in FEV1 is real and not a result of multiple comparisons. Given its exploratory 
nature and hence small numbers of participants it is likely that the study was 
slightly underpowered to conclusively demonstrate the change in FEV1 with 
treatment. A post hoc power calculation, based on the between patient standard 
deviation (285 ml) for the theophylline and inhaled corticosteroid group suggests 
that 48 subjects per group are required for 80% power to detect a FEV1 
difference of 165ml between the combination of theophylline and inhaled 
corticosteroid and inhaled corticosteroid alone arms. The power calculation for 
PEF based on the between patient standard deviation (46.4 L/min) for the 
theophylline and inhaled corticosteroid group, reveals that 23 subjects per group 
would be required to provide 80% power for the detection of a 40 L/min 
difference in PEF. 
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The size of the improvement seen following treatment with low dose 
theophylline and inhaled beclometasone (40 L/min) is likely to be clinically 
significant as it is larger (263, 264) or equivalent (265) to the improvements seen 
when long acting β2-agonists are added to inhaled corticosteroids in non-smoking 
asthmatics. Furthermore, this improvement is much larger than that produced 
by montelukast (9) and high dose inhaled corticosteroids in smokers with asthma 
(8). The improvements in lung function following treatment with low dose 
theophylline and inhaled beclometasone were also associated with a reduction in 
ACQ score that was just below the clinically significant threshold of 0.5 (254). 
Therefore further research, powered on these findings, should be carried out 
using low dose theophylline and inhaled corticosteroid to confirm and extend our 
understanding of the efficacy of this combination in smokers with asthma. 
Theophylline alone did not produce any significant changes in pre-bronchodilator 
lung function relative to that produced by inhaled beclometasone. Nevertheless 
low dose theophylline treatment did produce an increase in post-bronchodilator 
FVC, a clinically significant reduction in ACQ score and reduction in sputum 
supernatant cytokines. Previous research has demonstrated that theophylline has 
this effect in COPD (266). No direct comparison was made between low dose 
theophylline and the combination of low dose theophylline and inhaled 
corticosteroid. However, it would appear that if this comparison was made, 
there would be no clear difference between the two arms. Therefore low dose 
theophylline alone may provide an alternative therapy in smokers with asthma as 
it resulted in a clear improvement in asthma symptoms (as measured by the 
asthma control questionnaire) and could also produce a clear improvement in 
lung function relative to inhaled corticosteroid in an adequately powered trial 
(albeit smaller than that seen with the combination of low dose theophylline and 
inhaled corticosteroid).  
Theophylline has many modes of action including non-specific phosphodiesterase 
activity and adenosine receptor antagonism (100) and both of these mechanisms 
could produce bronchodilation. However the improvement in lung function with 
low dose oral theophylline in combination with inhaled beclometasone is unlikely 
to be due to a bronchodilating effect of theophylline alone, given the absence of 
statistically significant improvements in lung function with low dose theophylline 
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alone. Therefore there appears to be a synergistic interaction between low dose 
theophylline and beclometasone. 
Given the many suggested mechanisms of theophylline there are several ways by 
which low dose theophylline could synergise with corticosteroids to improve lung 
function in smokers with asthma. One potential mechanism that I have 
attempted to address is the ability of low dose theophylline to restore HDAC 
activity. Exposure to cigarette smoke in-vitro can reduce HDAC activity and this 
can be restored by low doses of theophylline (92, 102) leading to the hypothesis 
that reduced HDAC activity is responsible for the reduced corticosteroid 
response seen in smokers with asthma. The serum concentration of theophylline 
achieved in the subjects was within the range previously demonstrated to 
stimulate HDAC activity. Unfortunately an increase in HDAC activity was not 
observed in those subjects treated with theophylline and inhaled 
beclometasone. The reason for this may be explained by the low number of 
sputum macrophages harvested for analysis. The subjects recruited were able to 
produce specimens of sufficient quality for differential counting and supernatant 
analysis, but the number of macrophages harvested for HDAC was low and at the 
detection limit of the technique. Another consideration is that there was no step 
to allow for inspection of the cells selected for the HDAC assay. Therefore there 
is the possibility that contamination with non-viable cells and neutrophils may 
have affected the results and resulted in the observed low levels of HDAC 
activity. Future work examining theophylline in smokers with asthma needs to 
address the underlying mechanism/s responsible. Bronchoalveolar lavage 
samples should be obtained to allow sufficient macrophages for HDAC analysis 
and to ensure comparisons can be made with previous research. As previously 
mentioned theophylline can also act as a non-specific phosphodiesterase 
inhibitor and an adenosine receptor antagonist and the contribution of these 
(and other) mechanisms to synergism between theophylline and inhaled 
beclometasone should be examined in smokers with asthma. 
The present study has also demonstrated that treatment with theophylline and 
inhaled beclometasone is associated with a reduction in sputum lymphocytes. 
How a reduction in the number of airway lymphocytes following the addition of 
low dose theophylline would lead to an improved response to inhaled 
beclometasone is unclear at present. A possible explanation is that the reduction 
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observed is spurious due to the group treated with theophylline and inhaled 
beclometasone having a slightly higher sputum lymphocyte count at baseline 
(albeit non-significantly different). Therefore a small drop in the sputum 
lymphocytes in this group combined with a small increase in the inhaled 
beclometasone treated group could produce this apparent drop. Previous work 
addressing the reproducibility of induced sputum counts has also demonstrated 
that sputum lymphocyte counts display lower reproducibility compared to 
eosinophils and neutrophils so we may be observing the inherent variability of 
this aspect of induced sputum (267). However low dose theophylline has 
previously been demonstrated to reduce bronchoalveolar lavage lymphocyte 
numbers with an associated alteration in the CD4/CD8 ratio and reduction in the 
late asthmatic response to allergen challenge (268). Therefore the observed 
reduction in sputum lymphocytes may reflect a true effect of theophylline in this 
patient group. If this issue is to be addressed, in future studies examination of 
bronchial biopsy samples and bronchoalveolar lavage samples will be required. 
This approach would allow identification of lymphocyte sub-types and their 
response to low dose theophylline and inhaled corticosteroid therapy. The 
absence of other changes in sputum inflammatory cell profiles is likely to be due 
to both the short duration of treatment and the absence of sputum eosinophilia 
and neutrophilia in the patients studied. 
3.5 Conclusions 
This pilot study demonstrates improvements in both lung function and asthma 
control from the addition of low dose theophylline to inhaled beclometasone in a 
group of smokers with mild to moderate asthma. The presented results are 
encouraging given the documented poor response of smokers with asthma to 
standard doses of inhaled corticosteroids and the need for more effective 
therapies in this group. Important questions that need to be addressed in future 
trials include: 
•  the effect of lower doses of theophylline and hence the lowest effective 
dose 
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• the relative performance of the combination of low dose theophylline and 
low dose inhaled corticosteroid to  
o high dose inhaled corticosteroid 
o combined long acting beta agonist and inhaled corticosteroid 
o leukotriene receptor antagonists 
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4 Efficacy of a PPARγ agonist in a group of 
smokers with asthma 
4.1 Introduction 
Inhaled corticosteroids are recommended as the first-line treatment for chronic 
persistent asthma (1, 2). However a significant proportion of individuals with 
asthma fail to establish complete control with this approach (25). Despite the 
use of additional therapies (including oral corticosteroids) around 10% of 
subjects with asthma have poorly controlled symptoms and this group are 
estimated to consume 50% of the costs associated with the treatment of asthma 
(29, 32). Few new treatments have become available for asthma since the 
introduction of inhaled corticosteroids with the exception of leukotriene 
receptor antagonists and anti-IgE therapy, both of which offer some 
improvements in control but are generally regarded as inferior to 
corticosteroids. A number of targeted treatment approaches are in 
development, for example p38 MAPK inhibitors, with the hope that these will 
provide better control of corticosteroid resistant disease. However the 
beneficial effects of corticosteroids depend on their ability to act simultaneously 
via a number of mechanisms and pathways. Therefore the narrow focus of 
targeted therapies could mean that they will only be able to provide 
improvements in a small proportion of patients. 
Smokers with asthma exhibit an impaired response to both inhaled and oral 
corticosteroids (5-10, 22-24), an accelerated decline in lung function (15, 21), 
increased emergency department visits for asthma (with associated costs) (16, 
17) and increased severity of symptoms compared to non-smoking asthmatics 
(11, 12). The prevalence of smoking in asthma reflects that of the general 
population and therefore smokers with asthma comprise a large group of 
patients with poorly controlled disease (261). Smoking cessation is an effective 
therapy in this group (49), but as sustained quitting rates are low, additional or 
alternative therapies are needed for individuals with asthma who continue to 
smoke. 
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The glucocorticoid receptor is a member of the nuclear hormone receptor 
family, which includes peroxisome proliferator activated receptor-γ (PPARγ). 
PPAR-γ agonists exert anti-inflammatory effects on multiple inflammatory cell 
subtypes in-vitro and reduce inflammation in animal models of both asthma and 
neutrophilic airways disease (113, 114). Based on this evidence and the 
hypothesis that the PPAR-γ agonist rosiglitazone would have beneficial anti-
inflammatory actions in smokers with asthma I undertook an exploratory clinical 
trial to examine the effect of rosiglitazone on lung function and other outcomes 
in a group of smokers with asthma. 
4.2 Methods 
4.2.1 Subjects 
Subject characteristics, inclusion/exclusion criteria and recruitment methods 
were as described in the general methods chapter. All subjects provided 
informed consent and the study was approved by the West Glasgow Ethics 
Committee. 
4.2.2 Study design 
A full description of the study is provided in the general methods chapter. In 
brief the study was a randomised, prospective, double-blind, double-dummy, 
active comparator, parallel group design. Subjects were randomly allocated to 
one of four treatment groups, two of which are discussed in this chapter. 
Subjects were randomised to either 4 mg twice a day oral rosiglitazone maleate 
or 100mcg twice a day inhaled hydrofluoroalkane beclometasone dipropionate 
(figure 4.1). Subjects returned for pre-bronchodilator lung function at two weeks 
and repeated the assessments carried out at the baseline visit after four weeks. 
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Figure 4.1 Randomisation schedule 
 
4.2.3 Measurements 
A full description of the measurements is provided in the general methods 
chapter. Lung function assessments conformed to consensus guidelines (246). 
Sputum induction, differential count and supernatant analysis were performed 
as discussed in the general methods chapter. Continuation of smoking during the 
study was confirmed by history and the detection of urinary nicotine 
metabolites. Subjects were regarded as current smokers if their category was 
mild smoker or greater and their urine cotinine level was greater than 
1.1mg/ml. Treatment compliance was assessed by tablet count and inhaler 
weight. 
4.2.4 Statistical analysis 
The reduced response to inhaled corticosteroids in smokers with asthma 
combined with a lack of published information on the effect of 
thiazolidinediones in asthma prevented the performance of standard power 
calculations. The study was informed by FEV1 changes from a previous clinical 
trial employing oral corticosteroids in smokers with asthma (23). This resulted in 
the estimate that 22 subjects were required per group to detect a 230ml 
difference in FEV1 between the treatment arms and to allow for a 10% dropout 
rate. A slightly higher dropout rate occurred (13%) during the trial resulting in a 
short extension to allow a larger numbers of subjects to be randomised to 
treatment. 
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The primary endpoint was difference in pre-bronchodilator FEV1 between 
rosiglitazone and beclometasone alone at 28 days. The secondary endpoints 
were change in pre and post bronchodilator PEF, FVC, FEF25-75, FEF75 & ACQ. 
Exploratory endpoints were change in sputum differential & supernatant and 
serum cytokines. Lung function changes were examined using ANCOVA 
(incorporating Kenward & Roger’s method (262)) using SAS v8.2 (SAS Institute 
Inc, NC, USA). All data obtained after day one of treatment was used for 
analysis. The remaining statistical analysis was performed using Minitab 15 
(Minitab Inc. State College, PA, USA). α was set at 0.05. Due to the exploratory 
nature of the trial the analyses were not corrected for type 1 errors due to 
multiple comparisons. 
4.3 Results 
A total of 3895 subjects with asthma were invited to participate between August 
2005 and May 2007, of whom 294 gave positive responses. Following telephone 
screening, visits were arranged for 187 subjects and 91 subjects met criteria for 
randomisation (Figure 4.2). Forty five subjects were randomised to theophylline 
and theophylline and inhaled beclometasone. The results from the forty-six 
subjects randomised to either rosiglitazone or inhaled beclometasone will be 
discussed from this point. Twenty-three subjects were allocated to rosiglitazone 
and twenty-three to inhaled beclometasone alone. The baseline demographic, 
clinical (including previous inhaled corticosteroid and long-acting β2-agonist use) 
and inflammatory characteristics of recruited subjects in each group were well 
matched (tables 4.1 & 4.2). All the endpoints presented are the changes relative 
to the inhaled corticosteroid group response. 
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Figure 4.2 CONSORT diagram.  
SAE; serious adverse event. 
Allocation 
Follow up 
Analysis 
Screened (n=187) 
74 practices 
3895 invitation letters 
294 responses 
Enrolment 
Randomised (n=46) 
Excluded (n=96): 
Not meeting inclusion criteria (n=95) 
Pregnancy (n=1) 
Randomised to other treatments 
(n=45) 
 
Rosiglitazone 
Allocated n=23 
Received n=23 
Did not receive n=0 
Lost to follow up 
(n=2) 
Discontinued 
intervention 
(n=3) 
Analysed (n=18) 
 
Excluded from 
analysis (n=0) 
Inhaled 
beclometasone 
Allocated n=23 
Received n=23 
Did not receive n=0 
Lost to follow up 
(n=0) 
Discontinued 
intervention 
(n=2) 
Analysed (n=21) 
 
Excluded from 
analysis (n=0) 
SAE  
 
Rosiglitazone n=0 
 
Inhaled steroid n=0 
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Inhaled 
beclometasone Rosiglitazone 
No of patients 23 23 
Age (years) 
 
42 
(36, 53) 
 
 
41 
(33, 54) 
 
Gender 
Female (% of total) 61 57 
 
BMI (kg/m²) Mean (range) 
 
25.5 
(18.4, 34.2) 
26.1 
(19.5, 38.6) 
 
Pack years 
 
24 
(15, 30) 
21 
(13, 40) 
 
Duration of asthma (years) 
 
16 
(8, 31) 
18 
(6, 29) 
Inhaled corticosteroid use at 
screening 
 
(% of subjects) 
 
Dose, 
beclometasone 
equivalent mcg 
65 
 
 
800 
(400, 800) 
83 
 
 
800 
(400, 800) 
LABA use at screening (%) 26 30 
Specific IgE antibody positive (%) 61 78 
Total IgE level (IU/ml) 
 
87 
(34, 396) 
 
 
239 
(49, 488) 
 
Spirometry  
Pre-BD FEV1 (% predicted) 
 
75 
(72, 89) 
 
 
70 
(60, 89) 
 
Reversibility 
FEV1 % improvement 
 
16 
(13, 20) 
 
 
16 
(13, 26) 
 
Asthma Control 
Questionnaire score 
(0 to 6) Mean (SD) 
1.8 
(0.9) 
1.9 
(0.7) 
Table 4.1 Baseline demographics.  
Data presented as median (interquartile range) unless stated otherwise. Abbreviations; SD; 
standard deviation, BMI; Body Mass Index, FEV1; Forced expiratory volume in 1 second, pre 
BD; pre bronchodilator, ACQ; Asthma Control Questionnaire score (range, 0 to 6, with 
higher scores indicating worse asthma control), IgE; immunoglobulin E, LABA; long-acting 
β2-agonist., mcg; microgram, IU/ml; international units per ml, kg/m2; kilograms per square 
metre. 
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Inhaled beclometasone Rosiglitazone 
Sputum total cell count (106) 4.3 (2.6, 7.3) 
4.7 
(2.4, 9.9) 
Eosinophils % 0.9 (0.3, 1.6) 
1.1 
(0.5, 3.0) 
Eosinophils (104) 2.1 (0.8, 5.8) 
5.1 
 (1.5, 17.9) 
Neutrophils % 25.5 (9.6, 44.6) 
28.8 
(13.1, 46.2) 
Neutrophils (104) 122.7  (25, 188) 
150.3  
(27, 492) 
Macrophages % 52.8 (32.0, 64.4) 
48.0 
(26.1, 64.1) 
Macrophages (104) 184.2  (96, 437) 
185.8  
(105, 355) 
Lymphocytes % 1.3 (0.6, 2.6) 
1.4 
(0.7, 2.0) 
Lymphocytes (104) 4.9  (2.3, 11.2) 
8.0  
(2.1, 13.5) 
Bronchial epithelial cells  % 10.5 (8.3, 15.4) 
11.0 
(6.7, 18.8) 
Bronchial epithelial cells  (104) 40.7  (20.5, 99.4) 
49.6  
(28.4, 110.6) 
Table 4.2 Baseline sputum counts.  
Data expressed as median (IQR) 
 
4.3.1 Lung function 
At two weeks, rosiglitazone demonstrated a borderline improvement in pre-
bronchodilator FEV1 (164 ml, (95% CI –1 to 329), p=0.051), a significant 
improvement in pre-bronchodilator PEF (32.7 L/min, (5.7 to 59.7), p=0.018) and 
significant improvement in both FEF25-75 (0.36 L/sec, (0.088 to 0.632), p=0.010) 
and FEF75 (0.24 L/sec, (0.094 to 0.386), p=0.002)(table 4.3). After four weeks, 
the group treated with rosiglitazone demonstrated a borderline improvement in 
pre-bronchodilator FEV1 (183ml (–1 to 367), p=0.051) (figure 4.3) and a 
significant improvement in FEF25-75 (0.243 L/sec (0.025 to 0.461) p=0.030) (figure 
4.4 and table 4.3). There was no difference between the groups treated with 
rosiglitazone and inhaled beclometasone for other measurements of lung 
function. 
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4.3.2 ACQ score 
There was no difference between the rosiglitazone and inhaled beclometasone 
groups when changes in ACQ scores were compared (table 4.3). 
 Rosiglitazone 
∆ Pre BD FEV1 
 
ml (95% CI) 
Day 14 
 
 
Day 28 
  164 † 
(-1, 329) 
 
  183 † 
(-1, 367) 
∆ Pre BD FVC 
 
ml (95% CI) 
Day 14 
 
 
Day 28 
45 
(-114, 204) 
 
156 
(-42, 354) 
∆ Pre BD PEF 
 
L/min (95% CI) 
Day 14 
 
 
Day 28 
   33 * 
(5, 59) 
 
23 
(-6, 53) 
∆ Pre BD FEF25-75 
 
L/sec (95% CI) 
Day 14 
 
 
Day 28 
    0.360 * 
(0.088, 0.632) 
 
    0.243 * 
(0.025, 0.461) 
∆ Pre BD FEF75 
L/sec (95% CI) 
Day 14 
 
 
Day 28 
   0.240 * 
(0.094, 0.386) 
 
 0.111 
(-0.011, 0.233) 
 
∆ ACQ score 
 
∆ 
(95% CI) 
-0.07 
(-0.52, 0.38) 
Table 4.3 Change in lung function and ACQ following treatment (relative to response to 
inhaled beclometasone alone).  
PEF; peak expiratory flow, FVC; forced vital capacity, FEF25-75; forced mid-expiratory flow 
rate, FEF75; forced expiratory flow at 75% of FVC, 95% CI; 95 percent confidence intervals. *; 
p<0.05, †; p=0.05 
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Figure 4.3 Mean group FEV1 changes from randomisation to 14 and 28 days of treatment  
Paired t-test (error bars represent 95% confidence intervals)). p-values were derived from 
comparison of rosiglitazone group change to inhaled beclometasone dipropionate change 
using ANCOVA. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Mean group FEF25-75 changes from randomisation to 14 and 28 days of treatment   
Paired t-test (error bars represent 95% confidence intervals). p-values were derived from 
comparison of rosiglitazone group change to inhaled beclometasone dipropionate change 
using ANCOVA. 
 
0 
p=0.030 
p=0.010 
Day 14 Day 28 
ICS 
Rosi 
0.3 
0.1 
0.2 
0.4 
0.6 
0.5 
0.7 
-0.1 
-0.2 
-0.3 
Change in 
FEF25-75  
(L/sec) 
Change in  
FEV1 (ml) 
-200 
 200 
 100 
 300 
 400 
p=0.051 
Day 14 Day 28 
-300 
0 
-100 
p=0.051 
ICS 
Rosi 
Chapter 4  125 
4.3.3 Sputum samples 
4.3.3.1 Induced sputum cytology 
No relative treatment differences in sputum proportions were observed (table 
4.4). 
4.3.3.2 Sputum supernatant 
A borderline relative reduction in sputum IL-8 was observed in the group treated 
with rosiglitazone (-534.1pg/ml, (95% CI -1844.4, 36.5), p=0.068) (table 4.4). 
4.3.4 Compliance 
Eighty-five percent of the subjects who completed the study achieved greater 
than 80% compliance with therapy. 
4.3.5 Adverse events 
No serious adverse events occurred in the rosiglitazone and inhaled 
beclometasone arms during the trial. There were two withdrawals due to 
adverse events. One each occurred in the rosiglitazone (periorbital oedema) and 
inhaled beclometasone alone (diarrhoea and vomiting) arms. The frequency of 
headache was equal between the groups (five for low dose beclometasone and 
four for rosiglitazone). Three subjects in the low dose beclometasone alone 
group reported pharyngitis. 
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 Rosiglitazone 
∆ Sputum total cell count ∆ (10
6) 
(95% CI) 
 
1.3 
(-2.1, 4.7) 
 
∆ Sputum eosinophil 
% 
(95% CI) 
 
Absolute (104) 
(95% CI) 
 
0.1 
(-1.0, 1.3) 
 
1.42 
(-4.7, 6.4) 
 
∆ Sputum neutrophil 
% 
(95% CI) 
 
Absolute (104) 
(95% CI) 
 
4.5 
(-16.5, 26.5) 
 
32.9 
(-120.4, 201.1) 
 
∆ Sputum macrophage 
% 
(95% CI) 
 
Absolute (104) 
(95% CI) 
 
3.4 
(-13.3, 16.8) 
 
110.0 
(-27.2, 326.8) 
 
∆ Sputum lymphocyte 
% 
(95% CI) 
 
Absolute (104) 
(95% CI) 
 
-0.5 
(-1.1, 0.4) 
 
-0.19 
(-7.0, 5.2) 
 
∆ Sputum  
bronchial epithelial cell 
% 
(95% CI) 
 
Absolute (104) 
(95% CI) 
 
-4.7 
(-11.3, 2.0) 
 
5.9 
(-65.8, 78.4) 
 
∆ Sputum IL-8 pg/ml (95% CI) 
 
-534.1 
(-1844.4, 36.5) 
 
∆ Sputum MPO ng/ml (95% CI) 
 
-91.3 
(-335.1, 44.2) 
 
Table 4.4 Change in sputum counts and supernatant cytokines following treatment (relative 
to treatment with inhaled beclometasone alone).  
∆; change in endpoint, IL-8; interleukin-8, MPO; myeloperoxidase, pg/ml; picogrammes per 
millilitre, ng/ml; nanogrammes per millilitre. 
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4.4 Discussion  
There exists within asthma a sub-population of patients who fail to respond 
adequately to current therapies (25, 29). As a result this group have worse 
asthma control and consume a disproportionate share of healthcare budgets. 
Smokers with asthma comprise part of this difficult to control group. Previous 
research has demonstrated that the therapeutic response to inhaled 
corticosteroids is impaired in smokers with asthma (5-10). A recent post hoc 
analysis suggests that smokers with asthma also fail to gain the expected 
response to the combination of inhaled steroids and long acting beta agonists 
(compared to non smokers with asthma)(10). This randomised, controlled, 
exploratory clinical trial examined the impact of a novel alternative approach 
using the PPARγ agonist rosiglitazone, in a group of smokers with mild to 
moderate asthma. 
Treatment with rosiglitazone produced a trend to improvement in pre-
bronchodilator FEV1 over low dose inhaled beclometasone at both 14 and 28 
days. This improvement is much larger than the effect seen in previous trials in 
smokers with asthma examining inhaled corticosteroids (7, 8) and was associated 
with an improvement in PEF (albeit non-significant) and a significant 
improvement in the spirometric marker of small airway function FEF25-75. The 
improvements in the pre-defined secondary endpoints suggest that the change 
observed in FEV1 is real. The failure to produce a conclusive improvement 
relative to inhaled beclometasone is likely to be due to underpowering for the 
primary endpoint. A post hoc power calculation based on a standard deviation of 
286ml and power of 80% with α set at 5% suggests that 40 patients per group 
would have been required for sufficient powering for this endpoint. 
The improvement seen in FEF75 at 14 days and FEF25-75 at both 14 and 28 days is 
of interest as there are few therapies available for the treatment of small 
airway obstruction. Small airway obstruction, seen in many pulmonary conditions 
including asthma (269), the smoking related condition COPD (270) and several 
interstitial lung diseases (271), is associated with dynamic hyperinflation, 
reduced exercise tolerance and increased dyspnoea. Given the observed 
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improvement consideration should be given to studying PPARγ agonists in 
subjects with evidence of small airways obstruction. 
A surprising finding was that the improvement in lung function produced by 
rosiglitazone was not associated with a reduction in asthma symptoms (as 
detected by the ACQ score) or sputum profile or supernatant at 28 days. What 
can explain this discrepancy? With regards the lack of sputum change the 
subjects had relatively mild asthma and did not display sputum eosinophilia or 
neutrophilia at baseline. This would explain the lack of change in the proportion 
of these inflammatory cells and possibly the lack of change in sputum cytokines. 
One explanation for the lack of change in ACQ score is that the lung function 
change is a random chance event given the small number of subjects studied. 
However the secondary lung function endpoints demonstrate a similar 
improvement so whilst a random chance event is possible other explanations are 
worth consideration. A possible alternative is that we are observing dissociation 
between lung function improvements and change in the asthma control 
questionnaire score. Previous examples include a study comparing two inhaled 
steroid preparations which examined improvements in lung function and 
symptoms (as measured by the asthma quality of life questionnaire) (272). The 
study found a clear difference in asthma symptom control between the two 
preparations despite equivalence between the treatments for lung function 
changes. When examined, the asthma symptom change was found to correlate 
poorly with lung function changes (272). This dissociation between asthma 
symptoms measured by questionnaire and lung function change has been 
observed in other studies (273, 274). An additional alternative explanation for 
the lack of change in ACQ score is a waning of the beneficial effect of 
rosiglitazone on lung function by 28 days and hence a lack of detectable effect 
on asthma symptoms. This could be supported by the reduction in the size of in 
PEF, FEF25-75 and FEF75 differences between the rosiglitazone and inhaled 
beclometasone arms from 14 to 28 days. This waning of effect, if true, could be 
due to tachyphylaxis. Previous research has demonstrated a down-regulation of 
PPARγ expression in asthmatics following treatment (117) and future research 
should follow PPARγ expression in endobronchial specimens during and after 
treatment with PPARγ agonists.  
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What are the mechanism(s) by which rosiglitazone could be producing the 
observed improvements in lung function? The cause of the poor response to 
corticosteroids in smokers with asthma is currently unknown. However one 
possible reason is that cigarette smoking induces an oxidative stress mediated 
change in the glucocorticoid receptor, resulting in a change in its behaviour and 
efficacy (32). Recent research has demonstrated that rosiglitazone is able to 
bind to the glucocorticoid receptor ligand binding domain with properties 
suggestive of a partial agonist effect (177). Therefore the presented results may 
be a demonstration of an alternative mode of glucocorticoid receptor activation 
which has resulted in the detected improvements in lung function. Alternatively, 
PPARγ has been shown to modulate a distinct but partially overlapping set of 
inflammatory genes compared to corticosteroids (163). Further studies 
examining the relative effects of rosiglitazone on corticosteroid and PPARγ-
specific functional outputs are indicated in smokers with asthma and other 
conditions with relative corticosteroid insensitivity. 
Only one dose of rosiglitazone was employed in this study. This was due to the 
exploratory nature of the trial and the lack of previous data on the efficacy of 
rosiglitazone in asthma. The dose selected is in common use for the treatment 
of non-insulin dependent diabetes and within the dose range used in models of 
asthma. Given the suggestion of a response, future trials should incorporate a 
number of different doses to examine the lung function dose response. Another 
aspect of PPARγ stimulation not examined in this trial is the potential synergistic 
interaction between PPARγ and the glucocorticoid receptor (38, 176). Previous 
research suggests that PPARγ may be able to modulate glucocorticoid receptor 
function and hence in circumstances of glucocorticoid insensitive inflammation 
may restore corticosteroid sensitivity. Therefore future trials should also 
examine combinations of PPARγ agonists and corticosteroids to determine if 
there is a useful synergistic effect with this combination.  
Polymorphisms in the PPARγ receptor have recently been examined in a group of 
young subjects with asthma (178). Several single nucleotide polymorphisms were 
examined in this study and one common SNP combination, the ProC phenotype, 
was associated with increased asthma exacerbations and hospital admissions. 
Unfortunately PPARγ SNPs were not examined in this study and therefore the 
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role of SNPs in treatment response cannot be examined here. Clearly SNPs 
affecting the PPARγ expression level and behaviour may be of relevance to 
treatment response and future work should address the relevance of PPARγ 
receptor polymorphisms to response to treatment with PPARγ agonists. 
4.5 Conclusion 
This exploratory trial, the first to examine a PPARγ agonist in asthma, has 
demonstrated improvement in some lung function parameters in a group of 
smokers with mild to moderate asthma. The conclusions that can be drawn from 
the study are tempered by the exploratory nature of this work, reflected in the 
short duration of treatment and small number of subjects involved. However the 
results presented provide sufficient information for an adequately powered trial 
of this therapy in smokers with asthma and are encouraging given the 
documented poor response of smokers with asthma to standard doses of inhaled 
corticosteroids and the need for more effective therapies in this group. Further 
trials should be undertaken to examine PPARγ agonists in asthma and other 
obstructive airway conditions. PPARγ agonists may represent a new therapeutic 
class for inflammatory diseases. 
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5 Impact of smoking on cytokine profiles in 
asthma 
5.1 Introduction 
The cytokine family acts as a system of communication and control within and 
between the innate and adaptive immune system. Over 100 cytokines are 
recognised and many have important roles in the development and persistence 
of chronic inflammatory diseases. Multiple cell types from the innate and 
adaptive immune system express and respond to cytokines and there is 
considerable overlap in cytokine production. For example interleukin (IL)-13 can 
be produced by T lymphocytes, mast cells, eosinophils and basophils and IL-6 
can be produced by macrophages, bronchial epithelial cells, T cells and B cells. 
Several cytokines have been linked to the recruitment and continued activation 
of inflammatory cells within the airway lumen and bronchial walls and are being 
targeted by pharmaceutical companies as potential therapeutic targets as a 
result (275).  
Despite the crossover in expression that exists, cytokine profiles can be useful in 
characterising inflammation based on the expression of certain sets of cytokines 
by certain inflammatory cells. The classic example is the division of T 
lymphocyte CD4 helper cells into Th1 and Th2 subsets. Th1 cells develop from 
naive T helper cells in response to IL-12, interferon-γ (IFNγ) and transforming 
growth factor β (TGFβ) and produce IFNγ, TGFβ and IL-2. Th2 cells differentiate 
in response to IL-4 and produce IL-4, 5, 6, 9, 10, 13 and 25.  
Asthma, when introduced from an immunological perspective, is commonly 
portrayed as a prototypic Th2 disease. Whilst some evidence obtained from 
atopic subjects with asthma is available to support this view, it is an obvious 
oversimplification as it does not reflect the breadth of the inflammatory 
response in asthma, which is best described as heterogeneous (276, 277). The 
best current anti-inflammatory therapy for asthma is inhaled corticosteroids. 
Corticosteroids are effective in reducing eosinophilic inflammation, a range of 
inflammatory cytokines and provide a degree of asthma symptom control in the 
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majority of subjects. However not all subjects with asthma gain the expected 
benefits from this treatment and this probably reflects variations in the 
inflammatory response within asthma. Cigarette smoking is recognised to 
modulate the response to treatment with corticosteroids in asthma (261). This 
clinical observation suggests an altered immune response may be present in this 
sub group. Cytokines can alter corticosteroid responses, as demonstrated by 
previous in-vitro research using IL-2 & 4 to induce corticosteroid resistance in T 
lymphocytes (66-69). Previous research in smokers with asthma has identified 
increased sputum IL-8 (41) and reduced sputum IL-18 (42) (compared to matched 
non smokers with asthma). However no further information is available on 
differences in cytokine profiles in smokers with asthma compared to non-
smoking asthmatics.  
Recent developments allow the detection of multiple cytokines simultaneously in 
a small volume of sample. This unbiased approach permits the examination of a 
wide range of cytokines, providing increased levels of discrimination between 
different types of inflammatory diseases and more closely reflects the situation 
in-vivo. Therefore a cross sectional study was undertaken to obtain samples to 
examine the hypothesis that smokers with asthma have a reduced response to 
corticosteroids due to increased levels of IL-2 and 4 and that smokers with 
asthma display a generally altered cytokine profile in sputum and plasma 
compared to non-smokers with asthma. 
5.2 Methods 
5.2.1 Subjects 
Subject characteristics, inclusion/exclusion criteria and recruitment methods 
are as described in the general methods chapter. All subjects provided informed 
consent and the study was approved by the West Glasgow Ethics Committee. 
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5.2.2 Study design 
A full description of the study is provided in the general methods chapter. In 
brief, the study was a cross-sectional design with unblinded use of oral 
dexamethasone to determine corticosteroid sensitivity. 
5.2.3 Measurements 
Sputum induction and processing were as previously described in the general 
methods chapter. Briefly the whole sputum sample method was used and 
homogenisation was via mechanical processing with reduced levels of 
dithiothreitol. Sputum supernatants were collected post processing for sputum 
differential counts and stored in aliquots at -80°C until processing. Plasma was 
from heparinised blood samples. Subject demographics, baseline spirometry pre 
and post inhaled β2 agonist and pre and post oral corticosteroid trial, asthma 
control questionnaire (ACQ) score and exhaled nitric oxide levels (FENO 
performed at flow rate 50ml/sec) were used for the analyses reported in this 
chapter. Baseline results for all subjects were examined. Compliance with oral 
dexamethasone was confirmed by suppression of plasma cortisol below 
50nmol/l. If this criterion was met then the subject’s data post corticosteroid 
data was analysed. 
Initial cytokine analysis was performed using a 25-plex cytokine assay (Invitrogen 
Ltd, 3 Fountain Drive, Inchinnan Business Park, Paisley, UK). Through the use of 
spectrally encoded antibody conjugated beads, this assay can simultaneously 
detect eotaxin, granulocyte/monocyte-colony stimulating factor (GM-CSF), 
interferon-α (IFN-α), interferon-γ (IFN-γ), interleukin (IL) 1-receptor-antagonist 
(IL-1RA), IL-1β, IL-2, IL-2 receptor (IL-2R), IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-
10, IL-12 (p40/p70), IL-13, IL-15, IL-17, Interferon-inducible Protein of 10 kDa 
(IP-10 aka CXCL10), Monocyte Chemotactic Protein 1 (MCP-1), Monokine Induced 
by IFN-γ (MIG aka CXC9), Monocyte Inflammatory Protein 1α (MIP-1α aka CCL3), 
Monocyte Inflammatory Protein 1β (MIP-1β aka CCL4), Regulated upon 
Activation, Normal T cell Expressed and Secreted (RANTES aka CCL5), and 
Tumour Necrosis Factor-α (TNF-α). The assay allows for the detection of each 
individual cytokine in a single sample due to the unique fluorescent properties of 
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the individual bead with reference to a standard curve for each cytokine. The 
signal output and hence cytokine concentration was determined on a Luminex 
100TM analyser (Luminex Corporation, 12212 Technology Blvd, Austin, Texas, 
USA) by interpolation into a standard curve made up of standards of known 
concentration. The determined concentration of some cytokines, when below 
the lowest standard concentration but greater than zero, was accepted if the 
regression obtained from the standards was linear in that working range and was 
of sufficient gradient to allow for confident extrapolation. Otherwise the 
concentrations were accepted to be half of the lowest standard rather than zero 
in order that these values could be included. Sputum cytokines were performed 
in all groups and plasma cytokine measurements in smokers and non-smokers 
with asthma only. No reproducibility testing was performed for the Luminex 
assay. 
A high sensitivity ELISA for IL-6 (Abcam plc, Cambridge, UK) was employed to 
examine and corroborate the Luminex findings for this cytokine. Briefly, samples 
were diluted based on the Luminex result to ensure they were within the 
working range of the assay (0.8 to 50 pg/ml). One hundred microliters of sample 
was added to an equal volume of diluent in the pre-coated wells of the EILSA 
plate followed by fifty microliters of biotinylated anti-IL-6. The samples were 
then gently shaken for three hours at room temperature. The plate was then 
washed and horse-radish peroxidase solution was added to each well followed by 
gentle shaking for thirty minutes. The plate was then washed followed by the 
addition of tetramethylbenzidine solution. The plate was covered for five 
minutes and then read on a plate reader with 450nm as the primary wavelength 
and 620nm as the reference immediately after the application of stop solution 
(sulphuric acid). No reproducibility testing was performed. 
5.2.4 Statistical analysis 
Parametric data was assessed using t testing and non parametric using Mann-
Whitney testing. All comparisons are between smokers and non smokers. Ex-
smokers were not included in the formal comparison analyses due to the small 
number of subjects but some basic significance tests were performed. 
Correlations were performed using Spearman rank correlation testing (result 
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derived by this method designated by ρ) and Pearson correlation (result derived 
by this method designated by r). Adjustment for multiple comparisons was not 
performed routinely as all data was treated as exploratory. Correction where 
performed was by the Bonferonni method. α was set at 0.05. Analysis was 
performed on SAS v 9.1 (TS1M3) for Windows (SAS Institute Inc., NC, USA) and 
MINITAB 15 (Minitab Inc. State College, PA, USA). 
5.3 Results 
75 volunteers were screened for suitability. 22 smokers with asthma, 21 non 
smokers with asthma and 10 ex-smokers with asthma were recruited to the 
study. 20 smokers, 21 non smokers and 10 ex-smokers were able to provide a 
suitable sputum sample for analysis. 18 smokers, 9 ex-smokers and 16 non 
smokers with asthma completed the corticosteroid trial and were able to provide 
a sputum sample. 19 smokers and 20 non smokers with asthma provided plasma 
samples at baseline and 18 smokers and 17 non smokers with asthma provided a 
plasma sample at completion of the corticosteroid trial. 
5.3.1 Baseline demographics 
The recruited subjects were well matched for relevant clinical characteristics 
(tables 5.1, 5.2 & 5.3). Smokers with asthma had significantly higher daily 
inhaled corticosteroid dose and asthma control questionnaire scores. The 
bronchodilator response of smokers with asthma was lower than that observed in 
non-smokers with asthma. No significant difference was evident for baseline 
sputum eosinophil or sputum neutrophil percentage when smokers and non-
smokers with asthma were compared (table 5.3). 
5.3.2 Lung function response to oral corticosteroid trial 
Non-smokers with asthma made a significant improvement in lung function in 
response to the oral corticosteroid trial (figure 5.1 & table 5.4). This was in 
contrast to smokers and ex-smokers with asthma who both failed to make a 
significant improvement in lung function in response to oral corticosteroids. 
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There was no significant difference present when change in lung function was 
compared between the groups. 
 
Smokers 
(n=22) 
Ex-Smokers 
(n=10) 
Non-Smokers 
(n=21) 
Age  
(yrs) 
46.6 
(6.7) 
49.8 
(9.0) 
42.5 
(10.0) 
Sex (F:M) 12:10 5:5 11:10 
BMI  
(kg/m2) 
26.6 
(6.0) 
31.2 
(5.3) 
28.9 
(5.1) 
Asthma Duration 
(yrs) 
22.1 
(15.9) 
24.6 
(15.9) 
28.6 
(15.0) 
Pack yrs 27.6 (15.7) 
28.5 
(15.9)  
Ex-smokers (no of yrs)  7.7 (4.5)  
Inhaled steroid 
(mcg/day) 
   1046 * 
(611) 
1280 
(551) 
679 
(419) 
ACQ Score 
(0 to 6)   
   2.2 * 
(0.9) 
2.3 
(0.7) 
1.5 
(0.8) 
Oral daily 
dexamethasone dose 
(mg) 
6.6 
(0.9) 
7.3 
(0.9) 
7.1 
(0.8) 
Equivalent daily 
prednisolone dose (mg) 
44.1 
(6.1) 
48.3 
(6.1) 
47.1 
(5.0) 
Table 5.1 Baseline demographics.  
Data presented as mean (SD). *; p≤0.05.  
 
 
 
Smokers 
(n=22) 
Ex-Smokers 
(n=10) 
Non-Smokers 
(n=21) 
Pre BD FEV1  
(litres) 
2.24 
(0.58) 
2.47 
(0.79) 
2.43 
(0.69) 
Pre BD FEV1 
(% predicted) 
73.6 
(18.5) 
79.7 
(24.1) 
73.3 
(15.3) 
Pre BD PEF  
(l/min) 
360.5 
(77.8) 
388.0 
(124.8) 
399.1 
(98.6) 
Pre BD PEF  
(% predicted) 
81.7 
(20.8) 
85.4 
(24.7) 
85.8 
(19.1) 
Pre BD FVC 
(litres) 
3.33 
(0.8) 
3.63 
(0.9) 
3.68 
(0.9) 
Pre BD FVC 
(% predicted) 
89.6 
(12.8) 
96.4 
(19.8) 
92.9 
(12.2) 
Pre BD FEV1/FVC 68.1 (12.1) 
67.5 
(8.3) 
65.9 
(9.9) 
Pre BD FEF25-75 
(% pred) 
44.8 
(19.7) 
49.2 
(24.1) 
42.7 
(16.1) 
FEV1 BD response   15.1 * (8.5) 
19.5 
(17.7) 
23.3 
(15.9) 
Table 5.2 Pre steroid lung function.  
Data presented as mean (SD). *; p≤0.05. 
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Smokers 
(n=20) 
Ex-Smokers 
(n=10) 
Non-Smokers 
(n=21) 
Total cell count (106)  
mean (SD) 
6.1 
(6.5) 
8.3 
(9.8) 
7.1 
(14.8) 
Eosinophils % 0.4 (0.0, 1.0) 
1.0 
(0.1, 5.0) 
0.3 
(0.0, 2.0) 
Eosinophils (104) 2.0 (0.0, 4.0) 
5.0 
(1.0, 23.0) 
1.0 
(0.0, 7.0) 
Neutrophils % 34 (24, 56) 
37 
(22, 63) 
24 
(11, 41) 
Neutrophils (104) 125.0 (77, 240) 
151.0 
(99, 304) 
106.5 
(39, 178) 
Macrophages % 37 (25, 61) 
31 
(27, 60) 
45 
(32, 61) 
Macrophages (104) 168.0 (106, 243) 
132.0 
(82, 199) 
121.0 
(78, 254) 
Lymphocytes % 0.1 (0, 0.6) 
0.0 
(0, 0) 
0.0 
(0, 0.5) 
Lymphocytes (104) 1.0 (0.0, 3.0) 
0.0 
(0.0, 0.0) 
0.0 
(0.0, 2.0) 
Bronchial epithelial cells % 16 (9, 26) 
23 
(12, 31) 
23 
(12, 31) 
Bronchial epithelial cells 
(104) 
59.0 
(25, 98) 
57.0 
(24, 60) 
55.0 
(40, 109) 
Table 5.3 Baseline sputum profiles.  
Data presented as median (IQR) except where indicated 
 
 
 
Lung function response  
(FEV1 (ml)) 
(95% CI) 
 
Non-smokers with asthma   173 * (10, 336) 
Ex-smokers with asthma 257 (-154, 667) 
Smokers with asthma 32 (-115, 178) 
Table 5.4 Within group lung function response to oral steroid.  
Data presented as mean change (95% CI). *; p<0.05 
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Figure 5.1 Within group change in FEV1 in response to oral steroid trial.  
Data presented as mean (95% CI). Interval bars represent 95% confidence intervals and 
mean. *; p<0.05. 
 
5.3.3 Change in sputum cell profile in response to oral 
corticosteroid trial 
All groups demonstrated significant within group eosinophil changes in response 
to oral corticosteroids. The eosinophil response of smokers with asthma to the 
corticosteroid trial was equivalent to that observed in non-smokers with asthma 
(smokers change -0.4% (95% CI -0.8, 0.0), non-smokers -0.2% (-2.0, 0.0), 
p=0.430). Smokers with asthma also demonstrated a trend to a reduction in 
sputum neutrophil percentage following oral corticosteroids (change -12.0% (-
25.01, 1.99), p=0.081). However no difference was evident when compared to the 
neutrophil change observed in non-smokers. No significant changes were evident 
within or between the groups for the other sputum cell subtypes in response to 
the oral corticosteroid trial. 
* 
Change  
in FEV1  
(ml) 
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5.3.4 Change in asthma control questionnaire score 
No improvement was detected in asthma symptoms as measured by asthma 
control questionnaire score (ACQ) in smokers with asthma in response to oral 
corticosteroids (change -0.1 (95% CI -0.7, 0.6), p=0.804). Non-smokers with 
asthma did demonstrate a reduction in ACQ score but this was less than the 
minimal clinically significant reduction of 0.5 (254) (change -0.4 (-0.7, -0.0), 
p=0.031). Ex-smokers demonstrated a large and significant reduction in ACQ 
score (change -1.0 (-1.8, -0.1), p=0.029). No significant difference was present 
when change in ACQ score in non-smokers and smokers with asthma was 
compared.  
Change in ACQ score demonstrated a significant negative correlation with lung 
function improvement for non-smokers and ex-smokers with asthma. The 
correlation between ACQ score and lung function change in smokers with asthma 
demonstrated a trend to improvement: 
• Non-smokers; r = -0.63, p=0.007 
• Ex-smokers; r = -0.69, p=0.039 
• Smokers; r = -0.42, p=0.062 
5.3.5 Sputum supernatant cytokines 
The majority of the sputum cytokines detectable by the Luminex assay were 
measurable in the majority of subjects (table 5.5). Expression levels were close 
to the limit of detectability for IL-4 in all groups, IFN-γ in non smokers and ex-
smokers with asthma & IL-15 in non-smokers with asthma. 
Smokers with asthma tended to a higher median concentration for all cytokines 
and had significantly higher levels (relative to non-smokers with asthma) for: 
• IFN-γ (smokers with asthma 2.6 pg/ml (IQR 0.7, 7.7), non smokers 0.3 
pg/ml (IQR 0.3, 0.3), p=0.025) (figure 5.2),  
• IL-2 (4.4 pg/ml (3.7, 6.5), 3.6 pg/ml (3.3, 4.5), p=0.041) (figure 5.3),  
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• IL-4 (0.1 pg/ml (0.1, 4.9), 0.1 pg/ml (0.1, 0.1), p=0.038) (figure 5.4),  
• IL-6 (34.4 pg/ml (14.1, 72.4), 8.1 pg/ml (4.4, 11.1), p<0.001) (figure 5.5),  
• IL-7 (28.5 pg/ml (14.0, 65.6), 16.3 pg/ml (6.6, 18.8), p=0.044) (figure 
5.6),  
Sputum IL-12 and IL-17 levels demonstrated a trend to a difference between 
smokers and non smokers with asthma (IL-12; smokers 30.6 pg/ml (12.6, 49.6), 
non smokers 15.5 pg/ml (8.7, 22.2), p=0.050, IL-17; smokers 44.9 pg/ml (4.0, 
146.1), non smokers 4.0 pg/ml (4.0, 16.3), p=0.080). Performing corrections for 
multiple comparisons resulted in all sputum cytokine differences losing 
statistical significance save sputum IL-6 (p=0.023).  
Adjusting for inhaled corticosteroid dose did not remove any of the differences 
and strengthened several. For example sputum IL-12 and IL17 were significantly 
higher in smokers with asthma as a result of this change (IL-12; adjusted mean 
difference 37.2 pg/ml (95% CI 7.4, 67.1), p=0.016, IL-17; 102.4 pg/ml (14.9, 
190.0), p=0.023). 
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Figure 5.2 Baseline sputum supernatant IFNγ.  
Data presented as individual points with median. 
p=0.025 
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 Smokers Ex-Smokers Non-Smokers 
Eotaxin 2.6 (0.7, 7.7) 
4.6 
(0.7, 5.5) 
1.1 
(0.3, 2.1) 
GM-CSF 21.5 (8.4, 76.1) 
20.1 
(6.6, 96.9) 
17.0 
(6.6, 26.1) 
IFN-α 24.5 (20.8, 55.5) 
24.5 
(20.8, 85.5) 
20.8 
(16.8, 27.9) 
IFN-γ    2.6 * (0.3, 13.2) 
0.3 
(0.3, 25.0) 
0.3 
(0.3, 0.3) 
IL-1RA 12480 (3475, 18561) 
5205 
(3808, 7943) 
3448 
(2173, 8428) 
IL-1β 19.4 (14.1, 34.4) 
16.7 
(15.4, 42.1) 
16.7 
(12.7, 20.7) 
IL-2    4.4 * (3.7, 6.5) 
3.8 
(3.3, 5.1) 
3.6 
(3.3, 4.5) 
IL-2R 105.8 (11.9, 287.8) 
163.7 
(113.0, 568.1) 
40.2 
(11.9, 132.3) 
IL-4    0.1 * (0.1, 4.9) 
0.1 
(0.1, 2.0) 
0.1 
(0.1, 0.1) 
IL-5 4.7 (2.8, 10.6) 
3.5 
(3.1, 6.6) 
3.1 
(2.4, 4.2) 
IL-6    34.4 * (14.1, 72.4) 
34.9 
(13.6, 148.9) 
8.1 
(4.4, 11.1) 
IL-7    28.5 * (14.0, 65.6) 
36.2 
(14.5, 59.0) 
16.3 
(6.6, 18.8) 
IL-8 1096 (398, 3059) 
1715 
(476, 5862) 
650 
(332, 1030) 
IL-10 3.2 (1.8, 9.4) 
3.2 
(1.8, 6.4) 
1.8 
(1.5, 2.4) 
IL-12   30.6 
†
 
(12.6, 49.6) 
23.6 
(12.6, 56.8) 
15.5 
(8.7, 22.2) 
IL-13 29.4 (20.5, 47.6) 
29.9 
(22.5, 57.7) 
24.4 
(20.5, 28.1) 
IL-15 13.5 (0.6, 45.8) 
14.5 
(0.6, 79.8) 
0.6 
(0.6, 7.0) 
IL-17 44.9 (4.0, 146.1) 
36.3 
(4.0, 164.0) 
4.0 
(4.0, 16.3) 
IP-10 52.6 (31.6, 104.5) 
192.6 
(54.0, 327.1) 
59.8 
(26.3, 90.2) 
MCP-1 298.4 (162.5, 396.2) 
317.2 
(189.6, 452.6) 
192.8 
(140.6, 214.8) 
MIG 127.9 (50.8, 239.3) 
191.1 
(94.4, 229.0) 
124.8 
(47.8, 146.5) 
MIP-1α 26.9 (16.5, 62.9) 
45.4 
(29.0, 71.2) 
20.8 
(17.4, 29.0) 
MIP-1β 30.1 (19.3, 86.7) 
128.1 
(43.0, 352.1) 
27.8 
(17.6, 38.8) 
RANTES 42.8 (32.0, 64.1) 
58.4 
(38.1, 107.5) 
37.3 
(23.0, 44.9) 
TNF-α 3.7 (1.7, 7.6) 
4.0 
(2.5, 6.5) 
2.2 
(1.9, 2.8) 
Table 5.4 Sputum cytokine results-Baseline comparisons.  
Data presented as median (IQR). All pg/ml. *; p≤0.05, †; p=0.05 
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Figure 5.3 Baseline sputum supernatant IL-2.  
Data presented as individual points with median.  
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Figure 5.4 Baseline sputum supernatant IL-4.  
Data presented as individual points with median.  
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Figure 5.5 Baseline sputum supernatant IL-6.  
Data presented as individual points with median.  
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Figure 5.6 Baseline sputum supernatant IL-7.  
Data presented as individual points with median.  
 
p<0.001 
p=0.044 
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5.3.5.1 Baseline sputum cytokine correlations 
Smokers with asthma demonstrated a number of significant correlations between 
sputum cytokine concentrations and clinical endpoints: 
• Sputum IL-6 and IL-8 demonstrated negative correlations with baseline 
pre-bronchodilator FEV1: 
o IL-6; ρ= -0.47 (95% CI -0.75, -0.03), p=0.032 (Figure 5.7) 
o IL-8; ρ= -0.46 (-0.75, -0.03), p=0.034  
• Sputum IL-6 and 8 also demonstrated positive correlations with subject 
age: 
o IL-6; ρ= 0.45 (0.01, 0.75), p=0.039 
o IL-8; ρ= 0.59 (0.21, 0.82), p=0.004  
• Sputum IL-6 correlated negatively with exhaled nitric oxide (FENO) levels 
(ρ= -0.54 (-0.81, -0.08), p=0.020) 
• Sputum IL-8 levels correlated positively with baseline ACQ score (ρ= 0.45 
(0.01, 0.75), p=0.040) 
• Sputum IL-8 correlated positively with pack years (ρ= 0.62 (0.25, 0.84), 
p=0.002) 
• Sputum IL-1RA demonstrated a positive correlation with asthma duration 
(ρ= 0.44 (-0.01, 0.74), p=0.048) 
• Sputum MIP1α and MIP1β levels both correlated positively with subject 
age (MIP1α; ρ= 0.47 (0.03, 0.75) p=0.032, MIP1β; ρ= 0.50 (0.07, 0.77), 
p=0.020) 
No correlation was evident between sputum IL-6 and pack years in smokers with 
asthma (ρ=0.35 (-0.11, 0.69), p=0.124). 
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Figure 5.7 Scatter plot of smokers with asthma pre-steroid sputum Log IL-6 against pre-
bronchodilator pre-corticosteroid trial FEV1.   
 
Sputum cytokines from non smokers with asthma also demonstrated correlations 
with some clinical endpoints: 
• Sputum IFNγ correlated positively with baseline pre-bronchodilator FEV1 
(ρ= 0.44 (0.01, 0.73), p=0.041), and negatively with percentage change in 
FEV1 in response to corticosteroids (ρ= -0.53 (-0.80, -0.09), p=0.018) 
Multiple negative correlations were evident between sputum cytokines from non 
smokers with asthma and asthma duration: 
• IL-1β; ρ= -0.48 (-0.75, -0.05), p=0.025  
• IL-2; ρ= -0.52 (-0.78, -0.12), p=0.012 
• IL-5; ρ= -0.66 (-0.85, -0.33), p<0.001 
• IL-10; ρ= -0.62 (-0.83, -0.26), p=0.002 
• IL-13; ρ= -0.42 (-0.72, 0.01), p=0.049 
• GM-CSF; ρ= -0.47 (-0.75, -0.04), p=0.029 
ρ= -0.47 (95% CI -0.75, -0.03), p=0.032 
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• IFNα; ρ= -0.59 (-0.81, -0.21), p=0.003 
• MIP1α; ρ= -0.56 (-0.80, -0.16), p=0.007 
• MIP1β; ρ= -0.46 (-0.75, -0.04), p=0.029  
Sputum cytokines from ex-smokers with asthma also demonstrated a number of 
correlations. Negative correlations were present between sputum IL-8 and MCP-1 
and FENO: 
• IL-8 and FENO; ρ= -0.71 (-0.93, -0.09), p=0.022 
• MCP-1 and FENO; ρ=-0.69 (-0.93, -0.06), p=0.027 
Positive correlations were present between IL-6, MIP1α, MIP1β and baseline ACQ 
score in ex-smokers with asthma: 
• IL-6 and ACQ; ρ= 0.68 (0.09, 0.92), p=0.021 
• MIP1α and ACQ; ρ= 0.63 (-0.01, 0.90), p=0.042 
• MIP1β and ACQ; ρ= 0.67 (0.08, 0.92) p=0.023 
IL-6 and asthma duration also positively correlated (ρ= 0.67 (0.07, 0.91), 
p=0.024) and a strong correlation was present between sputum IL-6 and pack 
years (ρ= 0.68 (0.09, 0.92), p=0.022) in ex-smokers with asthma. 
5.3.6 Baseline plasma cytokines 
Several differences in median plasma cytokine concentrations were evident 
when smokers and non smokers with asthma were compared (table 5.6). Smokers 
demonstrated significantly reduced median plasma levels of IL-1RA, 10 & 13 and 
GM-CSF: 
• IL-1RA; smokers 209 pg/ml (IQR 160, 252) non-smokers 247 pg/ml (IQR 
224, 279), p=0.024 (Figure 5.8) 
• IL-10; smokers 1.5 pg/ml (1.4, 1.7), non smokers 1.7 pg/ml (1.5, 2.6), 
p=0.027 (Figure 5.9) 
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• IL-13; smokers 19.5 pg/ml (17.4, 21.5), non smokers 21.5 pg/ml (20.0, 
23.4), p=0.004 (Figure 5.10) 
• GM-CSF; smokers 6.6 pg/ml (5.1, 13.0), non smokers 10.3 pg/ml (10.3, 
26.1), p= 0.028 (Figure 5.11) 
A borderline significant difference in plasma IL-12 was also present (smokers 
69.1 pg/ml (46.0, 76.1), non-smokers 70.9 pg/ml (64.3, 85.7), p=0.053). 
Correcting for multiple comparisons resulted in all plasma cytokine differences 
losing statistical significance. 
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Figure 5.8 Baseline plasma IL-1RA levels in non-smokers with asthma and smokers with 
asthma. 
Data presented as individual points with median.  
p=0.024 
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 Smokers Non Smokers 
Eotaxin 88.8 (50.7, 129.5) 
75.4 
(42.7, 86.0) 
GM-CSF    6.6 * (5.1, 13.0) 
10.3 
(10.3, 26.1) 
IFN-α 31.2 (24.5, 34.3) 
32.7 
(28.7, 38.6) 
IFN-γ 2.0 (0.3, 4.2) 
2.6 
(0.6, 4.2) 
IL-1RA    209 * (160, 252) 
247 
(224, 279) 
IL-1β 13.4 (10.7, 20.1) 
15.4 
(12.7, 18.7) 
IL-2 4.4 (3.7, 5.6) 
5.0 
(4.6, 6.6) 
IL-2R 294 (165, 354) 
251 
(214, 306) 
IL-4 9.7 (6.3, 11.3) 
10.5 
(8.7, 12.7) 
IL-5 2.5 (2.2, 2.7) 
2.5 
(2.5, 2.9) 
IL-6 1.5 (1.2, 2.4) 
1.7 
(1.3, 3.2) 
IL-7 16.3 (7.7, 18.0) 
19.7 
(14.9, 25.0) 
IL-8 5.1 (3.6, 6.8) 
6.1 
(3.6, 8.0) 
IL-10   1.5 * (1.4, 1.7) 
1.7 
(1.5, 2.6) 
IL-12   69.1 
†
 
(46.0, 76.1) 
70.9 
(64.3, 85.7) 
IL-13   19.5 * (17.4, 21.5) 
21.5 
(20.0, 23.4) 
IL-15 4.1 (0.6, 8.0) 
7.5 
(1.4, 9.9) 
IL-17 22.6 (8.6, 47.7) 
33.4 
(16.3, 56.2) 
IP-10 10.0 (8.1, 17.0) 
14.5 
(10.8, 17.9) 
MCP-1 175 (116, 259) 
165 
(148, 234) 
MIG 12.0 (12.0, 12.0) 
12.0 
(12.0, 13.7) 
MIP-1α 24.1 (19.1, 25.7) 
24.1 
(24.1, 27.3) 
MIP-1β 27.8 (24.4, 31.3) 
31.3 
(27.2, 35.3) 
RANTES 4639 (3654, 6269) 
6387 
(4300, 9426) 
TNF-α 2.7 (2.1, 2.9) 
2.9 
(2.5, 3.2) 
Table 5.6 Baseline plasma cytokines.  
All pg/ml. Expressed as median (IQR). *; p≤0.05, †; p=0,05 
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Figure 5.9 Baseline plasma IL-10 levels in non-smokers with asthma and smokers with 
asthma.  
Data presented as individual points with median.  
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Figure 5.10 Baseline plasma IL-13 levels in non-smokers with asthma and smokers with 
asthma.  
Data presented as individual points with median.  
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Figure 5.11 Baseline plasma GM-CSF levels in non-smokers with asthma and smokers with 
asthma. 
Data presented as individual points with median.  
 
5.3.6.1 Baseline plasma cytokine correlations  
A number of correlations were present between baseline plasma cytokines and 
clinical characteristics.  
IL2 and IL2R correlated with pre corticosteroid pre BD FEV1 in smokers with 
asthma: 
• IL-2; ρ= -0.46 (95% CI -0.76, -0.01), p=0.040 
• IL-2R; ρ= -0.62 (-0.84, -0.24), p=0.003 
A trend to statistical significance was evident for the correlation between 
plasma IL-6 and IL-12 and pre corticosteroid pre BD FEV1 in the smokers with 
asthma: 
• IL-6; ρ= -0.42 (-0.73, 0.05), p=0.068 
p=0.028 
Chapter 5  151 
• IL-12; ρ= -0.39 (-0.72, 0.07), p=0.087 
Multiple correlations were also evident between baseline plasma cytokines from 
smokers with asthma and FEV1 response to oral corticosteroid: 
• IFN-α; ρ= 0.45 (-0.01, 0.75), p=0.049 
• IL-1RA; ρ= 0.68 (0.33, 0.87), p<0.001 
• IL-1β; ρ= 0.62 (0.23, 0.84), p=0.003 
• IL-2; ρ= 0.58 (0.17, 0.82), p=0.007 
• IL-5; ρ= 0.60 (0.20, 0.83), p=0.004 
• MIP-1α; ρ= 0.48 (0.03, 0.77), p=0.033 
• IL-12; ρ= 0.55 (0.13, 0.80), p=0.011 
• IL-15; ρ= 0.63 (0.25, 0.84), p=0.002 
Further correlations were observed between FENO and smokers with asthma 
plasma cytokines: 
• IL-17; ρ= 0.60 (0.17, 0.84), p=0.008 
• RANTES; ρ= -0.59 (-0.83, -0.15), p=0.009 
No correlation was evident between plasma IL-6 and pack years in the smokers 
with asthma (ρ= -0.31 (-0.67, 0.17), p=0.194).  
Non smokers also demonstrated correlations for plasma cytokines but these were 
with different clinical parameters. Correlations existed between ACQ score at 
baseline and non smokers with asthma plasma cytokines for: 
• IL-8; ρ= 0.44 (0.00, 0.74), p=0.043 
• MCP-1; ρ= 0.57 (0.16, 0.81), p=0.007 
A borderline significant correlation was also present between IFNγ and baseline 
ACQ score (ρ= 0.43 (-0.02, 0.73), p=0.055). Non smokers with asthma 
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demonstrated a significant correlation between plasma IFNγ and subject age (ρ= 
-0.48 (-0.76, -0.05), p=0.027) and several correlations between plasma cytokines 
and asthma duration: 
• IL-2; ρ= -0.52 (-0.78, -0.10), p=0.015 
• MCP-1; ρ= -0.45 (-0.74, -0.01), p=0.041 
• MIP-1β; ρ= -0.44 (-0.74, 0.00), p=0.047 
A borderline correlation was also evident between IL-1β and asthma duration (ρ= 
-0.42 (-0.73, 0.02), p=0.056). 
5.3.7 Correlation between sputum cytokines 
When sputum cytokine relationships were examined, using the data from all 
groups combined, a number of strongly significant relationships were evident. 
Sputum IL-2 & 4 demonstrated a strong correlation (ρ=0.73, p<0.001) and IFNγ 
correlated strongly with IL-2 (ρ=0.74, p<0.001), IL-4 (ρ=0.95, p<0.001) and IL-12 
(ρ=0.79, p<0.001). Sputum IL-6 correlated weakly with IL-17 (ρ= 0.29, p=0.039) 
and strongly with IL-8 (ρ= 0.70, p<0.001) and MCP-1 (ρ= 0.74, p<0.001). 
5.3.8 Correlation between plasma and sputum cytokines 
When the correlations between plasma and sputum cytokines from all subjects 
were examined only two statistically significant correlations were present. 
Plasma and sputum eotaxin demonstrated a positive correlation (ρ= 0.66 (95% CI 
0.43, 0.81), p<0.001). Plasma and sputum RANTES demonstrated a negative 
correlation (ρ= -0.33 (-0.59, -0.01), p=0.041). A number of cytokines 
demonstrated borderline significant associations: 
• IL-1RA; ρ= -0.28 (-0.55, 0.05), p=0.090 
• IL-2; ρ= 0.29 (-0.04, 0.56), p=0.079 
• IL-7; ρ= -0.30 (-0.57, 0.02), p=0.065 
• MIG; ρ= 0.31 (-0.02, 0.57), p=0.061 
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• MIP1α; ρ= 0.29 (-0.04, 0.56), p=0.080 
Non smokers with asthma demonstrated a significant correlation between plasma 
and sputum eotaxin (ρ= 0.54 (0.12, 0.79), p=0.011) and borderline significant 
correlations between plasma and sputum: 
• GM-CSF; ρ= 0.38 (-0.08, 0.70), p=0.094 
• IL-2; ρ= 0.39 (-0.06, 0.71), p=0.078 
• IL-15; ρ= 0.40 (-0.05, 0.72), p=0.072 
• MIG; ρ= 0.43 (-0.02, 0.73), p=0.055 
• MIP1α; ρ= 0.40 (-0.05, 0.72), p=0.074 
• MIP1β; ρ= 0.38 (-0.08, 0.70), p=0.092 
Smokers with asthma also demonstrated a significant correlation between 
plasma and sputum eotaxin (ρ= 0.63 (0.22, 0.85), p=0.004) and further 
significant correlations for IL-1RA (ρ= -0.56 (-0.82, -0.11), p=0.015) and IL-2 (ρ= 
0.51 (0.04, 0.80), p=0.029). No borderline significant correlations between 
plasma and sputum cytokines were evident for smokers with asthma. 
5.3.9 Cytokine response to oral corticosteroid trial 
5.3.9.1 Sputum cytokine responses 
When examined post corticosteroid trial sputum median cytokine levels 
demonstrated significant differences between smokers and non smokers with 
asthma for IL-1RA and eotaxin and a failure of sputum IL-6 levels to normalise 
(table 5.7 and figure 5.12): 
• IL1RA; smokers 16140 pg/ml (IQR 4208, 23359), non-smokers 4838 pg/ml 
(IQR 2626, 7892), p=0.033 
• Eotaxin; smokers 4.2 pg/ml (1.5, 9.9), non-smokers 0.8 (0.2, 1.7), 
p=0.012 
• IL-6; smokers 24.3 pg/ml (17.5, 74.2), non-smokers 7.3 (2.2, 21.1), 
p=0.027 
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A borderline difference was still present for sputum IL-12 (smokers 41.5 (20.3, 
114.0), non smokers 18.4 (7.7, 52.7), p=0.080).  
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Figure 5.12 Comparison of pre steroid and post steroid sputum IL-6 in smokers with asthma 
Data presented as individual points with median.  
 
Few statistically significant within group changes were evident in response to 
oral corticosteroids. Smokers with asthma demonstrated an increase in sputum 
IFNα (53.5 pg/ml (95% CI 12.1, 94.8), p=0.014) and IL-17 (119.6 pg/ml (30.7, 
208.5), p=0.011). A smaller but non-significant increase was also evident for 
these cytokines in the non-smokers in response to the corticosteroid trial (IFNα; 
24.5 pg/ml (-4.2, 53.3), p=0.089, IL-17; 67.4 pg/ml (-8.5, 143.3), p=0.078). An 
increase in MIP1β was detected in the non-smokers with asthma (31.6 pg/ml 
(4.6, 58.5), p=0.025). No significant differences were evident for change in 
sputum cytokines in smokers with asthma compared to non smokers with 
asthma. 
p=0.556 
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 Smokers Ex Smokers 
Non 
Smokers 
Eotaxin    4.2 * (1.5, 9.9) 
1.9 
(1.1, 6.1) 
0.8 
(0.2, 1.7) 
GM-CSF 56.4 (10.3, 144.9) 
38.6 
(23.1, 180.2) 
31.7 
(8.4, 102.8) 
IFN-α 58.5 (20.8, 137.2) 
48.1 
(27.9, 122.9) 
31.2 
(18.8, 74.2) 
IFN-γ 6.2 (0.3, 47.4) 
0.3 
(0.3, 68.5) 
0.3 
(0.3, 26.9) 
IL-1RA    16140 * (4208, 23359) 
12168 
(7528, 14239) 
4838 
(2626, 7892) 
IL-1β 28.9 (14.7, 82.4) 
62.4 
(20.7, 83.0) 
18.1 
(12.4, 40.9) 
IL-2 5.2 (3.6, 10.6) 
4.5 
(3.6, 11.8) 
4.2 
(3.3, 5.4) 
IL-2R 132.1 (5.0, 834.3) 
113.0 
(40.2, 976.8) 
60.3 
(5.0, 529.9) 
IL-4 3.5 (0.1, 22.0) 
0.1 
(0.1, 25.2) 
0.1 
(0.1, 7.6) 
IL-5 6.5 (2.9, 26.2) 
3.8 
(3.5, 24.0) 
3.8 
(2.4, 10.2) 
IL-6    24.3 * (17.5, 74.2) 
16.0 
(4.4, 52.4) 
7.3 
(2.2, 21.1) 
IL-7 22.6 (9.7, 66.6) 
29.3 
(8.7, 63.5) 
12.6 
(5.8, 38.1) 
IL-8 1389 (329, 3325) 
681 
(409, 1867) 
400 
(209, 1280) 
IL-10 5.6 (1.5, 11.8) 
4.8 
(1.6, 10.9) 
2.1 
(1.5, 7.1) 
IL-12 41.5 (20.3, 114.0) 
33.3 
(18.4, 113.2) 
18.4 
(7.7, 52.7) 
IL-13 45.5 (20.5, 97.3) 
35.3 
(28.1, 103.1) 
25.8 
(21.5, 68.7) 
IL-15 16.5 (0.6, 112.9) 
19.0 
(0.6, 152.1) 
3.1 
(0.6, 67.9) 
IL-17 116.4 (4.0, 303.6) 
86.3 
(4.0, 312.0) 
16.2 
(4.0, 201.2) 
IP-10 15.2 (7.2, 29.9) 
16.4 
(9.9, 23.6) 
16.4 
(6.4, 63.9) 
MCP-1 345 (185, 492) 
269 
(168, 383) 
184 
(124, 305) 
MIG 73.6 (12.0, 231.6) 
157.3 
(47.8, 239.3) 
60.1 
(24.9, 164.8) 
MIP-1α 41.9 (17.4, 96.6) 
82.6 
(22.4, 146.7) 
26.1 
(17.4, 57.0) 
MIP-1β 47.1 (21.0, 109.0) 
59.1 
(38.3, 113.4) 
36.5 
(14.9, 85.0) 
RANTES 29.3 (19.5, 54.8) 
31.1 
(20.0, 59.2) 
32.5 
(12.4, 47.8) 
TNF-α 5.0 (1.9, 11.3) 
11.8 
(2.6, 15.5) 
2.6 
(1.9, 7.1) 
Table 5.7 Post steroid trial sputum cytokines.  
Data presented as median pg/ml (IQR). *; p<0.05  
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5.3.9.2  Plasma cytokine responses to oral corticosteroids 
The difference between smokers and non smokers for plasma IL-1RA and IL-13 
was still present post oral corticosteroids. The difference between smokers and 
no-smokers for plasma GM-CSF and IL-10 was narrowed as a result of oral 
corticosteroids and lost statistical significance. However other plasma cytokines 
changed in response to the oral corticosteroid trial resulting in significant 
differences becoming evident when smokers and non smokers with asthma were 
compared (table 5.8): 
• IFNα; smokers 29.5 pg/ml (IQR 24.5, 34.3), non smokers 34.3 pg/ml (IQR 
31.2, 37.2), p=0.035 
• IL-5; smokers 2.2 pg/ml (1.9, 2.2), non smokers 2.5 pg/ml (2.2, 2.5), 
p=0.006 
• IL-7; smokers 7.6 pg/ml (6.8, 14.5), non smokers 15.4 pg/ml (13.5, 17.1), 
p=0.019 
• MIP-1α; smokers 20.8 pg/ml (20.8, 22.4), non smokers 24.1 pg/ml (22.4, 
27.3), p=0.016 
• MIP-1β; smokers 24.4 pg/ml (21.5, 30.1), non smokers 30.1 pg/ml (27.8, 
32.4), p=0.011 
• TNFα; smoker 2.1 pg/ml (1.9, 2.5), non smokers 2.7 pg/ml (2.4, 2.9), 
p=0.007 
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 Smokers Non 
Smokers 
Eotaxin 149.2 (97.9, 208.3) 
101.1 
(82.5, 123.5) 
GM-CSF 10.3 (5.1, 11.6) 
10.3 
(6.6, 18.6) 
IFN-α    29.5 * (24.5, 34.3) 
34.3 
(31.2, 37.2) 
IFN-γ 1.0 (0.3, 2.0) 
0.5 
(0.3, 3.1) 
IL-1RA    142.1 * (116.6, 178.5) 
178.5 
(160.3, 214.9) 
IL-1β 12.0 (9.3, 16.1) 
13.4 
(12.7, 19.4) 
IL-2   4.4 
†
 
(3.8, 5.3) 
5.0 
(4.4, 7.2) 
IL-2R 176.6 (132.2, 220.3) 
195.4 
(170.3, 232.6) 
IL-4 6.3 (4.8, 9.3) 
7.3 
(5.3, 11.3) 
IL-5    2.2 * (1.9, 2.2) 
2.5 
(2.2, 2.5) 
IL-6 1.4 (1.1, 1.8) 
1.6 
(1.2, 4.5) 
IL-7     7.6 * (6.8, 14.5) 
15.4 
(13.5, 17.1) 
IL-8 4.3 (3.1, 4.8) 
4.0 
(2.9, 6.1) 
IL-10 1.4 (1.4, 1.7) 
1.5 
(1.5, 2.4) 
IL-12 58.1 (39.8, 63.8) 
53.2 
(47.8, 59.4) 
IL-13   19.5 * (17.4, 21.5) 
21.5 
(19.5, 25.3) 
IL-15 1.3 (0.6, 4.0) 
2.2 
(0.6, 11.9) 
IL-17 6.1 (4.0, 39.6) 
28.3 
(4.0, 38.5) 
IP-10    3.9 * (3.2, 5.4) 
6.4 
(4.3, 9.7) 
MCP-1 116.8 (92.1, 181.5) 
122.3 
(103.7, 192.3) 
MIG 12.0 (12, 12) 
12.0 
(12, 12) 
MIP-1α    20.8 * (20.8, 22.4) 
24.1 
(22.4, 27.3) 
MIP-1β    24.4 * (21.5, 30.1) 
30.1 
(27.8, 32.4) 
RANTES 3273 (2888, 4134) 
4773 
(3390, 5449) 
TNF-α    2.1 * (1.9, 2.5) 
2.7 
(2.4, 2.9) 
Table 5.8 Post steroid trial plasma cytokines.  
Data presented as median pg/ml (IQR). *; p<0.05  
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Examination of within group changes demonstrated that a number of plasma 
cytokines changed in response to oral corticosteroid trial. Smokers with asthma 
demonstrated an increase in plasma eotaxin (48.5 pg/ml (95% CI 23.6, 73.4), 
p=0.001) and reduction in: 
• IFNγ; -1.5 pg/ml (95%CI -2.7, 0.2), p=0.022 
• IL-2R; -88.8 pg/ml (-137.4, -40.1), p=0.001 
• IL-4; -3.2 pg/ml (-5.2, -1.3), p=0.003 
• IL-5; -0.5 pg/ml (-0.8, -0.2), p=0.003 
• IL-7; -5.1 pg/ml (-10.2, -0.0), p=0.049 
• IL-8; -1.9 pg/ml (-2.8, -0.9), p=0.001 
• IL-12; -7.7 pg/ml (-12.0, -3.4), p=0.002 
• IP-10; -7.6 pg/ml (-10.0, -5.2), p<0.001 
• MCP-1; -59.2 pg/ml (-109.3, -9.0), p=0.024 
• MIP1β; -3.7 pg/ml (-6.5, -0.9), p=0.014 
• RANTES; -2207 pg/ml (-3706, -707), p=0.007 
Non smokers with asthma also made a number of significant within group 
changes in response to oral corticosteroid. Plasma eotaxin increased (36.8 pg/ml 
(95% CI 21.0, 52.6), p<0.001) and reductions were evident in: 
• IL-1RA; -71.7 pg/ml (95% CI -123.9, -19.5), p= 0.010 
• IL-2R; -54.7 pg/ml (-95.4, -13.9), p=0.012 
• IL-4; -2.4 pg/ml (-4.6, -0.3), p=0.027 
• IL-8; -1.2 pg/ml (-2.3, -0.1), p=0.033 
• IL-12; -20.8 pg/ml (-31.3, -10.4), p=0.001 
• IP-10; -5.9 pg/ml (-10.3, -1.6), p=0.011 
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• RANTES; -2106 pg/ml (-3961, -252), p=0.029 
Comparison of the within group changes in plasma cytokines demonstrated that 
plasma IL-12 was reduced to a greater degree in non-smokers with asthma 
compared to smokers with asthma in response to the oral corticosteroid trial 
(non-smokers change -19.0 pg/ml (-26.5, -6.6), smokers -8.9 pg/ml (-11.5, -1.1), 
p=0.025). 
5.3.10 IL-6 high sensitivity ELISA 
5.3.10.1 ELISA results 
A high sensitivity ELISA was performed to examine the IL-6 sputum supernatant 
result obtained by Luminex. By this method smokers with asthma again had a 
higher median concentration of sputum IL-6 compared to non-smokers with 
asthma at baseline (smokers 14.5 pg/ml (IQR 9.1, 59.9), non-smokers 3.1 pg/ml 
(IQR 0.4, 6.6), p<0.001) and post oral corticosteroids (smokers 10.0 pg/ml (2.7, 
33.5), non-smokers 3.1 pg/ml (0.0, 8.9), p=0.041) (table 5.9 & figure 5.13). Ex-
smokers levels of sputum IL-6 appeared to be equivalent to smokers with asthma 
at baseline. Post oral corticosteroid trial the ex-smokers appeared to have a 
sputum IL-6 level closer to non-smokers with asthma. 
High dose oral corticosteroids did not reduce sputum IL-6 levels in smokers 
(Change -17.4 pg/ml (95% CI -58.0, 23.1), p=0.376) and non-smokers with asthma 
(Change 7.1 pg/ml (-9.7, 23.1), p=0.383). 
 
Smokers Ex-smokers Non-Smokers 
Pre-steroid IL-6 
(pg/ml) 
  14.5 ‡ 
(9.1, 59.9) 
11.6 
(4.3, 50.3) 
3.1 
(0.4, 6.6) 
Post steroid IL-6 
(pg/ml) 
  10.0 * 
(2.7, 33.5) 
2.9 
(0.4, 23.9) 
3.1 
(0.0, 8.9) 
Table 5.9 Pre and post sputum IL-6 levels measured by high sensitivity ELISA.  
Data presented as median (IQR). *; p<0.05, ‡; p<0.001 
Chapter 5  160 
SmokersNon-smokers
400
300
200
100
0
IL
-6
 (
p
g
/m
l)
 
Figure 5.13 Individual plot of IL-6 levels obtained by high sensitivity ELISA in non-smokers 
with asthma and smokers with asthma. 
Data presented as individual points with median.  
 
5.3.10.2 Comparison of Luminex and ELISA results 
When the two methods were compared there was evidence of a strong 
correlation between the sputum IL-6 results obtained by Luminex and high 
sensitivity ELISA: 
• Smokers; r = 0.84, p<0.001 (figure 5.14) 
• Ex-smokers; r = 0.89, p=0.001 
• Non-smokers; r = 0.84, p<0.001 
p<0.001 
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Figure 5.14 Correlation between Log Luminex IL-6 and Log ELISA IL-6 results for smokers 
with asthma. 
 
5.4 Discussion 
Smokers with asthma fail to gain the expected benefits from both inhaled and 
oral corticosteroids (5-10, 22-24). This reduced response is associated with an 
accelerated decline in lung function (15, 21), increased emergency department 
visits (16, 17) and increased severity of asthma symptoms compared to non-
smoking subjects with asthma (11, 12). The route by which smoking alters the 
corticosteroid responsiveness of smokers with asthma is currently unclear with 
several mechanisms proposed (32, 40). However corticosteroids are recognised 
to reduce pro-inflammatory cytokine levels with associated beneficial effects in 
asthma, and an altered cytokine environment can induce corticosteroid 
insensitivity in T lymphocytes in-vitro (66-69). An altered cytokine environment 
has also been observed in non-smoking corticosteroid resistant asthmatics (64, 
65). Therefore altered cytokine profiles may be relevant to the development of 
reduced corticosteroid sensitivity in smokers with asthma. 
An important issue to consider is that multiple significance tests were performed 
to generate the results presented in this chapter. At a significance level of 5% 
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the odds of a false positive result is as high as one test in twenty. Therefore a 
number of false positive differences are possibly contained in the presented 
data. Correction through the use of the Bonferonni adjustment resulted in all 
baseline sputum (save IL-6) and plasma cytokines losing statistical significance. 
However the application of such methods can be viewed as a dubious way to 
deal with data gathered from a small exploratory study as strong and 
mechanistically significant observations will be dismissed as a result. Examining 
multiple cytokines in an unbiased fashion is also more likely to provide 
significant insights into the causes of corticosteroid resistance as cytokines do 
not work in isolation and determining patterns of alteration are important. The 
large number of significantly altered cytokines discovered using the multiplex 
approach suggests that smokers with asthma do have a significantly different 
cytokine profile compared to non smokers with asthma. Future adequately 
powered studies should examine these findings.  
In this cross sectional study, smokers with asthma failed to gain significant 
improvements in lung function during an oral corticosteroid trial. This reduced 
response reflects and confirms previous research in smokers with asthma (23, 
24). Smokers and non-smokers with asthma displayed equivalent sputum 
differential counts at baseline. The finding of a lack of corticosteroid response in 
this group of smokers with asthma despite the absence of sputum neutrophilia is 
interesting and suggests that the resistance in the recruited subjects is not due 
neutrophilic inflammation. The contrast in lung function response between the 
smokers and non smokers with asthma was associated with a number of 
differences in sputum and plasma cytokine levels. Sputum supernatants obtained 
from smokers with asthma demonstrated increased levels of IL-2, 4, 6, 7 & IFNγ 
and a borderline increased level of IL-12 and 17.  
Significant differences were present at baseline for inhaled corticosteroid dose 
and ACQ score between the smokers and non smokers with asthma. Previous 
research has demonstrated that smokers with asthma have higher ACQ scores 
despite matched lung function measures (12) and the increased symptoms in this 
group are likely to have led to the prescription of increased doses of inhaled 
corticosteroids. To examine the effect of this difference an adjustment of the 
sputum cytokine results for differences in baseline inhaled corticosteroid dose 
was performed. The expectation was that this adjustment would remove any 
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false associations. The adjustment did not reduce the significant differences in 
IL-2, 4, 6, 7 and IFNγ between smokers and non-smokers with asthma, resulted 
in multiple additional cytokine differences becoming evident and strengthened 
the difference present in sputum IL-12 and 17. The presence of increased levels 
of several cytokines in induced sputum supernatant from smokers with asthma 
suggests that this group display an altered and increased level of airway 
inflammation compared to non smokers with asthma with similar lung function. 
Are the increases in sputum cytokines demonstrated in this study responsible for 
the corticosteroid resistance seen in smokers with asthma?  
The largest difference in sputum cytokines between smokers and non-smokers 
was for IL-6 and this is the only cytokine difference that would survive p value 
adjustment. The presence of a significant difference between smokers and non-
smokers was also subsequently confirmed by high sensitivity ELISA. This increase 
in sputum IL-6 was resistant to oral corticosteroids and is a novel observation in 
smokers with asthma. IL-6 is a pleiotropic pro-inflammatory cytokine which sits 
at the junction between the innate and adaptive immune response and has an 
important role in Th-17 differentiation (278). Previous research has 
demonstrated an inverse correlation between IL-6 and lung function in COPD 
(279). IL-6 is also upregulated in subjects with COPD (280) and in both COPD and 
asthma during exacerbations (281, 282). Bronchoalveolar lavage samples from 
corticosteroid resistant non-smokers with asthma have been demonstrated to 
contain increased levels of IL-6 (65). The finding in this study that IL-6 is 
increased in smokers with asthma and is unresponsive to high dose oral 
corticosteroids suggests that sputum IL-6 may play an important role in the 
development of corticosteroid insensitivity in smokers with asthma. IL-6 signals 
via signal transducer and activator of transcription-3 (STAT3) resulting in 
increased gene transcription and activation of NF-κB (283-285). Therefore IL-6 
acting via STAT3 and other gp130 coupled pathways may induce persistent 
corticosteroid insensitive inflammation in smokers with asthma akin to a 
persistent viral infection. This finding is of interest in the light of the recent 
development of IL-6 receptor blockers for the treatment of inflammatory 
conditions. IL-6 receptor blockade may therefore represent a useful approach in 
smokers with poorly controlled asthma. 
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Previous research has demonstrated increased expression in IL-2 and 4 in cells 
obtained by bronchoalveolar lavage from corticosteroid resistant non-smokers 
with asthma (64). This finding was confirmed and extended by the 
demonstration that the combination of IL-2 and 4 can induce a corticosteroid 
resistant state in peripheral blood T lymphocytes in-vitro (66-69). The effects of 
the combination of IL-2 and IL-4 can be overcome by the simultaneous co-
administration of IFNγ in-vitro (69) and corticosteroid responsive asthmatics 
demonstrate an increase in IFNγ expressing cells following treatment with oral 
prednisolone (64). This alteration in IFNγ expression mirrors the narrowing of the 
difference in IFNγ concentration following corticosteroids observed in this study. 
The finding that detectable levels of IL-2 and 4 are present in the sputum 
supernatant of corticosteroid resistant smokers with asthma is intriguing and the 
finding of increased IFNγ at baseline may be an indication of an intrinsic attempt 
to overcome the effects of raised IL-2 & 4. However previous attempts at 
measurement of IL-4 in ex-vivo samples have been fraught with difficulty. Given 
the low levels of IL-2 and 4 detected in the samples in this study any conclusions 
for these cytokines must be cautious. Further work examining BAL cytokine 
levels of IL-2, 4 and IFNγ tied to clinical characterisation and examination of 
corticosteroid responses of ex-vivo samples is required before firm conclusions 
can be drawn. 
IFNγ is regarded as a characteristic Th1 cytokine with a role for the induction of 
various cytokines. Sputum IL-6 can also be regarded in this light. Can the 
alteration in sputum cytokines in smokers with asthma be a result of smoking 
producing a skewing of asthma from a Th2 to a Th1 phenotype? This could be 
possible. COPD is associated with increased pulmonary and systemic expression 
of IL-6 (286-288) and cells expressing IFNγ in bronchial biopsies (289, 290). IL-12, 
which was on the threshold of statistical significance, was also raised in the 
smokers with asthma and is important for the induction of IFNγ expression (291). 
Non smoking subjects with severe asthma who fail to gain the expected benefits 
from corticosteroids express increased levels of IFNγ (275, 292) and IFNγ is 
known to both promote the expression of Th1 cytokines and suppress those 
associated with Th2 environments (293). Given the presence of the common 
environmental factor of smoking it is tempting to extrapolate that smokers with 
asthma have an alteration in their inflammatory response from the Th2 response 
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characteristic of allergic asthma to the Th1 inflammation present in COPD. 
Smokers with asthma and subjects with COPD both display reduced 
corticosteroid responsiveness and accelerated lung function decline and if the 
inflammation present in subjects with COPD and smokers with asthma shares a 
common cytokine profile then therapies designed for COPD may also prove to be 
effective in smokers with asthma. 
IL-7 is essential for the development of T and B lymphocytes and may play a role 
in dendritic cell survival (294). The finding of increased sputum supernatant IL-7 
in smokers with asthma is novel and may reflect previous work which identified 
a reduction in bronchial biopsy B-lymphocyte and dendritic cell numbers in 
smokers with asthma (62). Raised sputum cytokine IL-7 levels may reflect an 
attempt at restoration of airway B lymphocyte numbers. No differences were 
evident in sputum lymphocyte proportions between smokers and non smokers 
with asthma. However sputum lymphocyte numbers are usually very low so it 
will be difficult to detect a difference in airway T lymphocyte numbers even if 
this is present. Further investigation of the role of IL-7 and IL-7 homologues such 
as Thymic Stromal Lymphopoetin in the control of airway T and B lymphocytes 
and airway dendritic cells in smokers with asthma should be considered. 
The lack of a difference for sputum IL-8 when smokers and non-smokers with 
asthma were compared contrasts with previous work in smokers with asthma 
(41). However direct comparison with the previous study is difficult as the 
smokers with asthma in the prior study were not prescribed inhaled 
corticosteroids. The mean pack year history of the smokers with asthma 
recruited to this trial were higher than the previous study and the standard 
deviations were equivalent. Therefore the narrowing of the difference between 
the two groups is not due to lower pack year histories in the recruited group and 
appears to be due to the existence of a group with lower levels of IL-8 reflected 
in the lower quartile which overlaps with the non-smokers with asthma. This 
could reflect alteration in smoking habits, with the current group of smokers 
with asthma smoking less per day. An alternative explanation is that the lack of 
a difference may reflect technical differences as the assay employed for the 
detection of IL-8 was different. The previous study employed an ELISA method 
and the current study used Luminex and this may be partially responsible for to 
the lack of difference in this study. However correlations were still present 
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between sputum IL-8 and a number of clinical characteristics corroborating the 
previous study and the importance of this cytokine in smoking related pulmonary 
responses. 
Overall the data presented in this chapter, allied to previous work 
demonstrating increased sputum IL-8 (41) and reduced IL-18 (42) in smokers with 
asthma, suggests that the inflammation present in this group is different from 
non-smokers with asthma and represents a unique inflammatory phenotype. 
Unfortunately it is not possible to be certain as to the cellular sources 
responsible for the altered sputum cytokines detected in smokers with asthma as 
samples were not processed for immunocytochemistry. A number of cells could 
be responsible for the increased cytokines and several cell types may be 
contributing. For example, macrophages (65, 70), bronchial epithelial cells (295) 
and T lymphocytes can all produce IL-6. It is difficult to conclude which of these 
or indeed if all cell types are responsible for the differences detected between 
smokers and non smokers with asthma. Future work needs to address this issue. 
The inclusion of a small group of ex-smokers with asthma allowed for a limited 
examination of the persistent effect of smoking on asthma. A previous study 
which examined oral corticosteroid responses in smokers with asthma suggested 
that ex-smokers with asthma have a heterogeneous response to corticosteroids 
(23). A similar response was evident in the group of ex-smokers recruited for this 
study despite the average duration of smoking cessation being over seven years. 
The ex-smokers with asthma had similarities in their cytokine profile to both 
smokers and non-smokers with asthma. Given the heterogeneous response of the 
ex-smokers with asthma to oral corticosteroids consideration should be given to 
an adequately powered study to determine the alterations in cytokine profiles 
following smoking cessation that predict the restoration of corticosteroid 
response. 
Examination of systemic cytokine profiles using peripheral blood samples also 
revealed differences between smokers and non smokers with asthma at baseline. 
However a different cytokine profile emerged with smokers with asthma 
generally expressing lower levels of plasma cytokines than non smokers with 
asthma. Smokers with asthma had significantly lower levels of plasma IL-1RA, 
10, 13 and GM-CSF and a borderline reduced level of IL-12 compared to non 
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smokers with asthma. No difference was evident in plasma IL-2, 4, 6, 7 or IFNγ. 
This reduction in plasma cytokines suggests that smokers with asthma, in 
contrast to COPD, do not suffer from a generalised systemic inflammation due to 
an ‘overspill’ of pulmonary inflammation. The presence of increased sputum 
supernatant IL-6 but similar peripheral IL-6 levels in smokers with asthma also 
suggests that smokers with asthma display a different phenotype to both 
subjects with COPD and non smokers with asthma. However high sensitivity CRP 
concentrations were not determined in this study and need to be performed to 
allow true comparison with the previous work in subjects with COPD. The 
disparity between the sputum and systemic cytokine levels means that future 
studies should concentrate on measurement of cytokines from airway samples in 
preference to peripheral blood. Future research should compare smokers with 
asthma to non smokers with asthma and subjects with COPD to determine the 
similarities and differences in inflammatory system activity between the groups. 
The cytokine profiles post corticosteroid trial revealed a number of interesting 
findings. Smokers with asthma, despite failing to respond clinically, did reduce a 
number of sputum supernatant cytokines. Non-smokers with asthma also reduced 
a number of sputum cytokines in association with an improvement in lung 
function. Which cytokines responded differently when the two groups were 
compared? Post corticosteroid sputum levels of IL-1RA, 6 and Eotaxin were 
significantly higher in the smokers with asthma.  Sputum IL-2, 4 and IFNγ did not 
significantly change in either smokers or non smoker with asthma in response to 
oral corticosteroids but statistical significance was lost. This may reflect an 
increase in IL-2, 4 & IFNγ in non smokers with asthma, a reduction in the 
cytokines in smokers with asthma or reflect variability in the assay. However 
comparison of within group changes did not reveal any cytokines that behaved 
differently in the non smokers with asthma and therefore the baseline 
comparisons are likely to provide the greatest insights. The failure of sputum IL-
6 to reduce in response to high dose oral corticosteroids again suggests that this 
cytokine is associated with the mechanism(s) responsible for the reduced lung 
function response in smokers with asthma. Further studies are required to 
examine this cytokine in characterised smokers and non smokers with asthma.  
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5.5 Conclusion 
Smokers with asthma display alterations of both sputum supernatant and 
peripheral cytokine profiles that are associated with reduced response to oral 
corticosteroids. The increase in sputum IL-6 displayed by smokers with asthma 
which is resistant to oral corticosteroids may reflect increased NF-κB activation 
via increased STAT3 leading to corticosteroid resistant inflammation. The 
dissociation between peripheral and sputum cytokine profiles demonstrates that 
direct sampling in smokers with asthma may be crucial to the determination of 
the causes of the altered corticosteroid response in this group. Future studies 
should endeavour to examine cytokine profiles in smokers with asthma with 
comparison to subjects with COPD using bronchoscopic sampling as this will 
allow reference to the responsible airway cell populations and allow further 
dissection of the inflammatory processes in this group. 
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6 Relevance of HDAC activity to corticosteroid 
response in smokers with asthma 
6.1 Introduction 
Smokers with asthma exhibit an impaired response to both inhaled and oral 
corticosteroids (5-10, 22-24). Previous research has demonstrated that smokers 
with asthma also suffer increased symptoms (11, 12), an accelerated decline in 
lung function (15, 21) and increased emergency department visits for asthma 
(16, 17) compared to matched non-smoking asthmatics. 
The prevalence of smoking in asthma reflects that of the general population and 
therefore smokers with asthma represent a large group of patients with poorly 
controlled disease (13). Smoking cessation is the obvious target for both health 
practitioners and smokers with asthma and this approach has been demonstrated 
to be an effective therapy in this group (49). However as sustained quitting rates 
are low either improvements on current treatments or alternative therapies are 
required for individuals with asthma who continue to smoke. Development of 
new treatments requires understanding of the alteration in the phenotype of 
asthma induced by smoking and its relationship to treatment response. 
The discipline of epigenetics has revealed a mechanism that may be of relevance 
to the reduced response to corticosteroids observed in smokers with asthma. 
Epigenetics examines the effect of post-translational covalent modifications of 
chromatin on the control of gene expression. An in-vitro model of inflammation 
has demonstrated that approximately half of the immunosuppressant activity of 
corticosteroids is produced via the removal of acetyl groups from DNA associated 
histone proteins (98). The removal of acetyl groups from histone proteins at 
areas of active transcription results in a conformational change in chromatin in 
the targeted area leading to cessation of active transcription (81). Cigarette 
smoke has been demonstrated to reduce HDAC activity in-vitro (92) and a 
reduction in HDAC activity in smokers with asthma could explain their relative 
corticosteroid insensitivity. 
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Therefore this cross sectional study was designed to test the hypothesis that 
smokers with asthma have a reduced level of HDAC activity compared to non-
smokers with asthma and that this is associated with reduced corticosteroid 
responsiveness. 
6.2 Methods 
6.2.1 Subjects 
Subject characteristics, inclusion/exclusion criteria and recruitment methods 
were as described in the general methods chapter. All subjects provided 
informed consent and the study was approved by the West Glasgow Ethics 
Committee. 
6.2.2 Study design 
A full description of the study is provided in the general methods chapter. In 
brief, the subjects were recruited to a cross-sectional study with unblinded use 
of oral dexamethasone to determine corticosteroid sensitivity. The baseline visit 
consisted of a number of assessments including sputum and blood for 
macrophage/monocyte HDAC activity assessment and lung function 
measurement by spirometry. At the completion of the corticosteroid trial 
subjects were re-assessed within 24 hours of their last dose and repeated 
spirometry, venesection and sputum induction for HDAC activity assessment.  
6.2.3 Measurements 
A full description of the measurements is provided in the general methods 
chapter. Lung function assessments conformed to consensus guidelines (246). 
Sputum induction and processing and blood processing for HDAC measurement 
was performed as discussed in the general methods chapter. Assay variability 
testing was not performed for the HDAC test utilised in this thesis. 
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6.2.4 Statistical analysis 
Parametric data was examined using paired t-testing or 2 sided t-testing and 
non-parametric data with Wilcoxon-Mann-Whitney testing. Comparisons were 
between smokers and non-smokers with asthma. Ex-smokers were not included 
in formal comparison analyses due to the small number of subjects in this group. 
Correlations were performed predominately with Spearman Ranks and 
supplementary calculations with Pearson’s (indicated by ρ for Spearman and r 
for Pearson when presented). Statistical analysis was performed using Minitab 15 
(Minitab Inc. State College, PA, USA) and SAS v 9.1 (TS1M3) for Windows (SAS 
Institute Inc., NC, USA). α was set at 0.05. No adjustments were performed for 
multiple comparisons. 
6.3 Results 
Sputum samples suitable for measurement of HDAC activity were obtained from 
18 non-smokers, 9 ex-smokers and 18 smokers with asthma at baseline and from 
14 non-smokers, 9 ex-smokers and 14 smokers with asthma at completion of the 
corticosteroid trial. Suitable baseline blood samples were obtained from 20 non-
smokers, 9 ex-smokers and 22 smokers with asthma and from 17 non-smokers, 9 
ex-smokers and 18 smokers with asthma at completion of the corticosteroid 
trial. 
6.3.1 Baseline comparisons 
The baseline characteristics are discussed in detail in chapter 5 sections 5.3.1 to 
5.3.4. A brief review of the relevant findings will be presented here. 
6.3.1.1 Clinical characteristics 
Subjects were well matched for clinical variables at baseline. Smokers with 
asthma were taking higher levels of inhaled corticosteroids and had higher ACQ 
scores compared to non-smokers with asthma. 
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6.3.1.2 Lung function measurements 
Smokers and non-smokers with asthma were well matched for lung function 
measures at baseline, although non-smokers with asthma demonstrated a 
greater degree of bronchodilator response compared to smokers with asthma. 
6.3.1.3 Baseline sputum characteristics 
No differences were present between smokers and non smokers when baseline 
sputum profiles were compared. There was an absence of eosinophilia in both 
smokers and non-smokers with asthma.  
6.3.2 Corticosteroid response 
Non-smokers with asthma made a significant lung function response to oral 
corticosteroids. This was in contrast to smokers and ex-smokers with asthma who 
failed to make a significant within group response to oral corticosteroids. No 
difference was evident when between groups responses were compared. 
6.3.3 Change in clinical characteristics and sputum profile 
Non-smokers with asthma demonstrated a reduction in ACQ score in response to 
the oral corticosteroid trial in contrast to smokers with asthma. No significant 
differences in the response of ACQ score and sputum to dexamethasone were 
detectable between the smokers and non smokers with asthma. 
6.3.4 Baseline HDAC activity 
6.3.4.1 Baseline sputum macrophage HDAC activity 
No differences were detectable between smokers and non smokers with asthma 
in baseline sputum HDAC activity levels (smokers 92.8 µmol/l/10-6 cells (IQR 7.2, 
277.8), non smokers 82.7 µmol/l/10-6 cells (34.3, 150.5) p=0.960) (table 6.1 and 
figure 6.1). Ex-smokers had a similar sputum HDAC activity level (55.4 
µmol/l/10-6 cells) to smokers and non smokers with asthma. 
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Figure 6.1 Baseline sputum HDAC activity in non-smokers, ex-smokers and smokers with 
asthma. 
 
6.3.4.2 Baseline blood monocyte HDAC activity 
Baseline blood HDAC activity was equivalent in both smokers and non-smokers 
with asthma (smokers 1.63 µmol/l/10-6 cells (IQR 1.19, 3.10) non smokers 1.99 
µmol/l/10-6 cells (1.52, 3.84), p=0.180) (table 6.1 and figure 6.2). Ex-smokers 
with asthma blood HDAC activity levels were equivalent to smokers and non 
smokers with asthma. 
 Smokers Ex-smokers Non smokers 
Baseline sputum HDAC 
activity µmol/10*6  
92.8 
(7.1, 299.2) 
55.4 
(20.7, 247.7) 
82.7 
(30.2, 153.1) 
Baseline blood HDAC 
activity µmol/10*6 
1.63 
(1.19, 3.10) 
2.51 
(1.81, 3.65) 
1.99 
(1.52, 3.84) 
Table 6.1 Comparison of HDAC activity across groups for sputum and blood.  
Data presented as median (IQR). 
 
p=0.960 
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Figure 6.2 Baseline blood HDAC activity in non-smokers, ex-smokers and smokers with 
asthma. 
 
6.3.4.3 Relationship of sputum HDAC activity to lung function response to 
dexamethasone 
The baseline sputum HDAC activity of smokers with asthma did not predict FEV1 
response to dexamethasone. When examined using a 15% improvement in FEV1 as 
the discriminator of corticosteroid responsiveness, the average HDAC activity of 
the two corticosteroid responsive smokers was 24.1 µmol/l/10-6 cells. Sputum 
HDAC activity of the unresponsive group was 135.3 µmol/l/10-6 cells (IQR 7.2, 
342.1). When the same comparison was made in the non-smokers with asthma no 
difference was obvious between the subjects who responded and those that 
failed to improve (responders 103.2 µmol/l/10-6 cells (2.3, 150.5), non 
responders 82.7 µmol/l/10-6 cells (30.2, 172.3) p=0.753).  
No correlation was evident between baseline sputum HDAC activity and FEV1 
response to oral corticosteroids (ρ=-0.10 (95% CI -0.41, 0.22), p=0.519) (figure 
6.3). When examined as separate groups no correlations were evident between 
baseline sputum HDAC activity and FEV1 response to corticosteroids: 
p=0.180 
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• Smokers with asthma; ρ=-0.14 (-0.59, 0.38), p=0.601 
• Non-smokers with asthma; ρ= -0.08 (-0.59, 0.47), p=0.764 
• Ex-smokers with asthma; ρ= 0.00 (-0.70, 0.70), p=1.000 
 
 
Figure 6.3 Relationship between FEV1 response to dexamethasone and baseline sputum 
macrophage HDAC activity.  
 
6.3.4.4 Relationship of blood HDAC activity to lung function response to 
dexamethasone 
Baseline blood HDAC activity similarly failed to predict lung function response in 
smokers with asthma (>15% response mean activity 1.6 µmol/l/10-6 cells, <15% 
response 1.7 µmol/l/10-6 cells (IQR 0.9, 3.2)) and non-smokers with asthma 
(<15% response 1.9 µmol/l/10-6 (1.3, 3.8), >15% response 1.5 µmol/l/10-6 (1.4, 
4.0)).  
To allow a further examination of the available data, correlations were 
performed between the lung function changes for all subjects and HDAC activity. 
No relationship was evident between the FEV1 response across all groups and 
baseline blood HDAC activity (ρ= -0.08 (95% CI -0.36, 0.21) p=0.611) (figure 6.4). 
When examined according to smoking history no positive correlations were 
evident between lung function response and blood HDAC activity: 
Baseline 
HDAC 
activity 
(µmol/l/106 
cells) 
FEV1 percentage improvement to dexamethasone 
ρ=-0.10 (95% CI -0.41, 0.22), p=0.519 
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• Smokers with asthma; ρ= -0.37 (95% CI -0.70, 0.08), p=0.097 
• Non-smokers with asthma; ρ= -0.05 (-0.54, 0.45), p=0.824 
• Ex-smokers with asthma; ρ= 0.38 (-0.38, 0.83), p=0.299 
 
Figure 6.4 Relationship between FEV1 response to dexamethasone and baseline blood 
monocyte HDAC activity. 
 
6.3.4.5 Correlation between sputum HDAC and blood HDAC activity 
No relationship was evident between blood and sputum HDAC activity at baseline 
(Pearson correlation; r= -0.22, p = 0.163) (figure 6.5) 
Baseline 
HDAC 
activity 
(µmol/l/106 
cells) 
FEV1 percentage improvement to dexamethasone 
ρ= -0.08 (95% CI -0.36, 0.21) p=0.611 
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Figure 6.5 Scatterplot of baseline blood and sputum HDAC activity (with regression). 
 
6.3.5 Change in HDAC activity in response to dexamethasone 
6.3.5.1 Change in sputum HDAC activity 
No change was detectable in sputum HDAC activity within the smoker, ex-
smoker or non smoker groups. Post dexamethasone sputum HDAC activity in 
smokers with asthma was equivalent to non-smokers with asthma (smokers HDAC 
activity 98.3 µmol/l/10-6 (IQR 23.9, 558.5), non smokers 33.8 µmol/l/10-6 (12.9, 
128.6), p=0.220). The change in sputum HDAC activity in response to 
dexamethasone was also equal (smokers change 53.2 µmol/l/10-6(6.2, 594.4), 
non-smokers -72.2 µmol/l/10-6 (-137.2, 23.7), p=0.120). Ex-smokers 
demonstrated an increase in HDAC activity of a similar magnitude to smokers 
with asthma (60.1 µmol/l/10-6 (-162.5, -424.6)). 
6.3.5.2 Change in blood HDAC activity 
No change was detectable in blood HDAC activity in response to dexamethasone 
in non smokers (HDAC within group change 0.82 µmol/l/10-6 (95% CI -0.98, 2.61), 
p=0.347) and ex-smokers with asthma (-1.83 µmol/l/10-6 (-7.03, 3.37), p=0.440). 
r= -0.22, p = 0.163 
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Smokers with asthma demonstrated a trend to an increase in blood HDAC activity 
in response to dexamethasone when within group response was examined (7.02 
µmol/l/10-6 (-0.38, 14.41), p=0.061). 
Post corticosteroid blood HDAC activity levels were significantly higher in 
smokers with asthma compared to non smokers with asthma (smokers 3.36 
µmol/l/10-6 (2.0, 10.7), non-smokers 1.86 µmol/l/10-6 (1.1, 3.2), p=0.022). A 
trend to significance was evident when changes in blood HDAC activity in 
response to dexamethasone in smokers and non smokers with asthma were 
compared (smokers 2.46 µmol/l/10-6 (-0.1, 7.2), non-smokers 0.52 µmol/l/10-6 (-
0.5, 1.4), p=0.074). Ex-smokers with asthma displayed similar levels of blood 
HDAC activity to smokers post oral corticosteroid trial (ex-smokers 2.50 
µmol/l/10-6 (2.0, 5.2)). 
No relationship was evident between change in blood HDAC activity and lung 
function response when all subjects were included (ρ= -0.18 (95% CI -0.5, 0.1) 
p=0.246). When examined as individual groups no correlations were evident 
between the change in blood HDAC activity and FEV1 response in smokers (ρ= 
0.24 (-0.3, 0.6), p=0.329) or non smokers with asthma (ρ= -0.01 (-0.5, 0.5), 
p=0.958). However a strong and highly significant correlation was found between 
change in blood HDAC activity and lung function response in ex-smokers with 
asthma (ρ= -0.94 (-1.0, -0.7), p<0.001) (figure 6.6). 
 
 
Figure 6.6. Relationship between change in blood HDAC activity and change in FEV1 in ex-
smokers with asthma 
 
FEV1 percentage improvement to dexamethasone 
 
Change in 
blood HDAC 
activity 
(µmol/l/106 
cells) 
 
Chapter 6  179 
6.4 Discussion 
Smokers with asthma display a reduced response to corticosteroids (5-10, 22-24). 
The cause (or causes) of this reduced response is currently unknown. The 
purpose of this exploratory study was to determine HDAC activity levels in this 
sub group of asthma in comparison to non-smokers with asthma and its 
relationship to corticosteroid response. Previous research carried out in-vitro 
(103), in subjects with COPD (86, 87) and non-smoking subjects with asthma (84) 
suggests that reduced HDAC activity is of relevance to corticosteroid 
responsiveness. Smoking has been demonstrated to reduce HDAC activity in-vitro 
(92) and therefore reduced HDAC activity was expected in smokers with asthma. 
However this study has provided no evidence to support the hypothesis that 
HDAC activity is suppressed in either sputum macrophages or blood borne 
monocytes in smokers with asthma. This was combined with a lack of correlation 
between lung function response to corticosteroids and HDAC activity.  
What can explain this discrepancy? An obvious conclusion is that smokers with 
asthma do not have a reduced level of HDAC activity and therefore altered HDAC 
activity does not explain the differences in response to corticosteroid displayed 
by smokers with asthma. However there are a number of technical issues to 
consider. The previous research examining the relevance of HDAC activity to 
corticosteroid response has been carried out in cell lines or cells obtained by 
bronchoalveolar lavage. Induced sputum has previously been demonstrated to 
provide different information compared to samples obtained by bronchoalveolar 
lavage (182) and induced sputum samples the central airways in contrast to 
bronchoalveolar lavage which obtains samples from smaller airways (183). 
Therefore a possible explanation that needs to be considered is that the 
macrophages obtained are of a different phenotype and hence HDAC activity 
compared to those that exist in the periphery of the lungs. Another 
consideration is that there was no step to allow for inspection of the cells 
selected for the HDAC assay. Therefore there is the possibility that 
contamination with non-viable cells and neutrophils may have affected the 
results and led to low levels of HDAC activity and lack of a difference between 
smokers and non-smokers with asthma. 
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The samples obtained for this study were processed at a research centre with an 
interest in the examination of HDAC activity in airways disease. Based on 
previous research using induced sputum, a new technique (in-cell assay) was 
developed for assessment of HDAC activity to allow for its determination in 
samples of lower cell numbers. Therefore as this study is the first to use this 
technique in the comparison of subjects with asthma with differing smoking 
histories we may be observing a flaw in the technique. Despite best efforts in 
validation the technique may be too insensitive to detect differences that are 
present between smokers and non smokers with asthma. An additional 
consideration is that the absence of a difference in HDAC activity between 
smokers and non smokers with asthma, if correct, may mask important 
differences in HDAC containing enzyme isoforms and subsequent alteration in 
substrate target levels of acetylation. The simple approach taken in this study to 
address differences in overall level of HDAC activity did not address these issues. 
Future studies should consider examination of HDAC isoforms and targets of 
HDAC containing complexes to determine which are important in determining a 
subject’s response to corticosteroids.  
An additional weakness of this study is that no attempt was made to assess 
histone acetyl transferase (HAT) activity. The epigenetic response to 
corticosteroids can be viewed as an alteration in the balance in HDAC/HAT 
activity. Previous research has identified HAT activity to be elevated in alveolar 
macrophages obtained from non-smoking corticosteroid naive subjects with 
asthma (84). Smokers with asthma may display large increases in HAT activity 
and this increased HAT activity may be insensitive to corticosteroid treatment. 
The balance between HDAC and HAT activity that exists in smokers with asthma 
needs to be addressed in future studies comparing smokers with asthma to non-
smokers with asthma and normal subjects. 
The absence of correlation between sputum macrophage HDAC activity and lung 
function change in response to corticosteroid is surprising. However the within 
group response of the non-smokers with asthma subjects to treatment with oral 
corticosteroids was slightly smaller than expected. This may reflect that most of 
the non-smoking subjects with asthma were already treated with moderate 
doses of inhaled corticosteroids and therefore may not have been able to 
demonstrate large increases in lung function. Future studies in this area may 
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need to consider examining groups divided by treatment level and symptom 
intensity using a system such as the GINA categorisation.  
A previous trial has demonstrated that non smokers with asthma do not have 
altered levels of HDAC activity in peripheral blood compared to normal subjects 
and that peripheral blood HDAC activity increases in non smokers with asthma in 
response to an oral corticosteroid trial (84). The presented data demonstrates 
that smokers with asthma also make a significant increase in peripheral blood 
monocyte HDAC activity in response to corticosteroids. Ex-smokers with asthma, 
a proportion of whom were able to demonstrate a good response to oral 
corticosteroids, demonstrated a highly correlated and significant relationship 
between lung function improvement and change in blood HDAC activity. 
However this relationship was reciprocal and currently defies explanation. 
Previous work in COPD has found that ex-smokers with COPD display differing 
HDAC responses to treatment compared to smokers with COPD (296) and this 
finding in ex-smokers with asthma may be a manifestation of an altered 
inflammatory phenotype that exists in ex-smokers. However there is also the 
possibility that this result is a type 1 error due to multiple comparisons so 
further examination of this relationship should be considered before any firm 
conclusions are drawn. 
6.5 Conclusions 
This exploratory cross sectional study has demonstrated that smokers with 
asthma have levels of sputum macrophage HDAC activity comparable to non 
smokers with asthma. This study has not confirmed a role for reduced HDAC 
activity in smokers with asthma but should be regarded as inconclusive at 
present. This finding is surprising but requires further examination and 
confirmation using techniques comparable to previous publications. Therefore to 
address these issues HDAC and HAT activity, HDAC isoform expression and the 
substrates of HDAC and HAT containing complexes should be examined in 
samples obtained by bronchoscopy from smokers and non smokers with asthma 
characterised for corticosteroid responses.  
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7 Non-invasive assessment of inflammation in 
smokers with asthma 
7.1 Introduction 
7.1.1 Extended flow nitric oxide analysis 
Non-invasive assessment of airway inflammation, through the measurement of  
exhaled nitric oxide at a flow rate of 50ml/sec, has developed into a useful 
exploratory endpoint in clinical trials since its discovery in the exhaled breath of 
subjects with asthma (47, 210). A raised exhaled nitric oxide concentration 
displays a degree of correlation with airway eosinophilia and therefore is 
thought to provide a quick method of assessment for this established indication 
for corticosteroid treatment (47). As a result it is likely that exhaled nitric oxide 
measurement will go on to become part of the routine assessment of subjects 
with asthma referred to secondary care. 
Unfortunately current cigarette smoking markedly reduces exhaled nitric oxide 
levels at the standard flow rate of 50ml/sec (50) rendering the test less useful, 
both for the assessment of airway inflammation in smokers with asthma and as 
an exploratory endpoint in clinical trials. A recent publication suggests that a 
percentage change in exhaled nitric oxide correlates with asthma control and 
may therefore provide an alternative approach in smokers with asthma (221). 
However further work is required to corroborate this evidence and its place in 
the investigation of smokers with asthma.  
An alternative approach involving examination of exhaled nitric oxide using 
multiple exhalation flow rates provides additional information beyond exhaled 
nitric oxide concentration. Mathematical modelling using the results from 
multiple flow rates, based on the assumption that the lungs can be divided into 
two compartments (composed of the conducting airways and the alveoli), has 
led to the development of a technique termed extended flow analysis. Extended 
flow analysis enables estimates to be derived for alveolar nitric oxide 
concentrations and flow independent measurements for the conducting airways 
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(airway wall nitric oxide flux (the rate of radial transport of nitric oxide across 
the airway into the exhaled air), airway wall concentration and diffusion rate) 
(222, 227, 255, 297). This approach has demonstrated elevated levels of alveolar 
nitric oxide in subjects with severe asthma (compared to subjects with mild 
asthma) (256, 257) and subjects with COPD (225, 258) (although this is not 
consistent (52)). Active smoking does not reduce alveolar nitric oxide levels in 
normal subjects (226, 259) and alveolar nitric oxide levels are equivalent in 
smokers and ex-smokers with COPD (52, 225). Therefore extended flow analysis 
may provide useful exploratory endpoints in the assessment of smokers with 
asthma. 
However the calculation of alveolar nitric oxide and associated measurements is 
complicated by the existence of multiple methods of derivation (227). The 
original paper examining nitric oxide exchange mechanics used three high 
exhalation flow rates with plots of the elimination rate of nitric oxide against 
flow rate and subsequent linear regression through the plotted data (222). A 
similar method, performed using two low flow rates and prolonged exhalation 
allows for estimates to be derived for airway wall nitric oxide concentration, 
nitric oxide diffusion across the airway and airway nitric oxide flux levels (227, 
255). An alternative method using non-linear regression enables the derivation of 
alveolar nitric oxide, airway wall nitric oxide concentration, nitric oxide 
diffusion and flux (255). Each of these models provides slightly different values 
for the derived parameters although normal values and values in subjects with 
asthma are available (table 7.1)(227). No research has been published to date 
examining extended flow nitric oxide analysis using these models in smokers 
with asthma. 
Therefore to test the hypothesis that smokers with asthma have elevated levels 
of alveolar nitric oxide compared to non-smokers with asthma, reflecting their 
increased symptoms from asthma and alterations in other exhaled nitric oxide 
parameters (compared to non-smokers with asthma) the following study was 
undertaken. The use of an oral corticosteroid trial also allowed for the 
examination of the supplementary hypothesis that smokers with asthma display a 
restoration of alveolar nitric oxide levels towards the range present in non-
smokers with asthma in response to corticosteroid therapy. 
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7.1.2 Exhaled breath condensate pH 
Exhaled breath condensate (EBC) assessment, which involves the collection of 
expiratory gas vapours in a cooled tube, has been suggested to show promise as 
an exploratory endpoint in studies of asthma. Previous research has 
demonstrated that the pH of EBC is reduced during periods of exacerbation in 
asthma, returning to normal in parallel with clinical resolution (57). EBC pH also 
correlates negatively with induced sputum neutrophilia in subjects with COPD 
and sputum eosinophilia in non-smoking subjects with asthma (238). Smokers 
with asthma have previously been demonstrated to have lower EBC pH values 
than non smokers with asthma (58). EBC can be collected outside of the research 
laboratory for subsequent pH analysis and potentially represents a simple and 
useful non-invasive marker. 
Therefore to examine the hypothesis that smokers with asthma display lower 
levels of exhaled breath condensate pH compared to non-smokers, and the 
additional hypothesis that following oral corticosteroids exhaled breath 
condensate pH is equivalent in smokers and non-smokers with asthma, the 
following study was undertaken. 
7.2 Methods 
7.2.1 Subjects 
Subject characteristics, inclusion/exclusion criteria and recruitment methods 
were as described in the general methods chapter. All subjects provided 
informed consent and the study was approved by the West Glasgow Ethics 
Committee. 
7.2.2 Study design 
A full description of the study is provided in the general methods chapter. In 
brief, the subjects were recruited to a cross-sectional study with unblinded use 
of oral dexamethasone to determine corticosteroid sensitivity. Subjects 
performed extended flow nitric oxide analysis and EBC collection for pH 
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measurement before and at the completion of the corticosteroid trial. A small 
sub-set of patients attended one month after completion of the corticosteroid 
trial to investigate the duration of corticosteroid effects on extended flow nitric 
oxide parameters. 
7.2.3 Measurements 
A full description of the measurements is provided in the general methods 
chapter. Briefly, subjects were asked to refrain from eating and to avoid 
caffeine containing drinks within three hours of performing the tests. Smokers 
with asthma were also asked to refrain from smoking for three hours. Exhaled 
carbon monoxide measurements were performed to confirm abstinence from 
smoking. Inhaled medications were withheld consistent with available guidelines 
(246) to facilitate spirometry testing later in the study visit. 
Nitric oxide measurements were performed at multiple flow rates (30, 50, 100, 
150, 200, 250 & 300ml/sec) using a Niox-Flex analyser within built-in Flex-Flow 
programme and automatic flow regulator (Aerocrine AB, Sundbybergsvägen 9, 
SE-171 73 Solna, Sweden). The Niox-Flex meets joint ATS/ERS criteria for the 
measurement of on-line FENO (47) and the Flex-Flow programme automatically 
assesses the NO measurements against pre-set accuracy criteria. At flow rates 
above 30ml/sec the permitted deviation was +/- 10% and below 30ml/sec +/- 
3ml/sec. Readings out with these boundaries were automatically rejected. The 
exhalation time for each flow rate was; 10 seconds for 30 ml/sec, 10 s for 50 
ml/sec, 6 seconds for 100, 150, 200, 250 and 300 ml/sec. Three acceptable 
readings were obtained for each flow rate. A built-in delay prevented subjects 
performing the measurements at less than 30 second intervals. A system check 
was carried out after six attempts to ensure drift had not occurred in the 
measurement. Calibration was performed fortnightly using a certified nitric 
oxide gas cylinder. The results collected and displayed by the Flex-Flow 
programme were exhaled nitric oxide concentration (FENO) and elimination rate 
of nitric oxide (VNO). No reproducibility testing was performed. 
Exhaled nitric oxide linear and non linear modelling was performed according to 
previously published methodology (222, 227, 255). This previous work utilises a 
‘two-compartment’ model where the model divides the lung into a fixed area 
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airway and an expansible alveolar compartment combined with the assumption 
that NO is produced at a constant rate per unit volume in both compartments. 
This division is hoped to detected differences that are masked by the standard 
flow rate i.e. a subject with small airway inflammation may have an equivalent 
exhaled nitric oxide level to a subject with well controlled asthma (using the 
standard flow rate) but a significantly higher alveolar nitric oxide. The currently 
available models have been demonstrated to provide good estimates of alveolar 
nitric oxide, with levels in the range of that observed during endobronchial 
sampling and are also able to replicate the observed linear relationship of 
exhaled NO with flow rate. To calculate estimates for the desired parameters 
subjects exhale at several flow rates and the exhaled nitric oxide concentration, 
elimination rate of nitric oxide (amount of NO absorbed from the airway wall 
into the airstream) and exhalation flow rate are plotted followed by linear or 
non-linear fitting to the data (examples provided in figures 7.1 and 7.2). 
 
Figure 7.1 Plot of elimination rate of exhaled nitric oxide against exhalation flow rate.  
Line represents linear regression through the data points. The slope of the line reflects the 
alveolar nitric oxide concentration and the y-intercept the airway wall flux. 
VNO; elimination rate of exhaled nitric oxide, pl/sec; picolitres per second, ml/sec; millilitres 
per second 
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Figure 7.2 Plot of exhaled nitric oxide concentration against exhalation flow rate. Line 
represents non-linear regression through the data points.  
FENO; exhaled nitric oxide concentration, ppb; parts per billion, ml/sec; millilitres per second 
 
Linear modelling was performed initially according to (222) using VNO results 
from 100, 200 and 300 ml/sec flow rates with subsequent comparison against 
results derived using data from 100, 150, 200 & 250 ml/sec and 100, 150, 200, 
250 & 300 ml/sec flow rates. Plotting VNO results against exhalation flow rates 
and linear regression allows derivation of alveolar nitric oxide and airway flux 
according to the following equation (see figure 7.1): 
VNO = Calv.VE + J’awNO 
Where VNO= elimination rate of exhaled nitric oxide (ml/s), VE = exhalation flow rate (ml/s), 
Calv= alveolar NO concentration (ppb), J’awNO=maximum NO flux (pl/sec). 
 
Where alveolar nitric oxide corresponded to the gradient of the line and flux was 
obtained from the y-intercept of the line. If a subject’s data provided a negative 
value for alveolar nitric oxide following regression their data was not included in 
the final analysis as this was felt to represent a test error. 
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Airway wall nitric oxide diffusion and concentration was obtained by linear 
regression using the VNO and FENO results from the 30 and 50ml/sec flow rates. 
VNO was plotted against FENO followed by linear regression. Nitric oxide flux was 
obtained from the y-intercept and nitric oxide diffusion from the reciprocal of 
the gradient of the slope. Airway wall concentration was obtained from the 
relationship (255): 
 
J’awNO = CawNODawNO 
Where J’awNO=maximum NO flux (pl/sec), CawNO=airway wall concentration (ppb), 
DawNO=diffusion from airway wall to airway (pl/sec/ppb) 
 
Nonlinear regression was performed using the FENO data from all flow rates with 
the restriction of positive boundaries for all parameters. Plotting FENO against VE 
(see figure 7.2) and solving for the following equation enabled the derivation of 
estimates for alveolar nitric oxide, airway nitric oxide concentration, airway 
wall nitric oxide diffusion and flux parameters. (255): 
 
FENO = CawNO + (Calv - CawNO)e
(-DawNO/VE) 
Where FENO=exhaled NO concentration (ppb), CawNO=airway wall concentration (ppb), 
DawNO=diffusion from airway wall to airway (pl/sec/ppb), Calv =alveolar NO level (ppb), 
VE=flow rate of exhalation (ml/sec) 
 
An estimate of airway flux was subsequently derived for this model from the 
relationship (227): 
J’awNO = CawNODawNO 
 
Previously published results using the presented models are presented in table 
7.1. This data will provide reference ranges for the data presented in the results 
section. 
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 Normal adults 
Non-smokers 
with asthma 
(No ICS) 
Non-smokers 
with asthma 
(ICS) 
Linear modelling    
Calv (ppb) 1.0-1.9 1.1-1.5 1.2-1.9 
Jaw (pl/s) 600-1200 2500-6512 700-2416 
Caw (ppb) 75-98 255 108-144 
Daw (pl/s/ppb) 7.7-11.0 25.5 11.8-22.3 
Non-linear 
modelling 
 
Calv (ppb) 3.2-5.0 
 
Jaw (pl/s) 1020 6512 2416 
Caw (ppb) 149 255.3 108.3 
Daw (pl/s/ppb) 5.7-7.4 25.5 22.3 
Table 7.1 Ranges for normal adults, non-smoking subjects with asthma not treated and 
treated with inhaled corticosteroid.  
Based on previous published results (52, 227, 255, 257, 298, 299). Mean values for groups 
presented. ICS; inhaled corticosteroid treated, Calv; alveolar nitric oxide, Jaw; airway nitric 
oxide flux, Caw; nitric oxide concentration in airway wall, Daw; airway wall diffusion rate of 
nitric oxide, ppb; parts per billion, pl/s; picolitres per second, pl/s/ppb; picolitres per second 
per parts per billion. 
 
Exhaled breath condensate was collected using a Jaeger EcoScreen®. The 
subjects performed tidal breathing for ten minutes whilst wearing a nose clip. 
De-aeration of the sample was performed for ten minutes using argon as per 
recommended guidelines and previous published methodology (56, 57). Sample 
pH was measured immediately on completion of de-aeration following a twenty 
second period to allow stabilisation of the probe reading in the sample. No 
reproducibility testing was performed. 
7.2.4 Statistical analysis 
Parametric data was assessed using t testing and non parametric using Mann-
Whitney testing. All extended flow analysis are presented as median (IQR) and 
all comparisons are between smokers and non smokers. Ex-smokers were not 
included in formal comparison analyses due to the small number of subjects in 
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this group. All data was treated as exploratory. α was set at 0.05. Analysis and 
linear and non-linear modelling was performed using SAS v 9.1 (TS1M3) for 
Windows (SAS Institute Inc., NC, USA). Results are presented as median 
(interquartile range) unless stated otherwise. 
7.3 Results 
7.3.1 Baseline comparisons 
The baseline characteristics are discussed in detail in chapter 5 sections 5.3.1 to 
5.3.4. A brief review of the relevant findings will be presented here. 
The subjects were well matched at baseline but mean ACQ score and inhaled 
corticosteroid dose were higher in smokers with asthma. Smokers with asthma 
had a smaller bronchodilator response compared to non-smokers with asthma. 22 
smokers, 10 ex-smokers and 21 non-smokers were recruited to the study. 20 
smokers, 9 ex-smokers and 17 non-smokers completed the oral corticosteroid 
trial. Non-smokers with asthma made a significant lung function response to oral 
corticosteroids in contrast to smokers and ex-smokers with asthma. 
19 smokers, 9 ex-smokers and 20 non-smokers with asthma were able to perform 
acceptable nitric oxide measurements at baseline and 19 smokers, 7 ex-smokers 
and 17 non-smokers with asthma performed acceptable measurements post 
corticosteroid trial. 16 smokers, 9 ex-smokers and 15 non-smokers with asthma 
performed acceptable exhaled nitric oxide measurements after a period of one 
month had elapsed from the oral corticosteroid trial. 
7.3.2 Exhaled nitric oxide-FENO50 
Clear differences were evident between smokers and non-smokers with asthma 
at baseline (table 7.2 and figure 7.3), on completion of the corticosteroid trial 
and one month after oral corticosteroids. There appeared to be a small 
reduction in FENO50 in smokers with asthma in response to oral corticosteroids. 
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 Smokers Ex-smokers Non-smokers 
FENO50 pre steroid 
(ppb)
 
  11.1 ‡ 
(3.6, 13.5) 
19.8 
(15.8, 43.5) 
32.8 
(17.7, 73.2) 
FENO50 post steroid 
(ppb) 
  6.1 † 
(3.3, 8.1) 
11.4 
(7.0, 22.0) 
12.4 
(10.1, 22.0) 
FENO50 1 month post 
steroid (ppb) 
  8.4 * 
(4.6, 13.9) 
20.6 
(8.9, 23.5) 
13.5 
(6.5, 23.7) 
Table 7.2 Exhaled nitric oxide measured at standard flow rate of 50ml/sec.  
FENO50; exhaled nitric oxide concentration at 50ml/sec, ppb; parts per billion. Data presented 
as median (IQR). p values refer to comparison of smokers and non smokers. *; p<0.05, †; 
p<0.01, ‡, p<0.001.  
 
 
 
Figure 7.3 Baseline exhaled nitric oxide (FENO50) levels.  
ppb; parts per billion. 
 
7.3.3 Exhaled breath condensate pH 
No significant differences in EBC pH were evident between smokers and non 
smokers with asthma at baseline, post oral corticosteroid trial or one month 
later (table 7.3). When within group responses to oral corticosteroid trial were 
compared there was no significant difference (smokers; median change 0.05 (IQR 
-0.08, 0.17) non-smokers; 0.03 (-0.09, 0.15), p=0.770). EBC pH one month post 
corticosteroid was equivalent to EBC pH at baseline and post corticosteroid trial.  
Exhaled 
Nitric 
Oxide  
50ml/sec 
(ppb) 
Non-smokers 
with asthma 
Ex-smokers 
with asthma 
Smokers 
with asthma 
p<0.001 
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 Smokers Ex smokers Non-smokers 
EBC pH Pre steroid 7.22 (7.16, 7.27) 
7.29 
(7.24, 7.33) 
7.26 
(7.16, 7.36) 
EBC pH Post steroid 7.29 (7.13, 7.36) 
7.36 
(7.20, 7.38) 
7.34 
(7.21, 7.36) 
EBC pH 1 month post 
steroid 
7.21 
(7.15, 7.27) 
7.25 
(7.25, 7.30) 
7.25 
(7.18, 7.31) 
Table 7.3 EBC pH at baseline, post corticosteroid trial and one month after oral 
corticosteroid trial.  
Data presented as median (IQR). EBC; exhaled breath condensate. 
 
7.3.4 Extended flow nitric oxide 
7.3.4.1 Alveolar Nitric Oxide and Airway Wall Flux 
 
Smokers with asthma displayed a lower median level of alveolar nitric oxide 
compared to non-smokers with asthma at baseline although this difference was 
lost after the oral corticosteroid trial (table 7.5). Smokers with asthma also had 
significantly lower levels for median nitric oxide flux pre and post steroid. The 
median alveolar nitric oxide concentration and flux in ex-smokers with asthma 
was intermediate to the non-smokers and smokers with asthma at baseline. 
However alveolar nitric oxide post corticosteroid appeared to be lower than that 
observed in smokers and the level of nitric oxide flux was equivalent to that 
observed in non-smokers with asthma. 
 Smokers Ex smokers Non-smokers 
Calv pre steroid 
(ppb)
 
   1.42 * 
(0.43, 2.01) 
1.71 
(0.59, 2.79) 
2.45 
(1.11, 3.52) 
Jaw pre steroid 
(pl/s)
 
   572.8 † 
(216.7, 734.4) 
987.6 
(695.2, 3308.3) 
1535.0 
(784.6, 3495.6) 
Calv  post steroid 
 
(ppb) 
1.79 
(0.68, 2.38) 
0.58 
(0.40, 0.76) 
1.89 
(1.37, 2.93) 
Jaw post steroid  
(pl/s) 
   147.6 † 
(65.0, 458.0) 
570.0 
(413.9, 932.6) 
577.0 
(456.9, 1361.7) 
Table 7.5 Linear regression analysis results for 100, 200, 300 ml/sec.  
Calv; alveolar nitric oxide, Jaw; nitric oxide flux. ppb; parts per billion, pl/s; picolitres per 
second. p values refer to comparison of smokers and non smokers. *; p<0.05, †; p<0.01, ‡, 
p<0.001. 
 
7.3.4.1.1 Linear analysis 
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Performance of linear regression with data from multiple additional flows (100, 
150, 200 & 250 and subsequently with the addition of data from 300 ml/sec) 
altered the concentrations derived for alveolar nitric oxide. For example, 
median alveolar nitric oxide values for smokers with asthma at baseline derived 
using four flows was 1.53 ppb (IQR 0.09, 2.50) and five flows was 1.03 ppb (-
0.03, 2.02). However the use of data from extra flow rates did not remove the 
significant difference between the groups at baseline or affect the narrowing of 
the difference following the oral corticosteroid trial. Values derived for nitric 
oxide flux were not obviously affected by the use of data from additional flow 
rates. 
Linear regression using the low flow rates of 30 and 50ml/sec produced different 
values for nitric oxide flux compared to higher flows. However in keeping with 
the previous models, smokers with asthma had significantly lower nitric oxide 
flux levels at baseline (smokers 396.8 pl/s (IQR 68.8, 834.7), non-smokers 1984.6 
pl/s (1257.9, 5580.5), p<0.001) and post oral corticosteroid (smokers 207.4 pl/s 
(-8.4, 635.2), non-smokers 587.2 pl/s (383.2, 1342.4), p=0.004) using this 
approach. When response to oral corticosteroids was compared smokers with 
asthma made a significantly smaller reduction in nitric oxide flux (smokers 
change -77.2 pl/s (-284.3, 139.2), non-smokers change -1363.8 pl/s (-4094.8, -
678.0), p=0.003). Ex-smokers with asthma displayed airway wall concentrations 
and flux levels similar to those observed in non-smokers with asthma. 
 
Non-linear regression produced equivalent median alveolar nitric oxide 
concentrations in smokers and non-smokers with asthma at baseline (smokers 
1.39 ppb (IQR 0.00, 1.95), non-smokers 0.78 ppb (0.00, 1.69), p=0.760) and post 
oral corticosteroid trial (smokers 0.97 ppb (0.00, 2.04), non-smokers 1.25 ppb 
(0.43, 2.14), p=0.360) (table 7.6 & figure 7.4). No significant difference was 
evident between smokers and non-smokers with asthma when change in alveolar 
nitric oxide in response to oral corticosteroid was compared (smokers median 
change 0.00 ppb (IQR -0.61, 0.64), non-smokers median change 0.43 ppb (0.00, 
1.27), p=0.240). Ex-smokers with asthma had alveolar nitric oxide levels slightly 
lower than those observed in smokers with asthma. 
7.3.4.1.2 Non-linear regression analysis 
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Figure 7.4 Baseline alveolar nitric oxide (Calv)-non-linear modelling.  
ppb; parts per billion. 
 
 Smokers Ex smokers Non-smokers 
Calv pre steroid 
(ppb)
 
1.39 
(0.00, 1.95) 
0.32 
(0.00, 0.97) 
0.78 
(0.00, 1.69) 
Jaw pre steroid 
(pl/s)
 
   697.4 † 
(322.5, 1204.8) 
1278.3 
(715.6, 4221.8) 
2087.8 
(1093.4, 5033.6) 
Calv  post steroid 
 
(ppb) 
0.97 
(0.00, 2.04) 
0.61 
(0.00, 0.78) 
1.25 
(0.43, 2.14) 
Jaw post steroid  
(pl/s) 
   335.7 † 
(278.7, 732.0) 
947.4 
(438.3, 1302.5) 
676.9 
(608.2, 1132.4) 
Table 7.6 Non linear regression analysis.  
Results presented as median (IQR). Calv; alveolar nitric oxide, Jaw; nitric oxide flux. ppb; 
parts per billion, pl/s; picolitres per second. p values refer to comparison of smokers and 
non smokers.  *; p<0.05, †; p<0.01, ‡, p<0.001. 
 
Nitric oxide flux values were significantly lower in smokers with asthma at 
baseline (smokers 697.4 pl/s (IQR 322.5, 1204.8), non-smokers 2087.8 pl/s 
(1093.4, 5033.6), p=0.002) and post oral corticosteroids (smokers 335.7 pl/s 
(278.7, 732.0), non-smokers 676.9 pl/s (608.2, 1132.4), p=0.004) (table 7.6 and 
figure 7.5). Smokers with asthma also demonstrated a trend to a reduction in 
nitric oxide flux in response to oral corticosteroids (smokers within group median 
change -260.1 pl/s (IQR -492.1, 33.1), p=0.064). This was in contrast to non-
Non-smokers 
with asthma 
Ex-smokers 
with asthma 
Smokers 
with asthma 
Alveolar 
nitric 
oxide 
(ppb) 
p=0.760 
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smokers where a large and strongly significant reduction was observed (non-
smokers -1363.0 pl/s (-3831.0, -725.0), p<0.001). Baseline levels for nitric oxide 
flux in ex-smokers with asthma were higher than those observed in smokers with 
asthma and suggested a trend towards the levels observed in non-smokers with 
asthma. 
 
Figure 7.5 Baseline nitric oxide flux (Jaw)-non-linear modelling.  
pl/s; picolitres per second. 
 
7.3.4.2 Airway wall Nitric Oxide concentration and Nitric Oxide diffusion 
 
The airway wall nitric oxide concentration was significantly lower in smokers 
with asthma at baseline (smokers 8.6 ppb (IQR -4.4, 53.3), non-smokers 147.6 
ppb (59.7, 243.3), p=0.002) (table 7.7). However post oral corticosteroids this 
difference was narrowed and became non-significant, although a trend to a 
difference was evident (smokers 15.0 ppb (0.2, 37.0), non-smokers 45.0 ppb 
(20.8, 89.4), p=0.08). Smokers with asthma made a significantly smaller 
reduction in airway wall nitric oxide concentration in response to oral 
corticosteroids when assessed by linear modelling (smokers median change -1.47 
ppb (IQR -24.4, 19.9), non-smokers -111.6 ppb (-188.3, 2.4), p=0.030). Levels 
obtained for ex-smokers at baseline were higher than smokers and were similar 
to the levels observed in non-smokers (ex-smokers; baseline 166.9 ppb (43.6, 
253.1), post corticosteroid 86.0 ppb (57.4, 118.9)). 
7.3.4.2.1 Linear regression 
Non-smokers 
with asthma 
Ex-smokers 
with asthma 
Smokers 
with asthma 
Airway 
wall 
flux 
(pl/s) 
p=0.002 
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Smokers with asthma had a trend to lower rates of airway wall nitric oxide 
diffusion compared to non-smokers at baseline (smokers 11.7 pl/s/ppb (IQR -
19.2, 17.7), non-smokers 18.0 pl/s/ppb (7.3, 26.0), p=0.070), but no difference 
was evident post oral corticosteroid trial (smokers 0.8 pl/s/ppb (-43.3, 30.4), 
non-smokers 12.2 pl/s/ppb (4.5, 20.0), p=0.240) (table 7.7). No significant 
difference in airway wall nitric oxide diffusion response to oral corticosteroids 
was evident when the two groups were compared. Ex-smokers diffusion levels 
were equivalent to smokers and did not appear to significantly change in 
response to oral corticosteroids. 
  Smokers Ex smokers Non-smokers 
Caw pre steroid 
(ppb)
 
   8.6 † 
(-4.4, 53.3) 
166.9 
(43.6, 253.1) 
147.6 
(59.7, 243.3) 
Daw pre steroid 
(pl/s/ppb)
 
11.7 
(-19.2, 17.7) 
6.0 
(0.8, 16.6) 
18.0 
(7.3, 26.0) 
Caw post steroid 
(ppb) 
15.0 
(0.2, 37.0) 
86.0 
(57.4, 118.9) 
45.0 
(20.8, 89.4) 
Daw post steroid 
(pl/s/ppb) 
0.8 
(-43.3, 30.4) 
6.7 
(3.1, 11.3) 
12.2 
(4.5, 20.0) 
Table 7.7 Airway wall concentration and diffusion of nitric oxide produced by linear 
regression using 30 and 50ml/sec flow rates.  
Caw; airway wall concentration of nitric oxide, Daw; airway wall nitric oxide diffusion, ppb; 
parts per billion, pl/s/ppb; picolitres per second per parts per billion. p values refer to 
comparison of smokers and non smokers. †; p<0.01. 
 
 
Smokers with asthma had significantly lower airway wall nitric oxide 
concentrations at both baseline (smokers 25.9 ppb (IQR 7.1, 32.2), non-smokers 
117.8 ppb (62.0, 173.5), p<0.001) (table 7.8) and post oral corticosteroid trial 
(smokers 10.8 ppb (7.0, 25.5), non-smokers 38.7 ppb (27.2, 81.6), p=0.021). 
When responses to the corticosteroid trial were compared it was evident that 
non-smokers with asthma made a significantly greater reduction in airway wall 
nitric oxide concentration (smokers median change -5.5 ppb (IQR -18.9, 0.9), 
non-smokers -54.1 ppb (-116.2, -24.8), p=0.020). Ex-smokers demonstrated a 
trend towards the levels observed in non-smokers with asthma at baseline. No 
change in airway wall nitric oxide concentrations were observed in response to 
oral corticosteroids in the ex-smokers with asthma. 
7.3.4.2.2 Non-linear regression 
Chapter 7  197 
Nitric oxide diffusion was equivalent in both groups at baseline and post oral 
corticosteroid trial. The changes in nitric oxide diffusion in response to the 
corticosteroid trial were equivalent and small in nature (smokers median change 
-8.9 pl/s/ppb (-28.0, 43.3), non-smokers -6.3 pl/s/ppb (-21.1, 0.0), p=0.700). 
Ex-smokers demonstrated parity for nitric oxide diffusion at baseline with an 
apparent reduction in response to oral corticosteroids. 
 Smokers Ex smokers Non-smokers 
Caw pre steroid 
(ppb)
 
  25.9 ‡ 
(7.1, 32.2) 
62.9 
(35.9, 269.3) 
111.8 
(62.0, 173.5) 
Daw pre steroid 
(pl/s/ppb)
 
25.7 
(6.0, 46.5) 
24.8 
(1.0, 33.4) 
27.8 
(15.7, 36.5) 
Caw post steroid 
(ppb) 
  10.8 * 
(7.0, 25.5) 
64.3 
(17.0, 177.7) 
38.7 
(27.2, 81.6) 
Daw post steroid 
(pl/s/ppb) 
29.8 
(1.0, 55.4) 
6.3 
(1.0, 20.1) 
16.2 
(7.5, 28.9) 
Table 7.8 Airway wall concentration and diffusion of nitric oxide produced by non-linear 
regression.  
Caw; airway wall concentration of nitric oxide, Daw; airway wall nitric oxide diffusion, ppb; 
parts per billion, pl/s/ppb; picolitres per second per parts per billion. p values refer to 
comparison of smokers and non smokers. *; p<0.05, ‡; p<0.001. 
 
7.3.4.3 Comparison of linear and non-linear models 
Comparison between the linear and non-linear methods was possible for the 
baseline results. A Bland-Altman plot for alveolar nitric oxide (figure 7.6), 
reveals that the models provided very different results for alveolar nitric oxide 
levels with disagreements of up to 8 ppb and a more routine difference of about 
4 ppb present.  
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Figure 7.6 Bland-Altman plot of Alveolar nitric oxide (Calv) difference (linear-non-linear) 
against alveolar nitric oxide (Calv) average for linear and non-linear models 
 
7.3.4.4 Impact of corticosteroids on extended flow measurements at one 
month 
Performance of extended flow nitric oxide measurements one month post oral 
corticosteroid trial allowed a simple examination of the duration of effect of the 
corticosteroid trial on these markers of inflammation.  
When alveolar nitric oxide derived by linear modelling (using three flow rates) 
was examined it was evident that corticosteroids continued to have an effect at 
one month. Alveolar nitric oxide was equivalent in smokers and non-smokers 
with asthma in contrast to baseline (table 7.9). Comparing the change in 
alveolar nitric oxide from pre corticosteroid visit to one month post 
corticosteroids demonstrated that alveolar nitric oxide significantly increased in 
the smokers with asthma (smokers median change 1.34 ppb (IQR 0.21, 2.31), 
non-smokers -0.52 ppb (-1.21, 0.18), p=0.007). Airway nitric oxide flux at one 
month post oral corticosteroid trial continued to be significantly lower in 
smokers with asthma (table 7.9). However nitric oxide flux showed a reduction 
in both groups with a trend to a larger reduction in non-smokers with asthma 
(smokers median change -136.9 pl/s (IQR -429.7, 209.6), non-smokers change -
281.7 pl/s (-875.0, -18.7), p=0.060). Ex-smokers with asthma demonstrated 
continued suppression of their alveolar nitric oxide level at one month whilst 
their flux had recovered towards baseline levels and showed parity with non-
smokers with asthma. 
Average Calv (linear and non-linear mean) 
Calv 
difference 
(linear–
nonlinear) 
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 Smokers Ex smokers Non-smokers 
Calv pre steroid 
(ppb)
 
    0.69 * 
(0.19, 1.93) 
0.87 
(0.07, 2.56) 
2.19 
(1.10, 3.34) 
Jaw pre steroid 
(pl/s)
 
    572.8 ‡ 
(216.7, 734.4) 
987.6 
(695.2, 3047.5) 
1563.7 
(797.4, 3659.0) 
Calv 1 month post 
steroid
 
(ppb) 
1.82 
(1.08, 2.65) 
0.00 
(-0.63, 0.69) 
1.37 
(0.13, 3.00) 
Jaw 1 month post 
steroid (pl/s) 
   462.2 † 
(215.1, 671.7) 
1129.6 
(433.2, 1235.7) 
1213.7 
(591.3, 2637.4) 
Table 7.9 Variation in alveolar nitric oxide and airway nitric oxide for linear modelling using 
100, 200 & 300ml/sec flow rates.  
Results presented as median (IQR). Calv; alveolar nitric oxide, Jaw; nitric oxide flux. ppb; 
parts per billion, pl/s; picolitres per second. *; p<0.05, †; p<0.01, ‡, p<0.001. 
 
Alveolar nitric oxide estimates generated by non-linear modelling demonstrated 
a trend to higher alveolar nitric oxide levels at one month in the smokers with 
asthma (smokers 1.61 ppb (IQR 0.0, 2.5), non-smokers 0.23 ppb (0.0, 0.6), 
p=0.059) (table 7.10). When alveolar nitric oxide change from baseline to one 
month post corticosteroid was compared there appeared to be a slight rise in the 
smokers with asthma (smokers median change 0.63 ppb (IQR -0.01, 1.20), non-
smokers 0.00 ppb (-1.67, 0.23), p=0.060). 
Non-linear modelling revealed that smokers with asthma continued to have 
significantly lower nitric oxide flux levels after one month (smokers 378.7 pl/s 
(IQR 130.2, 902.0), non-smokers 1379.8 pl/s (591.9, 3324.2), p=0.006) (table 
7.10). No difference was evident when change in flux from baseline to one 
month post oral corticosteroid trial was compared (smokers median change -92.3 
pl/s (IQR -607.7, 78.9), non-smokers -358.7 pl/s (-1161.9, 33.5), p=0.380). 
Reflecting the linear modelling result, non-linear modelling also suggested that 
ex-smokers with asthma displayed suppressed levels of alveolar nitric oxide at 
one month. Nitric oxide flux levels had also returned to the range observed at 
baseline in ex-smokers with asthma at one month. 
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 Smokers Ex smokers Non-smokers 
Calv pre steroid 
(ppb)
 
1.39 
(0.00, 1.95) 
0.32 
(0.00, 0.97) 
0.78 
(0.00, 1.69) 
Jaw pre steroid 
(pl/s)
 
   697.4 † 
(322.5, 1204.8) 
1278.3 
(715.6, 4221.8) 
2087.8 
(1093.4, 5033.6) 
Caw pre steroid 
(ppb)
 
   25.9 ‡ 
(7.1, 32.2) 
62.9 
(35.9, 269.3) 
111.8 
(62.0, 173.5) 
Daw pre steroid 
(pl/s/ppb)
 
25.7 
(6.0, 46.5) 
24.8 
(1.0, 33.4) 
27.8 
(15.7, 36.5) 
Calv 1 month post 
steroid (ppb)
 
1.61 
(0.00, 2.51) 
0.00 
(0.00, 0.18) 
0.23 
(0.00, 0.58) 
Jaw 1 month post 
steroid (pl/s)
 
   378.7 † 
(130.2, 902.0) 
1290.8 
(280.1, 1611.3) 
1379.8 
(591.9, 3324.2) 
Caw 1 month post 
steroid (ppb)
 
39.5 
(8.5, 113.9) 
91.8 
(44.5, 194.3) 
60.6 
(36.8, 152.2) 
Daw 1 month post 
steroid(pl/s/ppb) 
1.5 
(1.0, 25.4) 
5.8 
(1.0, 22.4) 
14.9 
(1.0, 29.8) 
Table 7.10 Variation in alveolar nitric oxide, airway nitric oxide flux, concentration and 
diffusion for non-linear modelling.  
Results presented as median (IQR). Calv; alveolar nitric oxide, Jaw; nitric oxide flux, Caw; 
airway wall concentration of nitric oxide, Daw; airway wall nitric oxide diffusion. ppb; parts 
per billion, pl/s; picolitres per second pl/s/ppb; picolitres per second per parts per billion. †; 
p<0.01, ‡, p<0.001. 
 
In contrast to baseline, airway wall nitric oxide (derived by non-linear modelling) 
was equivalent in smokers and non-smokers with asthma at one month. This 
narrowing of the difference appeared to be partly due to an increase in this 
marker in smokers with asthma and a sustained suppression in non-smokers (one 
month post levels; smokers 39.5 ppb (8.5, 113.9), non-smokers 60.6 ppb (36.8, 
152.2), p=0.370) (table 7.10). No obvious difference was evident in nitric oxide 
diffusion one month post oral corticosteroid trial when smokers and non-smokers 
were compared. However levels appeared to be lower in smokers with asthma 
compared to baseline (smokers 1.5 pl/s/ppb (1.0, 25.4), non-smokers 14.9 
pl/s/ppb (1.0, 29.8), p=0.110). Airway wall nitric oxide concentrations in ex-
smokers with asthma appeared to be higher than non-smokers with asthma at 
one month post oral corticosteroid trial. 
Airway wall concentrations at one month, derived using low flows and linear 
modelling, were equivalent (smokers 16.7 ppb (-4.7, 109.6), non-smokers 69.7 
ppb (24.2, 145.7), p=0.170). Comparison of the change in airway wall 
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concentrations demonstrated a trend to a larger reduction in non-smokers with 
asthma (smokers -5.1 ppb (-19.9, 64.1), non-smokers -37.9 ppb (-195.5, 61.8), 
p=0.055). Nitric oxide diffusion was significantly lower in smokers with asthma 
(smokers 2.6 pl/s/ppb (-15.4, 9.2), non-smokers 12.9 pl/s/ppb (4.6, 20.5), 
p=0.026). However when median change from baseline was examined no 
difference in response was evident (smokers 7.3 pl/s/ppb (IQR -11.4, 17.9), non-
smokers -1.6 pl/s/ppb (-13.3, 10.4), p=0.400). In contrast to the result derived 
by non-linear modelling, ex-smokers with asthma airway wall concentration at 
one month post oral corticosteroid was close to the level observed in smokers 
with asthma (ex-smokers one month post corticosteroid 15.9 ppb (-19.3, 112.0)). 
7.4 Discussion  
Smokers with asthma display a reduced response to inhaled and oral 
corticosteroids (5-10, 22-24). This altered response is associated with worse 
asthma control reflected in the higher ACQ scores of smokers with asthma (12). 
New treatments are currently being developed for corticosteroid resistant 
airway obstruction and may be useful in the management of this group. However 
to justify the cost and effort involved in performing definitive trials for these 
medications supportive evidence will initially be required from small exploratory 
trials in smokers with asthma. Therefore an exploratory endpoint that detects 
subtle anti-inflammatory effects which do not rapidly translate into lung 
function changes in smokers with asthma would be a useful additional test for 
the standard short exploratory trial. I chose to examine both exhaled breath 
condensate pH and extended flow nitric oxide analysis based on the hypothesis 
that both could provide a non-invasive test that reflects the poorly controlled 
inflammation present in smokers with asthma.  
Extended flow analysis provides additional insights into airway nitric oxide 
metabolism, compared to the standard measurement of exhaled nitric oxide at a 
flow rate of 50ml/sec. Active smoking does not appear to reduce the alveolar 
nitric oxide concentration (226, 259) and elevated alveolar nitric oxide has been 
detected in subjects with COPD (225, 258). Based on this work and the potential 
ability of extended flow analysis to provide further additional insights in smokers 
with asthma and that it may correlate with the increased symptoms present in 
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smokers with asthma I felt that it was worthy of study. The data produced by 
linear modelling demonstrates that smokers with asthma have reduced alveolar 
nitric oxide, nitric oxide flux and airway wall diffusion levels compared to non-
smokers with asthma and, when compared to previous research, perhaps lower 
alveolar nitric oxide levels than healthy non-smokers (table 7.1). The difference 
in alveolar nitric oxide levels in smokers and non-smokers with asthma is novel 
and contrasts with previous research in normal smokers (226) and COPD (52, 
225). The oral corticosteroid trial demonstrates that the difference in alveolar 
nitric oxide levels between smokers and non-smokers with asthma (as 
determined by linear modelling) can be reduced by oral corticosteroids and this 
effect persists for at least one month. 
In contrast, non-linear modelling demonstrates equivalency for alveolar nitric 
oxide in smokers and non-smokers with asthma. This result is consistent with 
previous work in normal smokers (226) and smokers and ex-smokers with COPD 
(52). Again alveolar nitric oxide levels were not raised in reflection of the 
increased symptoms in smokers with asthma and no clear change in alveolar 
nitric oxide was evident in either group in response to high dose corticosteroids 
leading one to question the usefulness of this endpoint. When the results from 
the linear and non-linear models were compared by Bland-Altman plot it was 
evident that the models could not be regarded as interchangeable.  
Airway nitric oxide flux derived by both linear and non-linear modelling 
demonstrates a clear difference for this endpoint between smokers and non-
smokers with asthma. Smokers with asthma display nitric oxide flux levels close 
to those previously observed in normal non-smokers. Nitric oxide flux also 
demonstrates sensitivity to oral corticosteroids in both smokers and non-smokers 
with asthma. The evidence of clear change in smokers with asthma nitric oxide 
flux following oral corticosteroids when derived by linear modelling and a trend 
to a reduction when derived by non-linear modelling is intriguing and suggests 
that nitric oxide flux is worthy of further study. Non-linear and linear modelling 
also revealed the novel finding that airway wall nitric oxide concentrations are 
significantly lower in smokers with asthma at baseline, post oral corticosteroid 
trial and at one month post oral corticosteroid in contrast to linear modelling. 
Airway wall nitric oxide, derived by both linear and non-linear modelling, 
appears to be sensitive to oral corticosteroids with non-smokers making 
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significantly greater reductions in response to oral corticosteroids. Smoking did 
not affect airway wall diffusion for nitric oxide and this is consistent with 
previously published work in normal smokers (226, 259) and ex-smoking subjects 
with COPD (52, 225). 
The finding of reduced airway nitric oxide flux, nitric oxide airway wall 
concentrations and alveolar nitric oxide (when derived by linear modelling) in 
smokers with asthma is intriguing and it is tempting to speculate on possible 
causes. This study is not able to demonstrate the mechanism(s) by which this 
occurs but possible causes include cigarette smoke induced consumption of nitric 
oxide (51, 52), competition for required substrates by other inflammatory 
pathways activated by cigarette smoke (53) and reduced inducible nitric oxide 
synthase (iNOS) concentrations in airway epithelial cells in response to smoking 
(55). Future studies examining nitric oxide synthesis and reaction products in the 
bronchial epithelium and submucosa in smokers and non-smokers with asthma 
should, in parallel, determine extended flow nitric oxide parameters. 
A final significant issue that needs to be resolved is the determination of a 
significant change in any of the flow independent nitric oxide parameters in 
response to treatment (similar to that which exhaled nitric oxide (measured at 
50ml/sec) has been undergoing). This study can be viewed as one of the first 
steps in addressing this issue. However the recent demonstration that significant 
changes can be detected in exhaled nitric oxide levels in smokers with asthma 
with an alternative simple approach (221) may hamper the development of this 
technique as a replacement method for assessing smokers with asthma. 
The inclusion of a group of ex-smokers with asthma in the study has allowed 
some simple observations to be made. Ex-smokers with asthma have previously 
demonstrated evidence suggestive of a restoration of corticosteroid sensitivity 
after many years of smoking cessation (23). The ex-smoking subjects recruited to 
this study failed to show clear improvements in lung function in response to oral 
corticosteroids despite a mean duration of quitting of seven years. When 
compared to smokers and non-smokers with asthma, ex-smokers appeared to 
represent a separate phenotype with the result for some parameters being 
equivalent to those observed in smokers and others to the results for non-
smokers with asthma. These findings coupled to the observation suggestive of a 
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restoration of corticosteroid sensitivity in a sub group of ex-smokers with asthma 
should prompt further research into this group. The proportion of ex-smokers 
with asthma in the population will substantially increase in coming years due to 
recent changes in legislation and public perception of smoking and too little is 
known about the characteristics and behaviour of this group. 
Exhaled breath condensate pH has been examined in asthma exacerbations and 
demonstrates correlation with clinical improvement (57), sputum neutrophilia in 
COPD and sputum eosinophilia in asthma (238). EBC can be collected outside of 
the research lab allowing the collection of samples by non-specialised personnel 
at, for example, the subject’s general practice. This facet of EBC may be useful 
as attendance at hospital based research units may be responsible for some of 
the reluctance observed in some subjects with regards clinical trial 
participation. EBC pH has previously been examined by one group in smokers 
with asthma (58). The authors demonstrated that smokers with asthma had a 
lower EBC pH than non-smokers with asthma. If this finding was corroborated 
then the restoration of EBC pH towards the level present in non-smokers with 
asthma would have provided a suitable exploratory endpoint. In this exploratory 
study EBC pH measurements were performed at baseline, immediately post oral 
corticosteroid trial and one month after oral corticosteroids in smokers, ex-
smokers and non-smokers with asthma. Surprisingly EBC pH was found to be 
equivalent in the three groups at all timepoints and therefore unresponsive to 
high dose oral corticosteroids. The reason for this discordant result is not clear. 
EBC was collected in this study using a commercially available apparatus and 
processed in accordance with previously published research. The authors of the 
previous trial used an unusual method (the subjects breathed through a frozen 
syringe) for EBC collection and this may have had an effect on the 
measurements. How this would have a greater effect on the pH of EBC collected 
from smokers with asthma is not immediately obvious. Another explanation is 
that both this and the previous trial are small and sampling error may have 
produced this disparity. Possible additional explanations are that the smokers 
with asthma recruited to the previous trial may have been experiencing subtle 
subclinical exacerbations or were not fully recovered from a previous 
exacerbation and hence would have had a spurious reduction in their EBC pH. 
The results obtained for this trial leads one to conclude that EBC pH is 
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insufficiently sensitive and discriminatory to be employed as an exploratory 
endpoint. 
7.5 Conclusion 
In conclusion, in the first trial to examine extended flow nitric oxide analysis in 
a group of smokers with asthma, linear modelling demonstrated that smokers 
display lower levels of alveolar nitric oxide compared to non-smokers with 
asthma whilst non-linear modelling demonstrated that alveolar nitric oxide in 
smokers and non-smokers with asthma was equivalent. Nitric oxide flux and 
airway wall concentration of nitric oxide are lower in smokers with asthma using 
both linear and non-linear modelling. Significant differences exist between the 
result derived for alveolar nitric oxide using linear and non-linear models. The 
use of extended flow analysis and non-linear modelling may eventually provide a 
useful exploratory endpoint for the assessment of smokers with asthma but 
consensus is required with regards the best form of modelling given the lack of 
agreement between linear and non-linear modelling. Research also needs to be 
performed to identify the minimal clinically significant change in the parameters 
derived by extended flow nitric oxide analysis. Finally exhaled breath 
condensate pH is equivalent in smokers and non-smokers with asthma and does 
not change in response to a two week oral corticosteroid trial. In light of this 
finding the utilisation of EBC pH as an exploratory endpoint in clinical trials in 
smokers with asthma cannot be justified. 
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8 Conclusions and future directions 
8.1 Summary of findings 
Smokers with asthma consistently display reduced responses to corticosteroids 
compared to non-smokers with asthma (5-10, 22-24). This response is associated 
with worse control of asthma (11, 12), accelerated decline in lung function (15, 
21) and increased use of emergency services (16, 17). Smoking is common in 
asthma with rates reflecting the prevalence in the general population (261) and 
therefore it represents a significant problem for patients and respiratory 
physicians. 
The results presented in this thesis show that smokers with asthma demonstrate 
improvements in lung function following treatment with the combination of low 
dose theophylline and inhaled corticosteroid and treatment with the PPARγ 
agonist rosiglitazone. Low dose theophylline appears to be acting in synergy with 
inhaled corticosteroids suggesting the possibility of a re-sensitisation to 
corticosteroids in smokers with asthma. Low dose theophylline when given alone 
also improves symptoms in smokers with asthma and should be investigated as a 
potential alternative treatment for those smokers with asthma not willing to 
take inhaled corticosteroid. The response to the PPARγ agonist rosiglitazone is 
the first demonstration of an anti-inflammatory effect through stimulation of 
this nuclear hormone receptor in humans and may herald a new class of anti-
inflammatory agents. 
The study attempting to identify mechanisms responsible for the reduced 
response displayed by smokers with asthma to corticosteroids demonstrated that 
smokers with asthma display alterations in the pulmonary and systemic cytokine 
environment suggestive of a deviation from a Th2 to a Th1 inflammatory 
response. The identification of increased sputum supernatant levels of IL-6 
which are resistant to high dose oral corticosteroids is significant given the 
important role that this cytokine has at the interface between acute and chronic 
inflammation and the innate and adaptive immune response. 
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Previous research has suggested that a reduced response to corticosteroids is 
partially due to an oxidative stress mediated reduction in total HDAC activity 
through post translational modification in HDAC enzyme isoforms. The results 
presented here suggest that total HDAC activity in smokers with asthma is 
equivalent to non-smokers with asthma. However as this is the first attempt to 
measure this marker in induced sputum technical issues may be preventing the 
demonstration of a difference and therefore the study should be regarded as 
non-conclusive. 
Smokers with asthma display worse symptoms from asthma when assessed using 
symptom questionnaires. However their exhaled nitric oxide level measured at 
the conventional flow rate of 50ml/sec is markedly reduced. Extended flow rate 
nitric oxide parameters were calculated in smokers with asthma based on the 
hypothesis that this would reveal increased levels of alveolar nitric oxide 
correlating with the increased asthma symptoms observe in this group. However 
smokers with asthma demonstrated lower or equivalent levels of alveolar nitric 
oxide. This observation combined with the cytokine findings from the same study 
and the observation that smokers with asthma display reduced response to 
corticosteroids is consistent with the possibility that inflammation in smokers 
with asthma is deviated from the eosinophilic/Th2 inflammation displayed by 
some non-smokers with asthma. 
8.2 Limitations of presented research 
Conducting a period of original independent clinical research with the aim of 
obtaining a higher degree requires several compromises. The first and 
overarching concern is undertaking a study that is feasible within the available 
time limits. The study examining theophylline and the PPARγ agonist 
rosiglitazone presented here is short and recruited a small number of subjects 
and therefore cannot be viewed as the definitive study of these approaches to 
the treatment of smokers with asthma. However large, multi centre definitive 
management trials examining these approaches in smokers with asthma can now 
be conducted as a result of the findings presented here. The study examining 
potential mechanisms for the reduced response to corticosteroids observed in 
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smokers with asthma also included a small number of patients and therefore the 
findings will also require corroboration in larger trials. 
Closely allied to the constraints of limited time and finance is the desire to fully 
interrogate the available data. However to adopt a data mining approach raises 
the possibility of false positive results due to multiple comparisons. To reduce 
this possibility each study was conducted according to a prearranged analysis 
plan and in the case of the trial examining theophylline and rosiglitazone the 
plan included predefined primary and secondary endpoints. Despite this 
approach both trials could contain false positive results. Therefore I have 
presented and discussed the available results with this in mind. All work 
presented in this thesis should be viewed as exploratory and therefore requiring 
corroboration. 
Another issue of great importance is the characterisation of patients and the 
differentiation of smokers and ex-smokers with asthma from subjects with COPD. 
COPD occurs as a direct result of prolonged exposure to inhaled noxious stimuli. 
In the developed world the agent predominantly responsible is cigarette smoke. 
Given the common link of smoking and the substantial smoking histories of the 
recruited subjects it is possible that some of the subjects could actually have 
COPD. COPD is characterised by chronic airflow obstruction, sputum neutrophilia 
and a reduced therapeutic response to treatment with corticosteroids (compared 
to non-smokers with asthma). However despite their substantial smoking 
histories the recruited smokers and ex-smokers with asthma did not display 
sputum neutrophilia, developed symptoms at a young age (majority teens to 
twenties) and also displayed significant bronchodilatory responses to inhaled β2 
agonists. Therefore I feel I can safely argue that the majority of recruited 
subjects have asthma and not COPD. An alternative view is that I could have 
recruited a number of subjects who display an overlap in characteristics shared 
by asthma and COPD. This is certainly possible especially in the older subjects 
with substantial smoking histories. To address this issue properly I would have 
had to perform a number of additional screening tests including measurement of 
transfer factor and high resolution CT scans. Unfortunately this was not feasible 
due to time and funding constraints. When confirmatory studies are performed 
to examine the findings presented in this thesis then these issues should be 
addressed to aid interpretation. The issue of overlap between asthma and COPD 
Chapter 8  209 
is an important one to address as this combination is regularly observed by the 
clinician and studies containing well characterised subjects who do display a 
mixture of the two conditions would provide useful insights for clinical care. This 
issue coupled to the lack of understanding of the treatment responses of ex-
smokers with asthma should stimulate some interesting and clinically relevant 
future research.   
8.3 Conclusions & future directions 
Smokers with asthma demonstrate detectable responses to treatment with the 
combination of low dose theophylline and inhaled corticosteroid, low dose 
theophylline alone and the PPARγ agonist rosiglitazone. All three treatment 
combinations should undergo detailed examination in adequately powered 
management trials in smokers with asthma. The identification of a 
bronchodilator response to treatment with a PPARγ agonist is intriguing and may 
herald a new group of anti-inflammatory agents.  
Smokers with asthma display altered pulmonary inflammatory conditions 
compared to non-smokers with asthma and therefore cannot be regarded as 
equivalent to this group. Further detailed research is required to properly 
understand the mechanisms responsible for this altered response. Comparison 
with smokers and ex-smokers with COPD, non-smokers with asthma and normal 
smoking and non-smoking subjects is required to detail the overlapping and 
differing patterns of inflammation. Consideration should also be given to the 
conduct of a large bronchoscopic biopsy study to characterise the histological, 
immunohistochemical and mechanistic differences between these groups. As 
smokers with asthma cannot be regarded as equivalent to non-smokers with 
asthma regulatory bodies should require current and future asthma therapies to 
demonstrate efficacy in this group as a pre-requisite for licensing. With 
increased understanding of the pattern of inflammation in this group it is likely 
that benefits for smokers with asthma and other groups with relative 
corticosteroid resistance will result.  
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